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Abstract 
A wide variety of bacterial pathogens evolved a panel of virulence factors in order to subvert 
cellular processes and achieve a successful infection. Bacteria of the genus Bartonella 
translocate a cocktail of effector proteins (Beps) via a type IV secretion system (T4SS) into 
mammalian cells. BepC, one of the most conserved effectors in the Bartonella species of the 
lineage 4, has been previously shown to be involved in the internalization of bacterial 
aggregates and migration defect in vitro.  
In this work, we show that the effector BepC localizes at cell-to-cell contact and triggers strong 
actin rearrangements as well as the formation of bacterial aggregates during infection of 
human cells. The actin phenotype is induced by BepC from different Bartonella species, 
indicating an important role of this effector during pathogenesis. 
BepC pull-down from infected cells led to the identification of two interacting partners, GEF-H1 
and MRCKα, which are two host proteins involved in the RhoA and Cdc42 pathways, 
respectively. We demonstrate that the ability of BepC to bind GEF-H1 and MRCKα highly 
correlates with its ability to trigger actin rearrangements. Accordingly, infected cells show an 
increase of GTP-bound RhoA and phosphorylated myosin light chain while both RhoA and its 
downstream effector ROCK are required for actin rearrangements mediated by BepC. Thus, 
our results indicate that BepC activates the RhoA pathway by interacting with GEF-H1 and 
thereby inducing actin rearrangements although MRCKα might also be involved. 
The majority of Beps, including BepC, carries an enzymatic FIC domain that is usually involved 
in posttranslational modifications. Most Fic proteins carry a canonical FIC motif that is essential 
for ATP binding and the transfer of AMP onto the target protein (AMPylation). By contrast, 
BepC is characterized by a non-canonical FIC motif and only displays a weak AMPylation and 
phosphorylation activity, independently from its conserved motif. Nevertheless, structural 
analysis and binding assays demonstrate that ATP binds to the FIC domain of BepC and is 
critical for its thermal stability.  
In absence of FIC domain, BepC loses its ability to localize at cell junctions, to interact with 
GEF-H1 and MRCKα, and to trigger actin rearrangement, suggesting a central role for this 
domain in the effector function. However, a conserved FIC motif is not necessary to trigger 
actin rearrangements, which indicates that BepC acts by protein-protein interaction rather than 
by posttranslational modification. Thus, we propose that BepC is recruited to cell contacts 
where it triggers the activation of the RhoA pathway by interacting with GEF-H1 and eventually 
leads to actin rearrangements, possibly with the help of MRCKα.  
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Ultimately, the subversion of RhoA signaling by BepC could help Bartonella to interfere with 
the immune response by preventing phagocytosis or impair cell migration. Furthermore, it 
could play an important role in the disruption of the endothelial barrier in order to reach the 
blood and establish a long-lasting bacteremia inside the host. 
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Infectious diseases imply the establishment of a competition between the host and the 
pathogen in which bacteria typically choose between two different tactics. In one hand, a frontal 
attack involving fast bacterial replication, acute symptoms, and a short period of incubation in 
order to overwhelm rapidly the host immune response. On the other hand, a stealth attack that 
is frequently characterized by a slow infection process in which the pathogens manipulate the 
immune system, establish a long-lasting infection, and adopt an intracellular lifestyle. To face 
the challenge to meet defensive attacks as well as to exploit the host functions to the 
pathogen’s benefit for survival, growth, and spreading, many stealth bacteria evolved a panel 
of virulence factors to interfere with cell functions. Among those are toxins, which are secreted 
in their surrounding environment, and effectors, which are directly translocated inside the host 
cell via a type III or a type IV secretion system (T3SS/T4SS). Signaling pathways regulated by 
small GTPases are often subverted by these virulence factors as they are involved in a 
multitude of cellular processes that can be modulated to the advantage of the pathogen.  
1.1 Rho GTPases 
The 20 GTPases of the Rho family are involved in many cellular processes, including cell 
migration, cell division, cell adhesion, lymphocyte development, and endothelial and epithelial 
permeability [1-8]. Thus, their activity is tightly controlled by different mechanisms. Rho 
GTPases are distributed in eight subgroups in which Rho, Rac, and Cdc42 are the most 
conserved among eukaryotes [9] (Fig. 1.1). 
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Figure 1.1. Rho GTPase family. 
Rho GTPases are divided into eight subfamilies according to their repartition in the 
phylogenetic tree. By contrast with classical Rho GTPases (in gray), which hydrolyze GTP, 
atypical Rho GTPases (in green) are predominantly GTP-bound due to the absence of a 
GTPase activity or an increased nucleotide exchange. They are regulated by protein stability, 
gene expression or phosphorylation rather than by GEFs (Guanine nucleotide exchange 
factors) and GAPs (GTPase activating proteins) [10, 11]. Amino acid sequence identity is 
indicated in %. Adapted from [12]. 
1.1.1 Rho GTPase regulation. 
Most GTPases alternate between an inactive GDP-bound conformation and an active GTP-
bound conformation. This switch is regulated by guanine nucleotide exchange factors (GEFs), 
GTPase-activating proteins (GAPs), and guanine nucleotide dissociation inhibitors (GDIs) (Fig. 
1.2). There are 79 identified mammalian GEFs of the Rho GTPase family, while between 59 
and 70 proteins containing a RhoGAP domain have been predicted in the human genome, 
indicating a complex degree of regulation [1, 13]. 
In order to get activated and to interact with downstream effectors, GDP-bound Rho GTPases 
need to localize to the plasma membrane. Most Rho GTPases are posttranslationally modified 
by prenylation on a C-terminal CAAX motif (where C represents cysteine, A an aliphatic amino 
acid, and X a terminal amino acid) and occasionally by palmitoylation, mediating the 
association with membranes [14, 15]. GDIs extract Rho GTPases from membranes by 
masking the hydrophobic tail linked to the prenyl group, thereby sequestering them in the 
cytosol and preventing their activation [16]. Additionally, GDIs act as chaperones and suppress 
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the degradation of inactive Rho GTPases to maintain a stable pool readily available for 
activation [17]. 
In response to a stimulus, GEFs promote the exchange of GDP by GTP and activate Rho 
GTPases. The mechanism of activation by GEF is a multi-step process leading to the decrease 
of the affinity for the nucleotide, resulting in the release of GDP. Although GTPases have 
generally similar affinity for GDP and GTP, the binding of GTP is favored due to a ten times 
higher cytosolic concentration in comparison with GDP [18, 19]. Due to conformational 
changes, Rho GTPases are able to interact with downstream effectors, leading to their 
activation. More than 70 Rho GTPase effectors have been described, many of them are 
kinases or scaffolding proteins playing a role in a multitude of cellular processes [20]. 
Despite their name, GTPases have a very slow intrinsic GTP hydrolysis activity, which by itself 
would not be suitable for a short-term activation of signaling pathways. GAPs interact with 
GTPases and insert a so-called arginine finger in the active site, thereby stabilizing the 
transition state and stimulating their hydrolysis activity [18, 21, 22]. Once inactivated, the Rho 
GTPases are available for a new cycle. 
 
Figure 1.2. Regulation of Rho GTPases. 
Rho GTPases (RHO, in green) are anchored in the plasma membrane via a lipid group (zigzag 
line) or sequestered in the cytosol by guanine nucleotide dissociation inhibitors (GDI, in blue). 
After an external stimulus, guanine nucleotide exchange factors (GEF, in purple) activate the 
GTPase by promoting the exchange of GDP for GTP. Once activated, they interact with their 
effectors and modulate downstream signaling pathways. GTPase-activating proteins (GAP, in 
red) stimulate the hydrolysis of GTP in GDP and inorganic phosphate (Pi), thereby inactivating 
the GTPase. Taken from [1]. 
 
1.1.2 Cellular processes regulated by Rho GTPases. 
Rho GTPases are regulating a multitude of cellular processes that require the mobilization of 
the actin cytoskeleton such as cell migration, endothelial and epithelial barrier integrity, and 
phagocytosis. Additionally, they also participate in the immune defense by regulating 
inflammatory response and bacterial killing mechanisms. 
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Rho (Ras homolog gene family member), Rac (Ras-related C3 botulinum toxin substrate), and 
Cdc42 (cell division control protein 42 homolog) are the best characterized Rho GTPase 
subfamilies and the most ubiquitously expressed in mouse tissues [9]. Once activated, they 
interact with a large set of downstream effectors that principally participate in the 
reorganization of the actin cytoskeleton (Fig. 1.3). In cell culture, the activation of RhoA and its 
isoforms RhoB and RhoC lead to actomyosin contraction and actin stabilization, thereby 
promoting the formation of actin stress fibers [23]. By contrast, Rac1, Rac2, Rac3, and RhoG 
trigger lamellipodia formation while Cdc42 stimulates the formation of filopodia [24, 25]. 
 
Figure 1.3. Downstream effectors activated by RhoA, Cdc42, and Rac1. 
The activation of Rho GTPases results in the stimulation of a wide variety of cellular processes 
via their downstream effectors, including cytoskeletal dynamics and NADPH oxidation [26]. 
Effectors with a kinase activity are indicated in grey. Taken from [20]. 
 
 Cell migration 
Cell motility is a complex process involved in many physiological and pathological events 
including embryogenesis, angiogenesis, cancer invasion, and immune response. Efficient 
migration requires a dynamic remodeling of the actin cytoskeleton and the formation of multiple 
cellular structures such as lamellipodia, filopodia, actin stress fibers, and cell adhesions. The 
migration starts with the initiation of cell protrusions at the leading edge, followed by the 
formation of new adhesions to the extracellular matrix (ECM). After anchorage, the next step 
consists of the contraction of the cell body, which is mediated by actomyosin. Finally, the 
retraction coupled to the detachment of the rear tail concludes the migration process.  
The spatiotemporal regulation of these events is tightly controlled by GTPases of the Rho 
family. The formation of filopodia is initiated by Cdc42 via the activation of N-WASP (neuronal 
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Wiskott–Aldrich syndrome protein) and WASP, which induces the ARP (actin-related protein) 
2/3 complex. Rac1 also activates the ARP2/3 complex but via the WAVE (WASP family 
verprolin homologous protein) complex to form the branched lamellipodial actin network. The 
ARP2/3 complex binds to pre-existing actin filaments and serves as a seed for the 
polymerization and the branching of a new actin filament, which contribute to the formation of 
protrusions [27].  
Cell motion requires the coupling of the actin cytoskeleton to the ECM via focal adhesions 
(FAs), which provides an anchorage for traction. The binding of integrins to ECM proteins 
initiates the formation of nascent adhesions at the leading edge of migrating cells. Clustered 
integrins recruit a multitude of proteins via their cytoplasmic domain, such as the adaptor and 
integrin-activator protein talin, vinculin and paxillin, and the focal adhesion kinase (FAK) [28, 
29].  As the lamellipodium moves forward, the assembly of adhesions in focal complexes is 
driven by Rac, FAK, and paxillin. In the lamellum, Rac signaling decreases while Rho mediates 
the maturation of focal complexes into stable focal adhesions [5, 30]. 
After stabilization of focal adhesions, the tension needed for forward movement is generated 
by actomyosin contraction, which is linked to actin stress fiber formation. Rho and Cdc42 
cooperate to regulate cell body contraction via their respective downstream effectors, ROCK 
(Rho-associated protein kinase) and MRCK (myotonic dystrophy kinase-related Cdc42-
binding kinase) [31].  
The two human homologs ROCK1 and ROCK2 (hereafter referred to as ROCK) share 64% of 
amino acid sequence identity and are ubiquitously expressed. ROCK  directly phosphorylates 
the myosin regulatory light chain 2 (MLC2), which increases the ATPase activity of non-muscle 
myosin II (MYO2) and promotes actomyosin contraction. In addition, ROCK also 
phosphorylates a regulatory subunit of the myosin light chain phosphatase (MLCP) complex, 
thereby inactivating it and leading to increased MLC2 phosphorylation. Finally, ROCK activates 
LIMK1/2 (LIM kinase) which, in turn, phosphorylates and inactivates the actin-severing protein 
Cofilin1 [32, 33]. As cofilin is depolymerizing F-actin, its inactivation results in the stabilization 
of actin filaments within the cells.  
There are three homologous MRCK proteins in humans (henceforth referred to as MRCK), 
which are annotated with a Greek letter (α, β, γ). MRCKα and MRCKβ share 61% of amino 
acid identity and are ubiquitously expressed, while MRCKγ is less related (44% identity with 
MRCKβ) and its expression is restricted to fewer tissues [34]. MRCK and ROCK belong to the 
DMPK (Dystrophia myotonica protein kinase) family of kinases that phosphorylate MLC2 [35]. 
As their kinase domains have a high amino acid and structural homology [36], it is not 
surprising that MRCK targets the same substrates as ROCK, including MLC2, MLCP, and 
LIMK1 [37-39].  
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However, MRCK and ROCK differ in the spatial regulation of actomyosin contraction. 
Depending on the heavy chain isoform, MYO2 preferentially localizes to the cell periphery at 
the leading front (MYO2A) or to the cell body and the rear end (MYO2B) [40]. Interestingly, 
MRCKα/β are recruited to the lamella and the lamellipodia via adaptor proteins and regulate 
the activity of MYO2A, which contribute to the actomyosin retrograde flow in the lamella and 
contractile force generation [37, 41, 42]. By contrast, ROCK regulates the distribution of 
MYO2B and participates in tail retraction during migration [43, 44]. 
The release of cell rear adhesions is the last step of cell migration. Although the exact process 
remains elusive, it is mainly controlled by the combination of actomyosin contraction and an 
activation of the protease calpain, which is able to degrade focal adhesions proteins, including 
FAK, integrins, vinculin, and talin [45, 46]. 
 Epithelial and endothelial permeability  
Epithelial and endothelial tissues serve as semipermeable barriers between different 
compartments in the body. Their permeability is strictly regulated by Rho GTPases and 
depends on the integrity of tight junctions (TJs) and adherens junctions (AJs) [4, 47]. Both 
junctions are composed of adhesive proteins, which form intercellular zipper-like structures 
and interact intracellularly with the actin cytoskeleton.  
TJs consist of claudins and occludins, which are connected to the actomyosin cytoskeleton via 
ZO proteins (Zonula occludens) [48]. In endothelial and epithelial cells, RhoA is involved in the 
regulation of TJs by being locally activated by p114GEF, while the activity of Rac1 and Cdc42 
is downregulated [49, 50]. 
Endothelial AJs are composed of VE-cadherin (vascular endothelial-cadherin) that is 
associated with α/β catenins, which mediate the interaction with the actin cytoskeleton. Rac1 
and Cdc42 participate in the stabilization of AJs by sequestering IQGAP1, a protein preventing 
the interaction between catenin and actin [51, 52]. By contrast, RhoA contributes to AJs 
destabilization by actomyosin contraction through the activation of ROCK [53].  
Such barrier structures do not only participate in compartmentalization, resilience against 
mechanical stress, and control of substance diffusion within an organism, but also serve as 
the first line of defense against intruding pathogens. 
 Inflammatory response 
Pattern recognition receptors (PRRs) recognize pathogen-associated molecular patterns 
(PAMPs), such as lipopolysaccharides (LPS), which are conserved molecules specific to 
pathogens. Toll-like receptors (TLRs) are PRRs located at the plasma membrane of innate 
immune cells and, once activated, lead to an inflammatory response via downstream signaling. 
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Rac1 is required for the activation of NF-κB, a key regulator of cytokine production, triggered 
by TLR2. While RhoA is needed for the synthesis of proinflammatory cytokines by human 
monocytes downstream of TLR2 and TLR4 [54-56]. Nucleotide binding oligomerization 
domain-like receptors (NOD-like receptors, NLRs) are cytosolic PRRs. Two of these receptors, 
NOD1 and NOD2, participate in the recognition of bacterial products [57]. NOD1 is ubiquitously 
expressed, while NOD2 is mainly restricted to monocytes and epithelial cells of the intestine 
[58, 59]. Upon stimulation, NOD1 or NOD2 form a complex, the nodosome, with receptor-
interacting protein (RIP) and other binding partners. The assembly of the nodosome induces 
the activation of NF-κB and mitogen-activated protein (MAP) kinases, leading to 
proinflammatory and antimicrobial responses [60]. Rac1 activity is required for the activation 
of the NOD1 signaling pathway by peptidoglycan, and activated Rac1 is associated with NOD2 
in membrane ruffles [61, 62]. Other Rho GTPases also seem to be involved in nodosome 
activation as constitutively active RhoA and Cdc42 activate the NOD1 signaling pathway [61]. 
 Phagocytosis 
Complementary to the immune response mediated by PRRs, phagocytosis of pathogens by 
immune cells constitutes an effective defense mechanism by physically eliminating the threat 
and promoting an inflammatory response. Macrophages can take up bacteria via the Fc 
receptor (FcR) or via the complement receptor αMβ2, which is composed of the integrin subunit 
αM (CD11b) and β2 (CD18) [63, 64]. After opsonization of the bacteria by immunoglobulins, 
phagocytic cells bind the antibody via the Fc receptor present at the cell surface. The 
subsequent engulfment of bacteria always requires a re-organization of filamentous actin (F-
actin), which is regulated by Rho GTPases. Cdc42, Rac1, Rac2, and RhoG participate in FcR-
dependent phagocytosis, while RhoA does not seem to be required [65]. By contrast, the 
activity of RhoA and RhoG, but not of Rac1 or Cdc42, is required for phagocytosis mediated 
by αMβ2 integrins [66, 67]. 
 Bacterial killing 
  After bacterial uptake by phagocytes, the enzyme complex NADPH oxidase (NOX) 2 is 
assembled at the membrane of the phagosome and reduces oxygen to superoxide in the 
phagosomal lumen, thereby contributing to bacterial killing [68]. NOX2 is necessary for host 
defense mediated by neutrophils but is also playing a role in macrophages [69, 70]. Rac2, 
which is the Rac isoform predominantly expressed in human neutrophils, participates in the 
activation of NOX2 and thereby enhances the production of reactive oxygen species (ROS) 
[71, 72]. Additionally, Rac2 is involved in the release of primary granules by neutrophils, which 
contain enzymes capable of damaging the bacteria [73]. Murine neutrophils and macrophages 
deficient in Rac2 show a reduction in superoxide production [74, 75]. In human patients with 
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recurrent bacterial infection, immunodeficiency due to the expression of dominant negative 
Rac2 was reported [76, 77]. 
1.2 Bacterial effectors and toxins acting on Rho GTPase signaling. 
In order to hijack the Rho GTPase signaling cascade for their own benefit, bacteria have 
developed a wide variety of strategies. Many of the virulence factors manipulate Rho GTPases 
by mimicking or directly activating the eukaryotic regulatory proteins GEF, GDI, and GAP.  By 
contrast, some virulence factors directly target Rho GTPases by posttranslational 
modifications in order to prevent their interaction with downstream effectors or to inhibit their 
GTPase activity (Fig. 1.4). As most cellular processes need a fine balance between activation 
and inactivation, a strong stimulation or inhibition of the same pathway will often have similar 
consequences such as an alteration of the epithelial and endothelial barriers, phagocytosis 
inhibition, cell entry facilitation, or host immune defense manipulation [78]. 
 
Figure 1.4. Inactivation and activation of Rho GTPase signaling by bacterial toxins and 
effectors. 
Left panel: inactivation of small GTPases by posttranslational modifications, cleavage, GAP 
mimicry, GDI mimicry, or GEF inhibition. Right panel: activation of small GTPases by GEF 
activation, GEF mimicry, and inhibition of intrinsic GTPase activity. Adapted from [78]. 
 
1.2.1 Activation of Rho GTPases. 
 GEF mimicry. 
Effectors harboring a WxxxE motif activate small GTPases by mimicking GEF and promoting 
the exchange of GDP for GTP. Although they do not have an overall structural similarity with 
eukaryotic GEFs, they share a conserved structure element characterized by helices arranged 
in a V-shape and a catalytic loop [79, 80].  
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During infection, Salmonella Typhimurium translocates four different effectors harboring a 
WxxxE motif via its T3SS into the host cell. SopE and SopE2 are playing key roles in 
pathogenesis, as they are involved in cell invasion, the alteration of tight junctions, and the 
activation of NF-κB [81-83]. The two other effectors, SifA and SifB, localize to the Salmonella-
containing vacuole but do not induce any actin rearrangements [84]. In cultured cells, SopE 
induces the formation of lamellipodia by activating Rac1/2, Cdc42, and RhoG, while SopE2 
promotes filopodia formation by activating Cdc42 [85, 86]. While the function of SifB is still 
unknown, SifA plays an important role in intracellular survival and is required in vitro for the 
replication of Salmonella in macrophages [87, 88]. Surprisingly, SifA does not trigger 
nucleotide exchange although it interacts with GDP-bound RhoA, possibly due to the presence 
of an additional N-terminal domain [89].  
IpgB1 from Shigella flexneri activates Rac1 via the Elmo-Dock180 complex and directly 
activates Cdc42 to induce the formation of membrane ruffles and promote cell invasion [90-
92]. By contrast, IpgB2 activates RhoA as well as ROCK, leading to stress fiber formation and 
NF-κB activation [80, 90, 93, 94]. 
Another example of a GEF mimicry for Cdc42 is the Map effector of enteropathogenic E. coli 
(EPEC) and enterohemorrhagic E. coli (EHEC). Other effectors of EHEC, EspM1 and EspM2, 
are only activating RhoA and induce actin stress fiber formation [90, 95, 96]. Map and EspM 
are promoting pathogenesis by altering tight junctions [97, 98]. 
EspT, from EPEC and the closely related mouse pathogen Citrobacter rodentium, induces 
lamellipodia formation and membrane ruffles by activating Rac1 and Cdc42, thereby promoting 
pathogen invasion of non-phagocytic cells [99, 100]. 
 Interaction with GEF. 
Instead of incorporating a GEF activity, bacterial effectors may directly activate host GEFs to 
provoke a similar outcome. VopO, from Vibrio parahaemolyticus, is interacting with GEF-H1, 
thereby activating the RhoA pathway and leading to actin stress fiber formation. This effector 
is involved in disruption of the epithelial barrier, which could facilitate bacterial dissemination 
in the host. Interestingly, VopO does not share any sequence homology or motif with any other 
effectors and the mechanism of activation is still unknown [101]. 
 Posttranslational modifications. 
To date, all virulence factors that have been shown to activate Rho GTPases by 
posttranslational modifications target the same glutamine residue that is critical for the intrinsic 
GTPase activity. Thereby unable to hydrolyze GTP, the modified Rho GTPases stay 
permanently activated.  
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The TccC5 toxin produced by the insect pathogen Photorhabdus luminescens is ADP-
ribosylating RhoA, Rac, and Cdc42 by using NAD (nicotinamide adenine dinucleotide) as a 
substrate. The activation of the Rho GTPases affects the actin cytoskeleton and participates 
in phagocytosis inhibition [102, 103]. 
Another strategy to impair the GTPase activity is the deamination of the glutamine into glutamic 
acid. The toxin CNF1 (cytotoxic necrotizing factor) from pathogenic E. coli and Yersinia 
pseudotuberculosis catalyzes the deamination of Rho, Rac, and Cdc42 [104]. The coordinated 
activation of Rho, Rac, and Cdc42 promotes cell invasion, while the activation of RhoA by 
CNF1 of E. coli seems to play a role in the transgression of the blood-brain barrier [105]. 
The T3SS effector VopC, from Vibrio parahaemolyticus, is a homolog of the catalytic domain 
of CNF1. Although it only deaminates Rac1 and Cdc42, it is able to induce actin stress fiber 
formation and facilitates the internalization of the bacteria by non-phagocytic cells [106, 107].  
DNT (dermonecrotic toxin) from Bordetella bronchiseptica, is also able to activate the same 
GTPases as does CNF1 by deamination. However, it preferentially modifies the glutamine by 
trans-glutamination using polyamines such as spermine and spermidine, leading to the 
assembly of actin stress fibers and the formation of focal adhesions [108-110]. 
1.2.2 Inactivation of Rho GTPases. 
 GEF inhibition. 
In order to prevent FcR-mediated phagocytosis by mouse macrophages, EPEC and EHEC 
modulate GTPase signaling to their advantage by translocating the T3SS effector EspH into 
eukaryotic cells [111]. This effector directly binds to several Rho GEFs, which prevents their 
interaction with Rho GTPases. The absence of Rho GTPase activation ultimately induces focal 
adhesion disassembly, caspase-3 activation, and cytotoxicity in HeLa cells [112]. 
 GDI mimicry. 
GEF activation can also be prevented by effectors that mimic GDIs and sequester Rho 
GTPases in their inactive form in the cytosol. The two Yersinia T3SS effectors YopO and YpkA 
do so based on an interaction of their C-terminal domain with RhoA and Rac. YpkA participates 
in the virulence in Yersinia by blocking the Rac-dependent phagocytosis mediated by the FcR 
[113-115]. 
 GAP mimicry. 
In the translocated cocktail of T3SS effectors of Yersinia and several other pathogens are 
proteins that regulate the Rho GTPase pathways by mimicking GAPs, leading to enhanced 
GTP turnover and eventually to the inhibition of phagocytosis. One of the best-characterized 
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effectors with this function is YopE from Yersinia, which targets Rac1, RhoG, RhoA, and 
Cdc42. Excepting the arginine finger necessary to its GAP function, YopE has no structural 
similarity with eukaryotic GAPs. However, the structure of YopE is similar to ExoS and SptP 
from Pseudomonas aeruginosa and Salmonella enterica, respectively [116, 117]. Interestingly, 
ExoS, and likewise ExoT and AexT from Aeromonas, have a dual activity with an ADP-
ribosylating domain in addition of their GAP domain, which adds another level of complexity to 
the regulation of host signaling pathways [118-121]. 
 GTPase release from the plasma membrane. 
A further strategy to reduce levels of active small GTPases is to manipulate their membrane 
binding. YopT and LopT, two effectors from Yersinia and Photorhabdus luminescens, 
respectively, are related to papain-like cysteine proteases and have an antiphagocytic effect 
[122, 123]. They inhibit Rho GTPase signaling by cleaving Rho, Rac, and Cdc42 at their C-
termini, which releases them from the membrane and leads to their inactivation by host GDIs 
[123-126]. 
 Posttranslational modifications. 
To enhance the association of Rho GTPases with GDIs, C3 exoenzyme is a toxin secreted by 
Clostridium botulinum while other pathogens, such as Staphylococcus aureus, produce related 
exoenzymes [127-130]. C3 toxin uses NAD as a substrate to ADP-ribosylate GDP-bound 
RhoA, RhoB, and RhoC on an asparagine residue [131-133]. In addition to preventing the 
activation of Rho by GEFs, this modification also promotes the association of the GTPases 
with GDIs, thereby leading to the accumulation of the inactive GTPase in the cytosol where 
they get degraded by the proteasome [134, 135]. The C3 toxin is involved in many aspects of 
pathogenesis, such as migration and invasion of lymphocytes as well as phagocytosis [136, 
137] 
The large clostridial glucosylating toxins (LCGTs) are expressed by various bacteria of the 
genus Clostridium. These toxins disorganize the actin cytoskeleton and intercellular junctions, 
thus participating in the alteration of the intestinal barrier [138]. LCGTs are characterized by a 
DxD motif that is necessary to catalyze the glucosylation of Rho GTPases by using UDP-
glucose or UDP-N-acetylglucosamine as a substrate [139, 140]. The modification of a specific 
threonine residue prevents the interaction with downstream effectors, the activation by GEFs 
and at last the GTP hydrolysis [141-143]. Ultimately, GTP-bound GTPases accumulate at the 
membrane without being able to activate their downstream signaling partners [144]. 
VopS from Vibrio parahaemolyticus and IbpA from Histophilus somni belong to another set of 
effectors modifying small GTPases during infection. They catalyze the transfer of an AMP 
moiety (AMPylation) from ATP to a threonine or tyrosine residue of Rac, Cdc42, and RhoA. 
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Also in this case, the modification prevents the interaction between the Rho GTPases and their 
respective downstream effectors, leading to the collapse of the actin cytoskeleton and the 
disruption of actin-dependent immune functions such as phagocytosis [145, 146]. In addition, 
VopS prevents the generation of superoxide by NOX2 and the activation of an NF-κB-mediated 
immune response [147]. The enzymatic activity of VopS and IbpA is linked to the presence of 
a FIC domain.  
Bacteria of the genus Bartonella also encode a multitude of Fic proteins that are translocated 
via a T4SS in the host cell during infection. Unpublished results indicate that several Bartonella 
effector proteins (Beps) modify Rho GTPases by transferring an AMP moiety catalyzed by their 
FIC domain. As they target the same tyrosine residue as IbpA, this modification is presumably 
preventing the activation of downstream effectors.  
1.3 Bacteria of the genus Bartonella 
The genus Bartonella is composed of gram-negative, facultative intracellular pathogens 
belonging to the class of α-proteobacteria. B. bacilliformis (Bba) is a human pathogen 
responsible for Carrion’s disease, which is characterized by an acute phase with hemolytic 
anemia (Oroya fever) and a subsequent chronic phase associated with multiple 
vasoproliferative lesions on the skin (Verruga Peruana) [148]. Recently, Bartonella 
ancashensis (Ban) has been discovered as a new human pathogen causing Verruga Peruana 
[149, 150]. Bartonella quintana (Bqu) also has human as its reservoir host in which it 
establishes a persistent infection. Bqu is the causative agent of trench fever, leading to a five 
days cyclic fever, bone pain, headache and lasting bacteremia. B. henselae (Bhe) is the most 
common species infecting humans although its natural host is the cat, which displays an 
asymptomatic intraerythrocytic bacteremia. After incidental transmission to humans via a bite 
or scratches, immunocompetent individuals develop the so-called cat scratch disease that 
leads to lymphadenopathy and fever. In immunocompromised humans, the infection by Bqu 
and Bhe leads to bacillary angiomatosis with multiple vasoproliferative tumors [151]. 
1.3.1 Infection cycle of Bartonella. 
The transmission of Bartonella between natural hosts can occur by direct contact or via blood-
sucking arthropods, in which the bacteria are present in the gut (Fig. 1.5). The infection cycle 
starts with the dermal inoculation via contaminated feces. It is speculated that the bacteria 
reach a dermal niche rich in intrinsically migratory dendritic cells. Subsequently, the infected 
dendritic cells are used by Bartonella as carriers in order to disseminate inside the host. There, 
bacteria supposedly invade endothelial cells to form the blood-seeding niche, from where they 
are synchronously released into the bloodstream. For Bartonella species of the lineage 4 
(lineages: see below, chapter 1.3.2), the adhesion to red blood cells is mediated via the Trw 
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T4SS and results in their colonization. Finally, bacteria replicate two or three times inside a 
vacuole and reside for the remaining lifespan of the erythrocytes in their lumen. The cycle is 
completed once Bartonella colonizes the gut of another arthropod after being taken during a 
blood meal from the infected host [152-154].  
 
Figure 1.5. Model of Bartonella infection cycle in the reservoir host. 
Bartonella replicates in the arthropod vector and is excreted in their feces (1). The dermis of 
the reservoir host is inoculated via a small lesion or abrasion (2). Bacteria colonize a “dermal 
niche”, which is proposed to be populated by dendritic cells (3) and which facilitates bacterial 
dissemination in the host (4). Endothelial cells are believed to be colonized and to form a “blood 
seeding niche” (5), from which the bacteria would be periodically released into the bloodstream 
to invade erythrocytes and re-infect the blood-seeding niche (6). After intra-erythrocytic 
replication (7), Bartonella persists in the red blood cells (8) before being taken up by another 
bloodsucking arthropod, which completes their infectious cycle (9). Adapted from [155]. 
1.3.2 Phylogeny of the genus Bartonella. 
The Bartonella genus contains over 30 species that are separated into four different lineages 
(L1-L4) (Fig. 1.6) [156]. The members of L1 are exclusively human pathogens, while the 
reservoir hosts of L2 are limited to ruminants, which suggests a low capacity to adapt to novel 
hosts. Additionally, the high virulence of B. bacilliformis associated with significant morbidity 
indicates a low adaptation to their human host. However, most Bartonella species of L3 and 
L4 adopt a stealth infection strategy that results in long-lasting infections that do not cause 
obvious disease symptoms in the reservoir host [151]. The variety of mammalian hosts is 
associated with the high diversity of species, which is presumably due to adaptive radiation in 
the evolution of Bartonella. This process and the host adaptability are thought to be significantly 
shaped by the VirB/D4 T4SS, which was several times independently acquired through 
horizontal gene transfer [151, 157].  
- Introduction - 
15 
 
 
Figure 1.6. Phylogenetic tree of the genus Bartonella.  
Phylogeny of Bartonella based on the nucleotide sequence alignment of 509 concatenated 
core genes. Lineages encoding a VirB/D4 T4SS are highlighted in grey. Corresponding 
reservoir hosts are indicated on the right-hand side of the tree. Adapted from [156]. 
1.3.3 VirB/VirD4 type IV secretion system. 
The T4SS are ancestrally related to conjugation systems and play an important role in the 
infection cycle of several bacterial pathogens such as Agrobacterium tumefaciens, Bordetella 
pertussis, Legionella pneumophila, Helicobacter pylori, Brucella, and Bartonella [158, 159].  
Bartonella species of the lineages 3 and 4, as well as B. ancashensis (L1), harbor a VirB/VirD4 
T4SS involved in the translocation of bacterial effectors into the host cell during infection. This 
secretion system is composed of 12 proteins encoded by the virB operon and the virD4 gene. 
The coupling protein VirD4 is an ATPase mediating the interaction between the T4SS and its 
substrates, such as bacterial effectors [160]. It also participates in providing energy for the 
assembly of the machinery and effector translocation with two other ATPases, VirB4 and 
VirB11 [161, 162]. VirB3 together with VirB6-10 form the translocation channel of the T4SS, 
spanning both bacterial membranes. VirB7, VirB9, and VirB10 compose its core complex, 
while VirB2 and VirB5 assemble to form the pilus structure [163, 164].  
Bartonella species of the lineage 4 encode a second T4SS in the trw locus, which is lacking a 
coupling protein. Although the Trw T4SS is probably not able to translocate bacterial effectors, 
it is required for red blood cell invasion and the establishment of an intraerythrocytic bacteremia 
[165]. 
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1.3.4 Bartonella effector proteins (Beps). 
Beps share a common domain architecture in which the C-terminus consists of at least one 
BID (Bep intracellular delivery) domain and a positively charged tail, while the N-terminus is 
more divergent and can harbor additional domains (Fig. 1.7).  
The majority of all Beps carries an N-terminal FIC (filamentation induced by cAMP) domain, 
indicating its central role in pathogenesis. The FIC-BID domain organization represents the 
ancestral effector gene from which other effectors derived via gene duplication, domain 
shuffling, and sequence variation [166]. 
A subset of effectors contains tandem-repeat tyrosine-phosphorylation motifs that serve as 
phosphorylation sites for host kinases. Once modified, some of these effectors recruit host 
proteins carrying a SH2 domain, which can dock to the phosphorylated tyrosines. This 
presumably leads to the modulation of cellular processes to the advantage of Bartonella [167].  
 
Figure 1.7. Domain architecture of Bartonella effectors proteins.  
Domain architecture of Beps found in B. ancashensis, B. clarridgeiae (lineage 3 - L3) and 
B. henselae (lineage 4 – L4).  The effectors absent in these species are shown from B. 
rochalimae (Bep4) or B. tribocorum (BepH and BepI). FIC domains are colored in orange, BID 
domains in purple and BiaA (Bep-interacting antitoxin) in blue. Predicted tyrosine 
phosphorylation motifs are depicted as vertical green lines. Taken from [156]. 
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 BID domain 
The BID domain, together with the positively charged tail, is an evolutionary conserved bipartite 
translocation signal that is also present in conjugative relaxases [168]. 3D structures indicate 
that the domain is folded into an antiparallel four-helix bundle, which is characterized by the 
presence of a positively charged hook at the top [169]. Despite some conserved residues 
exposed on the surface, the BID domain displays significant variability and could mediate 
specific protein-protein interactions with host proteins.  
The presence of additional BID domains in Beps of the lineage 4 and Ban indicates that during 
evolution they might have acquired functions beyond serving the effector translocation 
process. The BID domains of BepA, BepE, BepF, and BepG, have been shown to play a 
significant role during Bartonella infection [170-172]. However, the molecular mechanisms 
have been identified only for the BID domain of BepA, which binds the host adenylyl cyclase. 
The interaction increases the enzymatic activity of the cyclase by GαS and thereby leads to 
the elevation of the intracellular cyclic AMP (cAMP) concentration [173]. Ultimately, the 
translocation of BepA by Bartonella protects infected cells against apoptosis [174]. 
 FIC domain 
Fic proteins form a family of proteins harboring a conserved FIC domain catalyzing 
posttranslational modifications of a target protein. The acronym FIC originates from 
“filamentation induced by cAMP”, which corresponds to the phenotype caused by a mutation 
in the gene encoding the first identified Fic protein [175]. 
FIC domains are characterized by a core composed of six α-helices and containing a signature 
FIC motif (HxFx(D/E)GNGRxxR, hereafter referred to as the canonical FIC motif) [176]. This 
motif plays a key role in the transfer of a phosphate-containing group on residues containing 
a hydroxyl group (Thr, Ser, Tyr). Most of the modifications that have been described are using 
ATP as a substrate to add an AMP moiety (AMPylation) on a target protein.  
However, the activity of Fic proteins is not restricted to AMPylation and some Fic proteins are 
able to use various substrates to catalyze other posttranslational modifications. AnkX from 
Legionella pneumophila transfers a phosphocholine moiety onto small GTPases of the RAB 
family, which leads to the modification of vesicular trafficking and promotes bacterial survival 
[177]. The GTPase-related domain of the bacterial elongation factor Tu (EF-Tu) is 
phosphorylated by the Fic protein Doc of E. coli [178]. It is suggested that the modification of 
EF-Tu plays a role in the formation of persisters and the organization of the bacterial 
cytoskeleton [179-181].  
Fic proteins are not only targeting proteins with a domain related to small GTPases. AvrAC 
from the plant pathogen Xanthomonas campestris transfers a UMP moiety to two different 
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plant kinases that are involved in immune defense. Interestingly, AvrB from Pseudomonas 
syringae lacks all conserved residues of the FIC motif, although it shares the same topology 
with other Fic proteins [182]. Despite the absence of the catalytic residues, this effector induces 
the phosphorylation of the plant immune regulator RIN4 by RIPK [183]. Although the vast 
majority of proteins with a FIC domain is found in bacteria, they are present in all domains of 
life. HYPE (huntingtin-interacting protein E) is the only human Fic protein and has the 
particularity to form homodimers via its FIC domain [184]. HypE orthologs AMPylate the 
ATPase domain of BiP (also known as GRP78), a chaperone in the endoplasmic reticulum 
playing an important role in the unfolded protein response [185, 186]. 
In Bartonella species of the lineages 3 and 4, preliminary results indicate that the FIC domains 
of Bep1, BepA, and Bep197 share a conserved function by AMPylating Rho GTPases [187] 
(and unpublished results by Isabel Sorg and Jenifer Sen). Bep2 also targets the cytoskeleton 
by directly AMPylating vimentin and tubulin in vitro [188, 189]. However, the consequences of 
these modifications during infection remain elusive. For the majority of Beps harboring a FIC 
domain, the enzymatic activity and the host target remain largely unknown. 
 Class I Fic proteins are reminiscent of toxin-antitoxin modules 
Most proteins of the Fic family can be attributed to one of three different classes according to 
the configuration of their regulatory module. This module is characterized by an inhibitory α-
helix (αinh) with a conserved (S/T)xxxE(G/N) motif. The invariant glutamate modifies the 
conformation of the substrate in the active site, thereby inhibiting the posttranslational 
modification of the target protein [190]. While in class II and class III Fic proteins the inhibitory 
helix is directly linked to the N- or the C-terminus of the proteins, respectively, αinh of class I Fic 
proteins is present as a distinct protein. Class I Fic proteins are exclusively present in bacteria 
and represent 5 % of the bona fide AMPylation-competent Fic proteins. This arrangement of 
Fic protein and αinh is reminiscent of toxin-antitoxin modules [176]. Hence, the regulatory 
module of class I Fic proteins is often referred to as the antitoxin. The spatial separation of the 
inhibitory helix and the Fic protein allows to remove the regulatory module and thereby to tune 
the activity of the Fic protein. In absence of αinh the expression of class I Fic proteins is highly 
toxic to bacteria. 
VbhT of B. schoenbuchensis is the best-characterized class I Fic protein of Bartonella. When 
expressed in E. coli, VbhT inhibits bacterial growth by AMPylating DNA gyrase and 
topoisomerase IV [191]. The activity of VbhT is repressed by its interaction with VbhA antitoxin, 
which competes with ATP binding [190]. Bep1, Bep2, and BepA also belong to class I Fic 
proteins, while Bep3 and Bep4 from the lineage 3 belong to the class II [188, 189, 192]. For 
many other Beps, the attribution to the different classes of Fic proteins is not yet elucidated. 
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1.4 Bartonella effector protein C (BepC) 
One Bep for which the Fic protein class affiliation had not been studied is BepC. BepC is 
present in all Bartonella species of the lineage 4, suggesting an important role in pathogenesis 
and making it a prime candidate for further investigations. BepC displays the ancestral effector 
architecture consisting of a highly conserved N-terminal FIC domain (Alignment 1.1) and a 
more divergent C-terminal BID domain. A central OB (oligosaccharide binding) fold is also 
present between the FIC and BID domains of BepC. Its five-stranded β-barrel structure is found 
in many Beps and conjugative relaxases, suggesting that it has been acquired together with 
the BID domain during evolution [187]. Although its role remains elusive, the OB fold could 
simply serve as a linker as well as it may have acquired a new function. 
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Alignment 1.1. FIC domain of BepC (amino acids 1-220) from Bartonella species of the 
lineage 4. 
The first 19 amino acids of BepCBra are not displayed in this alignment. The first α-helix 
(positions 1-18) is framed in cyan, the Flap region in green and the FIC motif in magenta. 
Highlighted residues have a sequence identity of at least 75%. 
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Alignment 1.2. N-terminus, Flap region, and FIC motif of BepC and BepA from Bartonella 
species of the lineage 4. 
Comparison of the sequences of the N-terminus, the Flap and the FIC motif of BepC (framed 
in alignment 1) with the corresponding sequences of BepA. Highlighted residues have a 
sequence identity of at least 75%. 
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1.4.1 Structural studies of the BepC FIC domain. 
The FIC domain of BepC from Bartonella tribocorum (BepCBtr) was co-crystallized with AMP-
PNP, a non-hydrolysable analog of ATP, in the active site (Fig. 1.8). The FIC domain is 
organized in two lobes separated by a channel that is surrounded by highly conserved 
residues. The nucleotide occupies the central part of the channel and is framed by a β-hairpin 
(Flap) on one side and by the FIC motif on the other side. 
In Fic proteins with a canonical FIC motif (HxFx(D/E)GNGRxxR), the conserved histidine 
activates the hydroxyl group of a target protein residue for a nucleophilic attack on the 
substrate phosphodiester bond. The invariant arginine residues directly stabilize the negative 
charges of the nucleotide phosphate, while an ion of magnesium is mediating the interaction 
with the negatively charged residue in the FIC motif (D/E) (Fig. 1.9A).  
BepC is characterized by a non-canonical FIC motif (HxFxKGNGRxxR), which differs from the 
canonical motif in a lysine instead of the acidic residue (D/E). Alternatively, the lysine is 
replaced by a threonine residue in two Bartonella species (Alignment 1.2).  The 3D structure 
indicates that the lysine is directly interacting with the α- and β-phosphates of the ATP analog 
(Fig. 1.9B). The superimposition of the ATP crystallized in VbhT and the AMP-PNP that is 
present in the active site of BepCBtr suggests that the α-phosphate is in the right position to be 
targeted by a nucleophilic attack (Fig. 1.9C). All the other residues composing the FIC motif 
are strictly conserved, suggesting their importance for the function of BepC. 
A β-hairpin located next to the active site and referred to as the Flap is present in all Fic 
proteins, Doc of E. coli excluded. This region participates in the docking of the target protein 
by forming an intermolecular antiparallel β-sheet, which leads to the positioning of the target 
hydroxyl into the active site [182, 193, 194]. In BepC, the residues composing the Flap region 
are highly conserved except for three residues forming the extremity of the loop. The sequence 
strongly differs from the Flap of BepA, the only other Fic Bep present in all Bartonella species 
of the lineage 4, potentially indicating a specific role in host protein binding (Alignment 1.2). 
Some Fic proteins, such as IbpA and VopS, contain an additional N-terminal domain involved 
in target recognition [193, 195]. Although BepC does not harbor this distinct domain, its first α-
helix (residues 1-18) contains 14 residues highly conserved throughout different Bartonella 
species (Alignment 1.2). Eight of these residues are also highly conserved between BepC and 
BepA, which could indicate an important function in structural organization. However, this 
conserved patch exposed at the protein surface and localized next to the active site might also 
participate in target binding (Fig. 1.8). It is interesting to note that only BepC from B. 
rattimassiliensis has an extended N-terminus while this is a common feature among BepA 
proteins of different species.  
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Figure 1.8. Crystal structure of the FIC domain of BepCBtr (3-209) coordinating a 
nucleotide analog. 
A. Surface representation of the crystal structure of BepCBtr with AMP-PNP, a non-
hydrolysable derivative of ATP, in the active site. The red color gradient represents pairwise 
identity based on 14 alignments of BepC from different Bartonella species. The most 
conserved residues are represented in red and less conserved residues in white. B. Cartoon 
representation of (A) C. Reproduction of (A) with the first α-helix (amino acids 3-18) in cyan, 
the Flap region in green and the FIC motif in magenta. D. Cartoon representation of (C). 
Structure solved by the Seattle Structural Genomics Center for Infectious Disease (SSGCID) 
consortium. Models done in Pymol in collaboration with Markus Huber. 
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Figure 1.9. BepCBtr binds an ATP derivative in an AMPylation-compatible configuration. 
Cartoon representation of the FIC domain of BepCBtr. The core residues of the FIC motif are 
represented as yellow sticks. A. Crystal structure of the FIC domain of VbhT with ATP in the 
active site. Mg2+ mediates the interaction between the glutamate of the FIC domain (highlighted 
in red) and the phosphates of the ATP. B. Crystal structure of the FIC domain of BepCBtr with 
AMP-PNP in the active site. The conserved lysine (in red) directly interacts with the phosphate 
of the ATP derivative. The Flap is partially highlighted in blue. C. Superimposition of the ATP 
of VbhT (in black) and the crystal structure of the FIC domain of BepCBtr with AMP-PNP. 
Structure solved by the Seattle Structural Genomics Center for Infectious Disease (SSGCID) 
consortium. Models done by Frederic Stanger. 
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1.4.2 BepC in the context of pathogenesis. 
The role of BepC during infection has so far been investigated in the context of other effectors, 
primarily BepE and BepF. 
 Cell fragmentation induced by BepC. 
BepC induces cell fragmentation of infected endothelial cells due to a rear-end detachment 
defect during migration [170]. However, the presence of BepE is able to suppress this 
deleterious effect mediated by BepC. BepE is composed of a N-terminus containing tandem-
repeat tyrosine-phosphorylation motifs and two C-terminal BID domains. Interestingly, the 
phosphotyrosine-containing motifs, which recruit host signaling proteins with a SH2 domain 
[167], do not contribute to the phenotype reduction. By contrast, the two BID domains or the 
C-terminal BID domain alone are able to overcome cell fragmentation mediated by BepC. The 
molecular mechanism underlying this process and the putative host target of BepE remain 
elusive. As BepE interferes with the inhibitory effect of a C3-toxin derivative that inactivates 
RhoA, RhoB, and RhoC, it is conceivable that BepE interferes with the RhoA pathway acting 
on the cytoskeleton. The recruitment of BepE to cell-cell contacts and to the rear-end of 
migrating cells is supportive of an effect on the cytoskeleton. In vivo, rats infected intradermally 
(i.d.) with B. tribocurum lacking bepD and bepE (Btr ΔbepDE) do not develop bacteremia, while 
intravenous inoculation produces a long-lasting infection. Complementation with full-length 
BepE or the BID domains only restored the ability of Btr ΔbepDE to establish bacteremia after 
i.d. infection [170]. Based on these results, BepE plays an important role during the dermal 
stage of infection and is required to reach the blood. For this transition from the dermis to the 
blood, the ancestrally related Brucella abortus and also Bordetella bronchiseptica are known 
to use dendritic cells as a shuttle for the bacterial dissemination in the host [196, 197]. Thus, it 
is thinkable that Bartonella is able to take the same route. In such a scenario, it is proposed 
that the presence of BepE is necessary to ensure the migration, as BepC impairs cell motility 
in vitro. 
 BepC induces, together with BepF, invasome formation 
As it is the case on the organismic level, the detailed understanding of the Bartonella infection 
process is also limited on the cellular level. In vitro investigations with Bartonella henselae 
suggest a multi-step invasion process, the so-called invasome formation, during which large 
clusters of bacteria are engulfed via actin-rich protrusions [198] (Fig. 1.10). The term invasome 
corresponds to the host cellular structure characterized by a compact actin ring composed of 
stress fibers that participate in the internalization of a bacterial aggregate. 
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Figure 1.10. Bhe induces invasome formation. 
B. henselae binds to the extracellular matrix (ECM) via outer membrane proteins (1) and to the 
plasma membrane of the host cell (2). Individual bacteria are internalized in Bartonella 
containing vacuoles (BCVs), which localize to the periphery of the nucleus (3). After 
translocation of Beps into the cytoplasm of the host cell, the uptake of single bacteria is 
inhibited (4) and leads to the formation of large bacterial aggregates at the surface of the 
plasma membrane (5). Such bacterial clusters are engulfed via actin-rich protrusions to form 
an invasome (6). Taken from [199]. 
 
Invasome formation can be triggered by different effectors, either by BepG alone or by BepC 
in collaboration with BepF [172, 200]. It has been established that out of the three BID domains 
in BepF the two first ones are sufficient to give rise to invasome formation together with BepC. 
Interestingly, the invasome formation ability of the first BID domain depends on a WxxxE motif, 
which is found in GEF-mimicking bacterial effectors (see chapter 1.2.1.1). The function of BepF 
can be substituted by the expression of constitutively active Rac1 or Cdc42, suggesting that 
the effector is tuning their activity during the infection process. Speaking for such a stimulation 
are the formation of filopodia-like structures and membrane protrusions in cultured cells in 
presence of BepF [171] and that invasome formation requires WAVE, WASP, and Arp2/3, 
which are downstream effectors of Rac1 and Cdc42 signaling. Additionally, cofilin 1, a protein 
controlling the actin turnover and that is regulated by Rho and Cdc42, is also required for BepC 
and BepF-triggered invasome formation [200]. However, the exact molecular mechanism to 
initiate invasome formation is not fully resolved. The current model is based on the finding that 
BepC together with BepF (as well as BepG alone) lead to the inhibition of BCV formation 
following the endocytic uptake of single bacteria [172, 200]. The accumulation of B. henselae 
at the cell membrane induces a subsequent clustering of Bhe-bound integrin β1 and 
concomitant actin rearrangements, which ultimately leads to invasome formation. This 
hypothesis is supported by the requirement of integrin β1, talin1, paxillin, vinculin, FAK, and 
Src, which are all major contributors to integrin β1-mediated outside-in signaling and thus to 
invasome formation [201]. The actual correspondence to this model needs corroboration and 
the physiological role of invasome formation remains to be investigated. It may be speculated 
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that bacteria transcytose in invasomes to cross the endothelial barrier in order to be released 
into the bloodstream [159]. The clustering of Bhe observed in vitro resembles in vivo 
aggregates of Bartonella found in the proximity of proliferating endothelial cells of bacillary 
angiomatosis lesions [202].  
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Started in December 2013, the aim of my thesis was to address the function of one of the most 
conserved effectors within Bartonella species of the lineage 4, named BepC. Although it was 
established that BepC participates in the internalization of bacterial aggregates and impairs 
host-cell migration, the underlying cellular mechanisms, as well as its host target(s), have not 
yet been identified.   
To understand BepC involvement in Bartonella pathogenesis, I first investigated the role of this 
effector in the context of bacterial infection by using fluorescence microscopy. From these 
experiments, I could establish that BepC induces rearrangements of the host-cell actin 
cytoskeleton. Following this result, I aimed to demonstrate by which mechanism BepC triggers 
the actin phenotype by using molecular biology techniques, which revealed the activation of a 
Rho GTPase signaling pathway by host protein interaction. 
Additionally, I attempted to determine a possible enzymatic activity for the FIC domain of BepC 
by applying various biochemical techniques.  
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3.1 Results  
3.1.1 BepC is responsible for actin cytoskeleton rearrangements during 
infection of human cells. 
Previous studies have revealed that BepC of Bartonella henselae (BepCBhe) affects the actin 
cytoskeleton during infection. The ectopic expression of mCherry-BepCBhe in Human Umbilical 
Vein Endothelial Cells (HUVECs) induces cell fragmentation due to a deficiency in rear-end 
detachment during migration, which is abolished by another effector, BepE [1]. BepCBhe, 
together with BepFBhe, has been also shown to trigger the internalization of large bacterial 
aggregates in HeLa cells and HUVECs [2, 3]. The uptake is associated with the formation of a 
cellular structure characterized by an actin ring, known as invasome [4]. 
To study the effect of BepC in the context of infection and without having interferences from 
other effectors, a plasmid encoding BepC (pbepC) has been conjugated in a strain of Bhe in 
which all genes encoding Beps have been deleted (Bhe ΔbepA-G). The ectopic expression of 
BepC is under control of an IPTG-inducible promoter. As an in vitro infection model, human 
cells were infected with either Bhe ΔbepA-G expressing BepC or, as a negative control, with 
Bhe ΔbepA-G carrying the empty plasmid (pEmpty). After incubation and fixation, cells were 
stained for DNA, F-actin, and Bartonella before being analyzed by fluorescence microscopy. 
As Bartonella is associated with vascular tumor formation and endothelial cells are proposed 
to form the blood seeding niche [5, 6], we infected HUVECs as an in vitro model to mimic host 
cell infection (Fig. 3.1). In comparison with uninfected cells, HUVECs infected with Bhe 
ΔbepA-G pEmpty did not show any morphological change. As previously reported [7], 
Bartonella were distributed around the nucleus, indicating that Beps are not required for the 
internalization of the bacteria in HUVECs. The infection with Bhe ΔbepA-G expressing Flag-
tagged BepCBhe led to a reduction of cell density, suggesting cytotoxic effect, detachment, cell 
growth inhibition, or a combination of these factors. The remaining cells showed actin 
rearrangements, in accordance with previous results [1]. 
As BepC also contributes to invasome formation in HeLa cells [2, 3], we were wondering 
whether it would also induce actin rearrangements in this cell line. To verify it, we infected 
HeLa cells with Bartonella expressing BepCBhe using the same infection conditions as for 
HUVECs (Fig. 3.1). HeLa cells did not show a reduced cell density but displayed strong actin 
rearrangements such as stress fibers, which make them a suitable model to study the actin 
phenotype mediated by BepC. Interestingly, the bacteria were not equally distributed around 
the nucleus but formed aggregates. However, these bacterial clusters were different from 
invasomes as they were not surrounded by an actin ring. Although it is not clear whether the 
bacteria are extracellular or intracellular, this result suggests that, during invasome formation, 
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BepC may induce the clustering of bacteria at the surface of the host cell while BepF could be 
required to complete the internalization. 
In EA.hy926, a hybrid cell line with endothelial characteristics, BepCBhe also induced actin 
rearrangements and bacterial clustering (Fig. 3.1) but not as strong as the phenotype observed 
in HeLa cells. There was also no visible reduction of cell density in contrast to HUVEC infection. 
The reason why these cells are less sensitive to the effect of BepCBhe remains unclear.  
For each cell type, the intensity of the actin phenotype was proportional to the multiplicity of 
infection (MOI), the time of incubation, and the concentration of IPTG used to induce bepC 
expression (Fig. 3.S1). The influence of these parameters suggests that the effect on actin 
rearrangement directly correlates with the amount of BepC translocated inside the host cell. 
3.1.2 BepC from different Bartonella species induces actin stress fiber 
formation in HeLa cells. 
BepC is highly conserved among the Bartonella species of the lineage 4, which suggest a 
critical role in pathogenesis. To determine if the effect of BepC on the actin cytoskeleton is 
conserved among Bartonella, we infected HeLa cells with Bhe ΔbepA-G ectopically expressing 
BepC of Bqu, Btr, Bta, and Bgr. After 48 hours of infection, cells infected with Bhe ΔbepA-G 
expressing BepC of Bhe, Bqu, Btr, and Bta displayed actin stress fiber formation with different 
levels of intensity (Fig. 3.2). BepCBqu induced the strongest phenotype and generated some 
cell fragmentation while BepCBgr did not trigger any actin rearrangement during infection. 
Interestingly, only BepCBhe and BepCBqu expression resulted in the formation of bacterial 
aggregates on top of the cells. 
Although BepCBgr did not have an effect on the actin cytoskeleton, our data suggest that 
triggering actin rearrangements is a shared function among BepC of several Bartonella species 
of the lineage 4. Considering that the level of ectopic expression in Bhe ΔbepA-G was 
comparable (data not shown), the variations in phenotype intensity are probably related to a 
difference in function, translocation efficiency, host specificity, or a combination of these 
factors. 
As BepCBhe induces invasome formation together with BepFBhe in HUVECs and HeLa cells [2, 
3], we were interested to test whether BepC of other Bartonella species could also participate 
in this phenotype. To answer this question, we co-infected HeLa cells with Bhe ΔbepA-G 
expressing BepC from different species and Bhe ΔbepC,G, a strain that is expressing BepF 
but depleted of BepG, as this effector is inducing invasome formation by itself [7]. 
Surprisingly, only HeLa cells co-infected with Bhe ΔbepC,G and Bhe ΔbepA-G expressing 
BepCBhe triggered invasome formation (Fig. 3.3). Even BepCBqu, which also induced bacterial 
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aggregation on top of the cells (Fig. 3.2), was not able to participate to invasome formation. 
However, the co-infection with Bhe ΔbepC,G led to a reduction of actin stress fibers in all 
conditions. This observation suggests that other Beps translocated by Bhe ΔbepC,G, probably 
BepEBhe but also possibly other effectors, interfere with actin rearrangements mediated by 
BepC of Bhe, Bqu, Btr, and Bta. 
Overall, these results suggest that inducing actin rearrangements is not sufficient to participate, 
together with BepFBhe, in the uptake of bacterial clusters via invasome formation. 
3.1.3 The FIC domain of BepC is required for actin rearrangements. 
As BepC is composed of a N-terminal FIC domain, a central OB fold and a C-terminal BID 
domain, we wanted to determine which regions of the protein are required for the actin 
phenotype. Knowing that Fic proteins catalyze posttranslational modifications [8], we assumed 
that BepC might enzymatically modify a host protein via its FIC domain and thereby induces 
actin rearrangements. 
First, we infected HeLa cells and HUVECs with Bhe ΔbepA-G expressing BepCBhe without its 
FIC domain (BepCBhe OB-BID). The absence of actin stress fibers in HeLa cells (Fig. 3.4) and 
the absence of cell density reduction in HUVECs (Fig. 3.5) indicated that the FIC domain of 
BepC plays a critical role in these phenotypes. 
The next step was to analyze whether a potential enzymatic activity would be required to 
mediate the actin phenotype. Therefore, HeLa cells and HUVECs were infected with Bhe 
ΔbepA-G expressing BepCBhe harboring mutations in the conserved FIC motif. 
Since the exchange of the conserved histidine for an alanine is sufficient for some Fic proteins 
to lose their enzymatic activity [9], a similar mutation (H146A) was introduced into BepCBhe. 
Infection of HeLa cells (Fig. 3.4) with Bhe ΔbepA-G expressing BepCBhe H146A resulted in 
actin stress fiber formation with a similar intensity to BepCBhe wild-type. This suggested that 
the conserved histidine is not required for actin rearrangement. 
However, some Fic proteins keep a reduced enzymatic activity in vitro despite the mutation of 
the conserved histidine [10]. Thus, we also mutated the lysine and the two arginines that were 
shown to interact with the ATP derivative (Fig. 1.9) in addition to the mutated histidine 
(BepCBhe**** = BepCBhe H146A, K150A, R154A, R157A). Surprisingly, HeLa cells (Fig. 3.4) 
and HUVECs (Fig. 3.5) infected with Bhe ΔbepA-G expressing BepCBhe**** still showed strong 
actin rearrangements. The persistence of the phenotype suggests that a conserved FIC motif, 
and therefore a functional catalytic site, was not essential for the disruption of the actin 
cytoskeleton. Thus, it is unlikely that actin rearrangements result from an enzymatic activity 
catalyzed by BepC. 
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As BepC harbors a non-canonical FIC motif and has a lysine in place of an acidic residue 
(Alignment 1.2), it might have lost its enzymatic activity. Therefore, we analyzed whether BepC 
with a canonical FIC motif, and thus a putative AMPylation activity, would have an effect on 
actin stress fiber formation. To do so, a canonical FIC motif was restored by exchanging the 
lysine for a glutamate (BepCBhe K150E). As observed for the other FIC motif mutants, the actin 
phenotype was still visible in HeLa cell infected with Bhe ΔbepA-G expressing BepCBhe K150E 
(Fig. 3.4). Assuming that an enzymatic activity would have been restored with a canonical FIC 
motif, this result suggests that it would not interfere with the effect of BepC on the actin 
cytoskeleton. 
Since the conserved FIC motif does not seem to be required for actin rearrangements but the 
deletion of the FIC domain abolished the phenotype, we wanted to investigate which regions 
of the FIC domain would be functionally relevant. Considering the Flap as one of the most 
conserved regions of BepC (Alignment 1.2) and that this region participates in the interaction 
between Fic proteins and their host target [11-13], we proposed that it could induce actin 
rearrangements by interacting with a putative host protein. 
To test this hypothesis, we exchanged 10 amino acids of the Flap of BepCBhe (AMRPKGMRVP) 
for the corresponding residues of the Flap of BepABhe (EMKRTGWKNA), which differs by eight 
amino acids (Alignment 1.2). HeLa cells (Fig. 3.4) and HUVECs (Fig. 3.5) infected with Bhe 
ΔbepA-G expressing BepCBhe (Flap BepABhe) were still displaying actin rearrangements, 
indicating that a conserved Flap is not required for actin rearrangements. 
Another highly conserved region of the FIC domain of BepC is the first α helix, which contains 
tyrosine residues that could be targeted by auto-modification (Alignment 1.2). To check 
whether this region plays a role in actin rearrangements, we infected HeLa cells with Bhe 
ΔbepA-G expressing BepCBhe without the helix (BepCBhe 19-532). In comparison with BepCBhe 
wild-type, the deletion of this region did not show an influence on actin stress fiber formation 
(Fig. 3.4). 
In summary, the FIC domain of BepC is required for both actin stress fiber formation and cell 
fragmentation. However, the FIC motif does not seem to participate in actin rearrangements, 
suggesting that the actin phenotype is not linked to an enzymatic activity. Additionally, the first 
helix and a conserved Flap are not necessary to trigger the actin phenotype. As these regions 
are highly conserved, it is plausible that they have another function that is not associated with 
the actin phenotype. The region of the FIC domain that is essential to the effect on the actin 
cytoskeleton remains unidentified. 
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3.1.4 A conserved BID domain is required for actin stress fiber formation 
mediated by BepC. 
As already demonstrated for several Beps [1, 2, 7, 14], individual BID domains have acquired 
supplementary functions in host cells in addition to their role as a translocation signal. Although 
the BID domain of BepC is not sufficient to induce the actin phenotype by itself, we wanted to 
determine if it participates in actin rearrangements. 
To answer this question, we exchanged the BID domain of BepCBhe with the one of BepABhe 
and ectopically expressed the hybrid protein in Bhe ΔbepA-G. Infected HeLa cells did not show 
any actin rearrangements or bacterial aggregates (Fig. 3.4). Assuming a correct folding and 
the translocation of the hybrid protein, the absence of the phenotype suggests that the BID 
domain of BepC has also an important role in actin rearrangements and is not only required 
for protein translocation. 
3.1.5 GEF-H1 and MRCKα interact with BepC during cell infection. 
In order to identify which host protein could interact with BepCBhe during cell infection and 
participate in the actin phenotype, we infected HeLa cells with Bhe ΔbepA-G expressing 
BepCBhe with a triple Flag-tag on the N-terminus. After cell lysis, BepCBhe was pulled down with 
antibodies targeting the Flag-tag and bound proteins were analyzed by mass spectrometry. In 
comparison with HeLa cells infected with Bhe ΔbepA-G carrying an empty plasmid, six proteins 
showed an increase of more than 8 fold with a q-value lower than 0.01 (Fig. 3.6A). As only one 
peptide was identified for three of these six proteins, their relevance is uncertain. As expected, 
one of the three other proteins was identified as BepCBhe. The two other proteins, GEF-H1 and 
MRCKα, were particularly interesting as they play a role in actin rearrangements. GEF-H1 
promotes the activation of RhoA pathway by exchanging GDP for GTP, thereby leading to 
actin stress fiber formation via ROCK. However, MRCKα directly phosphorylates myosin light 
chain (MLC2) and inhibits the myosin light chain phosphatase (MLCP), which also result in 
actin stress fiber formation (Fig. 3.6B). 
To validate the results of the mass spectrometry, an additional pull-down experiment was 
performed and subsequently analyzed by western blot against Flag-tag, GEF-H1 or MRCKα. 
The detection of GEF-H1 and MRCKα among the bound proteins confirmed the interaction 
between BepCBhe wild-type and these two proteins (Fig. 3.7A). Moreover, the absence of GEF-
H1 and MRCKα in the pull-down fractions of cells infected with Bhe ΔbepA-G carrying the 
empty plasmid and uninfected cells excluded any unspecific binding. 
To determine which domain is necessary for the interaction between BepCBhe and GEF-H1 or 
MRCKα, we infected HeLa cells with Bhe ΔbepA-G expressing truncated forms of 3XFlag-
BepCBhe (Fig. 3.7A). Interestingly, the deletion of the FIC domain (BepCBhe OB-BID) completely 
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prevented both GEF-H1 and MRCKα to co-immunoprecipitate with BepCBhe. This result 
indicates that the FIC domain of BepCBhe is required to interact with the two host proteins. 
In order to identify which region of the FIC domain could be involved in the interaction, we 
performed a pull-down on HeLa cells infected with Bhe ΔbepA-G expressing BepCBhe with a 
mutated FIC motif (Fig. 3.7A). The mutation of the catalytic histidine (BepCBhe H146A) and the 
restoration of a canonical FIC motif (BepCBhe K150E) did not have any influence on the 
interaction, suggesting that a functional active site is not required for binding. Nevertheless, 
the mutation of the residues (BepCBhe ****) that were shown to interact with the ATP derivative 
in BepCBtr (Fig. 1.9) reduced the interaction with GEF-H1 and MRCKα. This finding suggests 
that the ability of the FIC domain to bind a nucleotide might help for the interaction. 
However, the replacement of the Flap (BepCBhe (Flap BepABhe)) or the deletion of the first α-
helix (BepCBhe 19-532), two highly conserved regions of the FIC domain, did not reduce binding 
of GEF-H1 and MRCKα (Fig. 3.7A). Therefore, the two host proteins probably interact with 
another region of the FIC domain. 
Finally, the exchange of the BID domain of BepCBhe with the domain of BepABhe also showed 
a reduction of interaction but this rather seems to be linked to a lower amount of effector in the 
pull-down fraction (Fig. 3.7A). Although it would require more investigation, this result tends to 
show that a conserved BID domain is not necessary for the interaction and that the FIC-OB 
domains of BepC might be sufficient to bind GEF-H1 and MRCKα. 
The pull-down of BepC from infected HUVECs showed similar results and confirmed that GEF-
H1 co-precipitated together with BepCBhe full-length (Fig. 3.7B). The mutations of the FIC motif 
(BepCBhe****) also decreased the interaction between GEF-H1 and BepCBhe while the deletion 
of the whole FIC domain totally prevented it. The interaction with MRCKα during infection of 
HUVECs has not been investigated yet. 
To further confirm BepC interaction with GEF-H1 and MRCKα, we decided to check whether 
we could co-immunoprecipitate BepC by reciprocal pull-down (Fig. 3.8). As before, HeLa cells 
were infected with Bhe ΔbepA-G expressing BepCBhe with or without its FIC domain or carrying 
the empty plasmid. 
After MRCKα pull-down, only BepCBhe full-length was detected in the pull-down fraction, which 
confirms that the FIC domain is necessary for the interaction (Fig. 3.8). Surprisingly, GEF-H1 
also co-immunoprecipitated with MRCKα, even in absence of BepCBhe. This either suggests 
that MRCKα and GEF-H1 are directly or indirectly interacting together, which has never been 
demonstrated before, or that GEF-H1 unspecifically binds to agarose beads. Nevertheless, the 
presence of GEF-H1 was not detected in the negative controls of the previous experiment (Fig. 
3.7) and mass spectrometry showed an enrichment of 32 fold in comparison with the negative 
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control (Fig. 3.6A). Thus, our previous results exclude an unspecific binding of GEF-H1 to the 
beads, which support the hypothesis of a complex between BepCBhe, GEF-H1, and MRCKα. 
However, the pull-down of GEF-H1 indicated that neither BepC nor MRCKα co-
immunoprecipitated with GEF-H1. A possible explanation is that the antibody used to pull-
down GEF-H1 is binding to the site of interaction for BepCBhe and MRCKα, thereby preventing 
the co-immunoprecipitation of the two proteins.  
In summary, our results indicate that the FIC domain of BepCBhe is required for the interaction 
with GEF-H1 and MRCKα. Although the ability to bind a nucleotide might help for target 
binding, the presence of the first helix or the conservation of the FIC motif, the Flap, or the BID 
domain is not critical for the interaction. So far, it remains elusive whether BepCBhe interacts 
directly or indirectly with MRCKa and GEF-H1 or if they form a complex during cell infection. 
3.1.6 BepCBhe increases GTP-bound RhoA during infection of HeLa cells. 
Once GEF-H1 is activated in physiological conditions, it interacts with RhoA and promotes the 
exchange of GDP for GTP to activate the small GTPase [15]. Thus, if BepC modulates the 
activity of GEF-H1, it should have an effect on the amount of GTP-bound RhoA. 
To test this hypothesis, we infected serum-starved HeLa cells, which should have a reduced 
basal activation of the RhoA pathway [16], with Bhe ΔbepA-G expressing BepCBhe or carrying 
the empty plasmid. After 24 hours, the active form of RhoA was quantified by G-LISA in two 
independent experiments (Fig. 3.9). Preliminary data showed more than 20% increase in GTP-
bound RhoA in comparison with the uninfected cells and the negative control. Therefore, this 
result suggests that BepC is activating the RhoA pathway, presumably by interacting with GEF-
H1. 
3.1.7 The inhibition of the RhoA pathway decreases BepCBhe-mediated actin 
stress fiber formation. 
As BepC seems to activate GEF-H1, the inhibition of RhoA pathway components should 
decrease actin stress fiber formation mediated by BepC (Fig. 3.6B). For this purpose, we used 
two different inhibitors targeting either RhoA or ROCK. Rho inhibitor I is composed of the 
exoenzyme C3 transferase from Clostridium botulinum that inhibits RhoA, RhoB, and RhoC by 
ADP-ribosylation. This modification prevents the activation of the small GTPases by GEF and 
increases their sequestration in the cytoplasm by GDI [17]. The other inhibitor (Y27632) is a 
small molecule binding to the active site of the kinase ROCK, which thereby prevents the 
phosphorylation of myosin light chain. It is important to note that this inhibitor was also 
described to inhibit MRCKα, which is a close relative of ROCK, but with a ten-fold lower 
efficiency [18]. 
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After infection of HeLa cells with Bhe ΔbepA-G expressing BepCBhe and the apparition of the 
actin phenotype, we treated the cells with the two inhibitors (Fig. 3.10). The inhibition of Rho 
or ROCK led to the loss of actin stress fibers, indicating that the RhoA pathway plays a major 
role in maintaining the actin phenotype. This result also demonstrates that actin stress fiber 
formation mediated by BepCBhe can be reverted or modulated by regulating the RhoA pathway 
at the level of RhoA or ROCK. 
3.1.8 BepCBhe increases myosin light chain phosphorylation in HeLa cells and 
HUVECs during infection. 
According to our findings, the translocation of BepC into the host cell should lead to an increase 
of myosin light chain (MLC2) phosphorylation via an indirect activation of ROCK and, possibly, 
MRCKα. MRCKα mono-phosphorylates MLC on the serine 19 while ROCK is able to di-
phosphorylate MLC on both threonine 18 and serine 19 [19]. Furthermore, the two kinases 
also inhibit the myosin light chain phosphatase (MLCP) via phosphorylation (Fig. 3.6B). 
To confirm that BepC increases MLC phosphorylation, we infected HeLa cells and HUVECs 
with Bhe ΔbepA-G expressing BepCBhe (Fig. 3.11) and determined MLC phosphorylation on 
Ser19 by immunostaining. Fluorescence microscopy showed an increase of myosin light chain 
phosphorylation in both HeLa cells and HUVECs. This increase was also independent of the 
conserved FIC motif, suggesting that it is not linked to a potential enzymatic activity of BepC. 
The increase of phosphorylation is in accordance with a BepC dependent activation of the 
RhoA pathway via GEF-H1 and, possibly, an activation of MRCKα. 
3.1.9 BepCBhe localizes to cell-to-cell contacts during infection. 
During Ea.hy926 infection with Bhe wild-type, BepCBhe localizes to the invasomes via its BID 
domain [20]. In absence of other effectors, the ectopic expression of mCherry fused to BepCBhe 
in HUVECs suggests a localization of the effector to the membrane [1]. 
To further study BepC localization during cell infection, we expressed BepCBhe in Bhe ΔbepA-
G with a triple Flag-tag on the N-terminus. After translocation in HUVECs, BepCBhe was 
enriched at cell-to-cell contacts in several cells (Fig. 3.12). The fluorescent dots could 
correspond to BepCBhe localized in bacteria although this requires further confirmation. 
Interestingly, BepEBhe was also shown to localize to cell junctions during infection of HUVECs 
[1]. 
To determine which domain of BepCBhe was important for the localization to cell contacts, HeLa 
cells were infected with Bhe ΔbepA-G expressing truncated versions of BepCBhe (Fig. 3.13A 
and Fig. 3.13B). Although BepCBhe localization to cell junctions was less consistent in HeLa 
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cells, preliminary results showed that the deletion of the whole FIC domain resulted in the 
relocalization of BepCBhe (OB-BID) to the cellular membrane and/or to the cytoplasm. 
Knowing that the FIC domain is necessary for the recruitment to cell contacts, we wanted to 
determine if the FIC motif, the Flap, or the first helix play a role in BepC localization. BepCBhe 
with the mutated conserved histidine (H146A) or a canonical FIC motif (K150E) showed both 
a localization pattern similar to BepCBhe wild-type. However, the localization of BepCBhe with 
mutated residues that are important to bind a nucleotide derivative (BepC Bhe****) appeared 
more diffused. Additionally, the exchange of the Flap or the deletion of the first helix did not 
have any influence on localization, despite their high degree of conservation. 
To test whether a conserved BID domain is also necessary for localization to cell contacts, we 
infected HeLa cells with Bhe ΔbepA-G expressing BepCBhe with the BID domain of BepABhe 
(Fig. 3.13A and Fig. 3.13B). However, only some spots were visible, indicating either that the 
effector is not translocated inside the cells, which could explain the absence of actin 
phenotype, or that it is not detected by the antibody targeting the Flag-tag. An improper folding 
of the chimeric protein could also be an explanation. 
Overall, our data indicate that the FIC domain is required for localization to cell-to-cell contacts 
while the OB-BID domains localize to the plasma membrane or distribute in the cytosol. 
However, the absence of the first helix, the exchange of the Flap, and mutations of the 
conserved histidine and lysine in the FIC motif does not have an influence on localization. 
Interestingly, the ability of the FIC domain to bind a nucleotide might have a slight influence on 
localization although this needs further investigation. 
3.1.10 BepCBhe does not trigger RhoA pathway activation by microtubules 
depolymerization. 
The T3SS effectors EspG, EspG2, and Orf3 of enteropathogenic Escherichia coli (EPEC) were 
shown to induce the collapse of the microtubule network in mouse fibroblasts, leading to the 
release of GEF-H1 and to actin stress fiber formation via the activation of the RhoA pathway 
[21, 22]. 
To test whether BepC could also use the same strategy to induce actin rearrangements, HeLa 
cells and HUVECs infected with Bhe ΔbepA-G expressing BepCBhe were stained for tubulin. At 
a late stage of infection, infected HeLa cells showed a reorganization of the microtubules 
around actin stress fibers (Fig. 3.S2A). The regions with high actin density had a low 
abundance of microtubules, presumably due to space constraints inside the cell. Although the 
microtubule network appeared denser, BepCBhe did not have a strong influence on 
microtubules organization in HUVECs at an intermediate state of actin phenotype (Fig. 3.S2B). 
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This result confirms that BepC does not induce actin rearrangements during infection via the 
disruption of the microtubule network in order to release GEF-H1. 
3.1.11 BepCBhe induces the aggregation of vimentin intermediate filaments. 
Vimentin is a type III intermediate filament playing a role in maintaining cell integrity and 
anchoring organelles [23]. Interestingly, HeLa cells and HUVECs infected with Bhe ΔbepA-G 
expressing BepCBhe showed vimentin clustering (Fig. 3.S3). Mutations in the FIC motif did not 
have an influence on this phenotype in HUVECs, suggesting that a functional active site is not 
required to induce this phenotype. 
3.1.12 Focal adhesions and adherens junctions are maintained in presence of 
BepC. 
As the RhoA pathway is known to regulate cellular adhesions [24], we wanted to know if BepC 
has an influence on focal adhesion assembly. 
To do so, we infected HeLa cells with Bhe ΔbepA-G expressing BepCBhe and stained them for 
phosphorylated paxillin (pPaxillin) and talin, two components of focal adhesions [25]. The 
staining of pPaxillin did not show any obvious influence of BepCBhe on the abundance or on 
the localization of focal adhesions in HeLa cells (Fig. 3.S4A). This would suggest that BepC 
does not alter the ability of the cells to bind to the extracellular matrix. Interestingly, the 
cytosolic fraction of talin seems to relocalize to the extremity of elongated cells in presence of 
BepCBhe. However, it did not seem to correspond to focal adhesions as pPaxillin staining did 
not show such relocalization (Fig. 3.S4B). It is still unclear whether the relocalization of talin is 
directly linked to an effect of BepC or related to cytoskeleton rearrangements.  
Pathogenic bacteria often target cell junctions via their effectors in order to cross the 
endothelial or the epithelial barrier and colonize new compartments [26]. As the RhoA pathway 
is known to regulate adherens junctions [27], which are essential to maintain the integrity of 
the endothelial barrier, we wanted to determine if BepC could disrupt this type of cellular 
junctions during infection. 
To answer this question, we infected HUVECs with Bhe ΔbepA-G expressing BepCBhe and 
stained cells for VE-cadherin, a component of adherens junctions (Fig. 3.S5). In presence of 
BepCBhe, the remaining infected cells that were still in contact with each other were able to 
maintain adherens junctions. According to this result, the translocation of BepC does not seem 
to have a drastic effect on adherens junctions during cell infection although the reduction of 
cell density would certainly impair endothelial permeability. 
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3.2 Discussion 
Pathogenic bacteria subvert cellular processes by activating Rho GTPases via bacterial 
effectors and toxins in order to facilitate the infection [21, 28-34]. As the cytoskeleton plays a 
major role in bacterial uptake, endothelial and epithelial barrier integrity as well as immune cell 
migration, it is a common target for bacterial effectors. During infection, bacteria of the genus 
Bartonella translocate effector proteins (Beps) into mammalian cells via a type IV secretion 
system. BepC, one of the most conserved effectors in the Bartonella species of the lineage 4, 
participates in the engulfment of bacterial aggregates and affects dendritic cell (DCs) migration 
in vitro [1-3].  In this study, we demonstrate that BepC interacts with GEF-H1 and MRCKα to 
induce actin rearrangements in human cells via the activation of the RhoA pathway. 
The cytoskeleton rearrangements mediated by BepC correlate with the function 
of GEF-H1 and MRCKα. 
GEF-H1 and MRCKα are involved in the RhoA and the Cdc42 pathways, respectively, which 
participate in actin stress fiber formation and actin polymerization (see representation below). 
In physiological conditions, the stimulation of GEF-H1 activates RhoA by promoting the 
exchange of GDP for GTP [35]. Subsequently, GTP-bound RhoA interacts with ROCK, which 
increases phosphorylated myosin light chain (pMLC2) by direct modification via its kinase 
domain and indirectly by inhibiting MLCP (myosin light chain phosphatase). The increase of 
pMLC2 promotes actomyosin contraction and ultimately leads to actin stress fiber formation 
[36-38]. Additionally, the activation of the RhoA pathway promotes actin polymerization via the 
activation of LIMK1 by ROCK, which in turn phosphorylates and inactivates the actin-severing 
protein cofilin1 [36, 39]. Furthermore, RhoA activates the formin mDia (mammalian 
diaphanous), which induces unbranched actin polymerization [40]. MRCKα phosphorylates 
exactly the same targets as ROCK via its kinase domain, leading to actin stress fiber formation 
and actin polymerization [39, 41, 42]. Therefore, the stimulation of GEF-H1 or MRCKα by 
BepCBhe could both results in the increase of phosphorylated myosin light chain and the actin 
rearrangements observed during cell infection. However, our data indicate that the RhoA 
pathway plays a major role in the actin phenotype as inhibitors of RhoA and ROCK drastically 
reduce the actin stress fibers in HeLa cells infected with Bhe ΔbepA-G expressing BepCBhe. 
Therefore, the interaction of BepCBhe with MRCKα is probably not sufficient to maintain actin 
rearrangements during infection. Nevertheless, ROCK and MRCKα have distinct roles in the 
spatial regulation of MLC2 phosphorylation and cooperate during cell migration [43]. ROCK is 
involved in actin stress fiber formation in the center of the cell and in rear-end retraction during 
migration [44, 45]. By contrast, MRCKα is recruited via adaptor proteins to the cell periphery 
where it participates in cell migration via the regulation of lamellar actomyosin retrograde flow 
and lamellipodial F-actin dynamic [39, 46]. In conclusion, a potential activation of both GEF-
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H1 and MRCKα would have a synergic effect on actin rearrangements rather than being 
redundant. 
 
Involvement of the Cdc42 (in blue) and the RhoA (in red) pathways in actin stress fiber 
formation and actin polymerization. 
Interestingly, the translocation of BepCBhe in HUVECs and HeLa cells leads to the aggregation 
of vimentin, which also participates in the cytoskeleton [47]. Vimentin is one of the most 
frequent components of intermediate filaments and is involved in many processes such as 
angiogenesis, cell migration, and cell adhesion [48, 49]. Considering that ROCK 
phosphorylates vimentin on Ser71 and inhibits its ability to form filaments in vitro [50, 51], the 
activation of the RhoA pathway by BepCBhe probably leads to vimentin rearrangements. 
Furthermore, the inactivation of vimentin increases actin stress fiber assembly via the 
stimulation of GEF-H1 by phosphorylation [52]. Thus, the aggregation of vimentin might boost 
the effect of BepC on actin rearrangements. Interestingly, the Fic effector Bep2 from Bartonella 
rochalimae has been described to AMPylate vimentin in vitro [53], although the biological 
function of this modification remains elusive. Additionally, SpyA from Streptococcus pyogenes 
ADP-ribosylates vimentin on Arg 44/49 and induce the collapse of vimentin in HeLa cells [54], 
suggesting that targeting intermediate filaments could have a positive impact on pathogenesis.  
The actin phenotype, the localization to cell contacts, and the interaction with 
GEF-H1 and MRCKα are correlated. 
Strikingly, there is a high correlation between the ability of BepCBhe to localize to cell contacts, 
to trigger the actin phenotype and to interact with GEF-H1 and MRCKα (Table 1). Therefore, 
it is tempting to speculate that BepC is recruited to cell contacts by interacting with GEF-H1 
and/or MRCKα, which results in the activation of the RhoA pathway and actin rearrangements. 
This model is further supported by the fact that GEF-H1 localizes to tight junctions [55]. 
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Table 1. Summary of actin rearrangements, interaction with GEF-H1 and MRCKα, and 
localization for all the tested conditions. 
The color code corresponds to the comparison with the wild-type condition. Green: 
comparable, orange: reduced, red: negative. 
 
According to this model, as the FIC domain of BepCBhe is required to interact with GEF-H1 and 
MRCKα during infection of HeLa cells and HUVECs, its absence should result in the 
redistribution of the truncated effector to the plasma membrane or to the cytoplasm, which is 
observed in HeLa cells infected with Bhe ΔbepA-G expressing BepCBhe (OB-BID). 
Furthermore, the absence of actin rearrangements in these cells is also in accordance this 
model. 
By contrast, the deletion of the first helix and the exchange of the Flap do not impair the ability 
of BepCBhe to bind GEF-H1 and MRCKα, indicating that they do not participate in the binding 
interface. Thus, BepCBhe (19-532) and BepCBhe (Flap BepABhe) could be recruited to cell 
contacts where they induce actin rearrangements.  
Interestingly, mutations of the conserved histidine (H146A) and the conserved lysine (K150E) 
do not influence actin rearrangements. Thus, it is likely that BepCBhe does not induce actin 
rearrangements via a posttranslational modification of GEF-H1 or MRCKα but rather via 
protein-protein interaction. 
However, multiple mutations in the FIC motif of BepC (BepCBhe****) reduce the binding with 
GEF-H1 and MRCKα, which could explain the more diffuse localization in HeLa cells. As the 
mutated residues (H146A, K150A, R154A, R157A) participate in the binding of the nucleotide 
in the active site of the FIC domain (Fig. 1.9), the presence of a nucleotide might help for the 
stabilization of the FIC domain and thereby facilitate the interaction. Nevertheless, the reduced 
interaction and the scattered localization were sufficient to promote actin rearrangements. 
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The only inconsistency with the proposed model is that BepCBhe with the BID domain of 
BepABhe is still able to interact with GEF-H1 and MRCKα although it does not localize to cell 
contacts or induce actin stress fibers in HeLa cells. However, it is possible that the chimeric 
protein is not translocated during infection and is sequestered in the bacteria, as suggested by 
the localization pattern. Thus, BepC (BID BepABhe) would only interact with the two host 
proteins during the co-immunoprecipitation assay after cell lysis of bacteria and HeLa cells. 
Nevertheless, we can conclude that a conserved BID domain is not required to bind GEF-H1 
and MRCKα. Whether the FIC domain alone is sufficient for cell-to-cell contact localization, 
actin phenotype, or protein interaction remains to be tested. 
In order to validate this model, co-localization studies involving the detection of GEF-H1, 
MRCKα, and BepC in host cells by confocal microscopy will be required.  
How GEF-H1 and MRCKα might be regulated by BepC. 
The virulence factors produced by bacterial pathogens are using a wide variety of strategies 
to activate the Rho GTPase pathways, including GEF mimicry, GEF interaction and 
posttranslational modifications [56] (See chapter 1.2.1). However, the molecular mechanism 
by which BepC is activating the RhoA pathway via its interaction with GEF-H1 is still unknown. 
As BepC does not contain a WxxxE motif that is shared by GEF mimicking bacterial effectors 
and as a conserved FIC motif is not required for actin rearrangements, it is unlikely that BepC 
activates the RhoA pathway by exchanging GDP for GTP or by posttranslational modification. 
In a physiological state, the activity of GEF-H1 is negatively regulated by the phosphorylation 
of serine residues located on its C-terminus. This modification leads to the recruitment of the 
14-3-3 protein and to the localization of the GEF-H1 to the microtubules, which inhibits its 
ability to activate Rho GTPases [57-60]. Thus, some bacterial effectors induce microtubule 
depolymerization to release GEF-H1 and activate the RhoA pathway, thereby manipulating the 
actin cytoskeleton [21]. However, our data indicate that BepC does not induce the activation 
of the RhoA pathway via the collapse of the microtubule network, although it seems to be 
reorganized around actin stress fibers.  
Interestingly, the T3SS effector VopO from Vibrio parahaemolyticus also activates the RhoA 
pathway by interacting with GEF-H1, thereby leading to actin stress fiber formation [32]. 
Although they do not share any sequence homology and the mechanism of activation by VopO 
is elusive, it is conceivable that BepC may act in a similar manner by protein-protein interaction. 
Concerning MRCKα, it is not clear whether the interaction with BepC would lead to its 
activation. As the stimulation of the RhoA pathway via GEF-H1 is likely to be sufficient to induce 
actin rearrangements, it is possible that BepC posttranslationally modifies MRCKα and that 
the modification would not have a drastic impact on the actin phenotype. Reciprocally, it cannot 
- Research article - 
54 
 
be excluded that MRCKα could act on BepC as some effectors have been shown to be 
modified and regulated by host enzymes [61]. To date, no molecular mechanism involving the 
manipulation of a downstream binding partner of Rho GTPases and a virulence factor has 
been described. Interestingly, GEF mimicking effectors with a WxxxE motif were initially 
proposed to induce actin rearrangements via a GTPase mimicry function as they interact with 
downstream ligands of the Rho GTPases in vitro [62]. Whether this function is biologically 
relevant during pathogenesis remains unclear. 
Conservation of BepC function among Bartonella species of the lineage 4. 
BepC from various Bartonella species of the lineage 4 induces actin stress fiber formation in 
HeLa cells, suggesting that rearrangements of the cytoskeleton mediated by BepC play a 
critical role in the establishment of infection by Bartonella. Whether the difference in actin 
rearrangements intensity is due to a translocation defect, a loss of function, or host specificity 
remains to be tested. As heterologous GEF-H1 and MRCKα have high sequence identities 
between the different mammalian hosts targeted by Bartonella of the lineage 4 (Table 2), it is 
conceivable that BepC from a specific species would be able to interact indifferently with GEF-
H1 and MRCKa from rodents, cats, dogs, and humans. Thus, if Bartonella infects a mammal 
that is not its reservoir host, such as Bhe infecting humans, BepC will probably be able to 
participate in pathogenesis by mediating actin rearrangements. 
GEF-H1 Homo sapiens Felis catus Rattus norvegicus Mus musculus 
Homo sapiens  93.4% 89.1% 88.6% 
Felis catus 93.4%  88.0% 87.7% 
Rattus norvegicus 89.1% 88.0%  98.3% 
Mus musculus 88.6% 87.7% 98.3%  
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MRCKα Homo sapiens Felis catus Rattus norvegicus Mus musculus 
Homo sapiens 
 
97.2% 96.0% 96.1% 
Felis catus 97.2% 
 
95.4% 95.5% 
Rattus norvegicus 96.0% 95.4% 
 
98.3% 
Mus musculus 96.1% 95.5% 98.3% 
 
Table 2. Sequence identities between GEF-H1 and MRCKα of different mammalian hosts 
of Bartonella. 
Biological consequences of the activation of the RhoA pathway by BepC. 
The translocation of BepC by Bartonella stimulates the RhoA pathway by interacting with GEF-
H1 and possibly modulates the activity of MRCKα. As the RhoA pathway and MRCKα are 
involved in a wide variety of cellular processes, the function of BepC might vary according to 
the cell types infected by Bartonella through the different stages of the infection cycle.  
As Bartonella successfully invade dendritic cells in vitro and requires to be transported from 
the dermis to the blood-seeding niche, it has been proposed that dendritic cells are colonized 
during the dermal stage of host infection [1]. In absence of BepE, the translocation of BepC 
impairs the migration of DCs through an endothelial cell layer in vitro [1]. According to 
experimental data on migrating endothelial cells, the migration defect is due to a defect in rear-
end detachment [1], which is controlled by the actomyosin contraction and the degradation of 
focal adhesion [63, 64]. As RhoA promotes actomyosin contraction via ROCK and MLC2 
phosphorylation [65-67], the activation of the RhoA pathway via the interaction of BepC with 
GEF-H1 is likely responsible for the migration defect. Additionally, MRCKα is involved in cell 
migration by contributing to the actomyosin lamellar retrograde flow [68]. Thus, a potential 
modulation of its activity by BepC would possibly have an increased defect on cell migration. 
Furthermore, RhoA also plays a role in the maturation of focal adhesions during migration [24, 
45, 69]. As BepC activates the RhoA pathway, it might stabilize focal adhesions and interfere 
with their dissociation from the extracellular matrix, which could then results in the cell 
fragmentation observed in migrating endothelial cells due to a deficiency in rear-end 
detachment [1]. This hypothesis is further supported by our data suggesting that HeLa cells 
are able to maintain focal adhesions in presence of BepC despite actin rearrangements. 
Eventually, BepC could interfere with immune cells motility by disturbing the regulation of the 
RhoA pathway, as reported for the C3 toxin that impairs macrophage migration [44, 70]. By 
contrast, a spatiotemporal regulation of BepC function by BepE could allow the dissemination 
of Bartonella in the host by using DCs as a shuttle in a similar manner as the ancestrally related 
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Brucella abortus as well as Bordetella bronchiseptica, Burkholderia pseudomallei, and 
Francisella tularensis [71-74].  
To colonize new compartments, pathogens specifically target cellular junctions of the 
endothelium and the epithelial barriers in order to increase their permeability, which is 
controlled by Rho GTPases (See chapter 1.1.2.2). As Bartonella establishes a bacteremia into 
the reservoir host, it has probably developed a strategy to cross the endothelial barrier. 
Interestingly, GEF-H1 is involved in endothelial barrier regulation and is recruited to tight 
junctions in epithelial cells, thereby regulating the paracellular permeability [55, 75].  
Accordingly, RhoA is involved in the regulation of tight junctions and adherens junctions in 
endothelial and epithelial cells [76-78]. More specifically, the activation of the RhoA pathway 
increases vascular permeability [78-81] by targeting adherens junctions [27, 82]. Surprisingly, 
BepC does not seem to have a strong effect on adherens junctions of infected HUVECs. 
Nevertheless, the remaining cells that are still in contact are probably less affected by BepC 
and the reduction of cell density completely disorganizes the confluent cell layer. Thus, the 
interaction of GEF-H1 and the subsequent activation of the RhoA pathway by BepC might help 
Bartonella to disrupt the endothelial barrier and establish bacteremia.  
A wide variety of pathogens blocks phagocytosis via virulence factors that modulates Rho 
GTPases pathways (See chapter 1.2). In Bartonella, BepGBhe and BepCBhe together with 
BepFBhe prevent the endocytosis of single bacteria, which is a prerequisite to bacterial 
aggregation on the cell surface and to invasome formation [3, 7]. However, the presence of 
bacterial clusters in HeLa cells and EA.hy926 displaying a strong actin phenotype suggests 
that BepC alone is sufficient to block bacterial uptake and to initiate the first step of invasome 
formation. Furthermore, bacterial aggregates seem to correlate with the intensity of actin stress 
fiber formation as only BepC of Bhe and Bqu are able to induce it, in contrast to BepC from 
other Bartonella species that displays a weaker phenotype. Therefore, the activation of the 
RhoA pathway by BepC and the resulting formation of actin stress fibers might prevent the 
phagocytosis of Bartonella by immune cells. 
Although the exact function of invasome formation remains elusive and its biological relevance 
needs to be confirmed in vivo, it might reflect a unique strategy of Bartonella henselae to invade 
host cells. As knocking down GEF-H1 significantly reduces invasome formation mediated by 
BepCBhe and BepFBhe (unpublished data from Dr. Simone Eicher), it is likely that BepC 
participates in the engulfment process by activating the RhoA pathway via its interaction with 
GEF-H1. Surprisingly, only BepC of Bhe is able to participate in invasome formation together 
with BepFBhe although BepC of Bqu, Btr and Bta induce actin rearrangements. Furthermore, 
BepCBqu is not able to trigger invasome formation while it triggers bacterial aggregates in HeLa 
cells. These observations indicate that neither actin stress fiber formation nor bacterial 
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clustering mediated by BepC is sufficient to promote invasome formation in collaboration with 
BepFBhe. As BepFBhe is proposed to modulate the Rac1 and Cdc42 pathways [2] and BepC 
activates the RhoA pathway, a fine tuning of the different pathways might be necessary for 
invasome formation. Therefore, BepC from other Bartonella species might not be able to 
cooperate efficiently with BepFBhe to promote the internalization of bacterial clustering. Another 
possibility would be that BepCBhe has acquired an additional function that is necessary for 
invasome formation. Reciprocally, BepF of other Bartonella species might also not be able to 
participate in invasome formation as only BepFBhe and BepFBgr harbor in their first BID domain 
a conserved WxxxE motif, which participates in invasome formation and is found in GEF 
mimicking bacterial effectors (See chapter 1.2.1.1) [2]. Thus, more investigations are required 
to determine whether invasome formation could be specific to Bhe.  
Bartonella triggers NF‐κB‐dependent proinflammatory response related to the VirB/D4 T4SS 
in HUVECs, which could contribute to angiogenesis but also initiate innate and adaptive 
immune responses [83-85]. Interestingly, the activation of NF-κB upon epithelial cell invasion 
by Shigella is mediated by GEF-H1, which interacts with the pattern recognition receptor NOD1 
[86]. Additionally, GEF-H1 is also regulating the NOD2-dependent NF-κB activation that 
controls proinflammatory cytokines expression in mouse macrophages [87]. Furthermore, 
constitutively active RhoA stimulates the NOD1 signaling pathway in HEK293 cells [88]. Thus, 
it is tempting to speculate that the interaction of GEF-H1 with BepC, and the following 
stimulation of the RhoA pathway, could be sensed via the NOD1 and NOD2 signaling pathways 
that would activate NF-κB and thereby an immune response. If this hypothesis can be 
confirmed, BepE could play an important role in maintaining Bartonella below the radar of the 
immune system by reducing the activation of the RhoA pathway. 
Summary. 
In conclusion, we identified a new strategy by which Bartonella can exploit the host cell 
functions by targeting signaling pathways regulated by Rho GTPases. The translocation of 
BepC into the host cell leads to its recruitment at cell-to-cell contact and to actin 
rearrangements due to the activation of the RhoA pathway via the interaction with GEF-H1 
and possibly to the modulation of MRCKα. As a result,  the subversion of cellular processes 
by BepC could help Bartonella to escape the immune system by preventing phagocytosis and 
immune cell migration and/or play a role in disrupting the endothelial barrier and eventually 
allow the bacteria to reach the blood and establish a bacteremia into the reservoir host. 
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3.3 Figures 
 
Figure 3.1. BepCBhe induces actin rearrangements in various human cells. 
HeLa cells and HUVECs were infected at a MOI = 400 and EA.hy926 at a MOI = 800 with the 
indicated bacterial strain. After 48 hours of infection, the cells were fixed and stained by 
immunocytochemistry before being analyzed by fluorescence microscopy. F-actin is 
represented in green, DNA in blue, and Bartonella in red (scale bar = 50 µm). 
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Figure 3.2. BepC of different Bartonella species induces actin stress fibers in HeLa cells. 
HeLa cells were infected with the indicated bacterial strain at a MOI = 400. After 48 hours of 
infection, the cells were fixed and stained by immunocytochemistry before being analyzed by 
fluorescence microscopy. F-actin is represented in green, DNA in blue, and Bartonella in red 
(scale bar = 50 µm). 
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Figure 3.4. The FIC and the BID domains of BepCBhe are required for actin stress fiber 
formation in HeLa cells but not a conserved Flap or FIC motif. 
HeLa cells were infected with the indicated bacterial strain at a MOI = 400. After 48 hours of 
infection, the cells were fixed and stained by immunocytochemistry before being analyzed by 
fluorescence microscopy. F-actin is represented in green, DNA in blue, and Bartonella in red 
(scale bar = 50 µm). BepCBhe**** = BepCBhe H146A, K150A, R154A, R157A. 
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Figure 3.5. The FIC domain of BepCBhe is required for cell fragmentation in HUVECs but 
not a conserved Flap or FIC motif. 
HUVECs were infected with the indicated bacterial strain at a MOI = 400. After 48 hours of 
infection, the cells were fixed and stained by immunocytochemistry before being analyzed by 
fluorescence microscopy. F-actin is represented in green, DNA in blue, and Bartonella in red 
(scale bar = 50 µm). BepCBhe**** = BepCBhe H146A, K150A, R154A, R157A. 
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Figure 3.6. GEF-H1 and MRCKα co-immunoprecipitate with BepCBhe after HeLa cell 
infection 
A) HeLa cells were infected with Bhe ΔbepA-G expressing 3XFlag-BepCBhe, or carrying the 
empty plasmid as a negative control, at a MOI = 200. After 24 hours of infection, the cells were 
lysed and incubated in presence of anti-Flag antibody. 3XFlag-BepCBhe and its interacting 
partners were pulled-down with protein G agarose beads before being eluted with SDS. 
Samples were analyzed by mass spectrometry and compared to the negative control (technical 
triplicates). Proteins enriched after pull-down of 3XFlag-BepC from infected HeLa cell lysates 
are indicated on the volcano plot and summarized in the table. B) GEF-H1 and MRCKα 
participate in actin stress fiber formation by activating the RhoA pathway or directly 
phosphorylating myosin light chain, respectively. MLCP = Myosin light chain phosphatase. 
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Figure 3.7. The FIC domain is necessary for the interaction between BepCBhe and GEF-
H1 or MRCKα but not a conserved FIC motif or Flap. 
Human cells were infected with Bhe ΔbepA-G carrying the empty plasmid or expressing Flag-
tagged BepCBhe wild-type, mutants, or truncated versions at a MOI = 200. After 24 hours of 
infection, the cells were lysed and incubated in presence of anti-Flag antibody. BepCBhe was 
pulled-down with protein G agarose beads before being eluted with SDS. Cell lysates before 
pull-down and samples after pull-down were analyzed by western blot. A) Samples from HeLa 
cells infected with Bhe ΔbepA-G expressing 3XFlag-tagged BepCBhe were analyzed by western 
blot against Flag-tag, GEF-H1, and MRCKα. B) Samples from HUVECs infected with Bhe 
ΔbepA-G expressing 1XFlag-tagged BepCBhe were analyzed by western blot against GEF-H1. 
BepCBhe**** =  BepCBhe H146A, K150A, R154A, R157A. 
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Figure 3.8. BepCBhe co-immunoprecipitates with MRCKα but not with GEF-H1 after HeLa 
cells infection. 
HeLa cells were infected with Bhe ΔbepA-G expressing 3XFlag-tagged BepCBhe, or carrying 
the empty plasmid, at a MOI = 200. After 24 hours of infection, the cells were lysed and 
incubated in presence of anti-MRCKα or anti-GEF-H1 antibody. MRCKα or GEF-H1 were 
pulled-down with protein G agarose beads before being eluted with SDS. Cell lysates before 
pull-down and samples after pull-down were analyzed by western blot against Flag-tag, GEF-
H1, or MRCKα.  
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Condition Experiment 1 Experiment 2 
Uninfected 1 1 
Empty plasmid 1.01 1.08 
BepC 1.21 1.35 
 
Figure 3.9. BepCBhe increases GTP-bound RhoA during infection of HeLa cells. 
Serum-starved HeLa cells were infected with Bhe ΔbepA-G carrying the empty plasmid or 
expressing BepCBhe at a MOI = 400. After 24 hours of infection, G-LISA was used to evaluate 
the relative RhoA activation level. The experiment was performed in independent duplicates 
(red and blue). 
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Figure 3.10. Inhibition of RhoA or ROCK reduces actin stress fiber formation mediated 
by BepCBhe. 
HeLa cells were infected with the indicated bacterial strain at a MOI = 200. After 24 hours of 
infection, the cells were treated with inhibitors before being fixed, stained by 
immunocytochemistry and analyzed by fluorescence microscopy. F-actin is represented in 
white (scale bar = 50 µm). A) HeLa cells have been incubated 2 hours in absence or in 
presence of 2 µg/ml of Rho inhibitor I. B) HeLa cells have been incubated 1 hour in absence 
or in presence of 20 µM of Y27632. 
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Figure 3.11. BepCBhe increases myosin light chain phosphorylation in HeLa cells and 
HUVECs during infection. 
Human cells were infected with the indicated bacterial strain. After infection, the cells were 
fixed and stained by immunocytochemistry before being analyzed by fluorescence microscopy. 
Phosphorylated myosin light chain is represented in green or white, DNA in blue, and F-actin 
in red (scale bar = 50 µm). A) HeLa cells were infected at a MOI = 800 for 48 hours. B) HUVECs 
were infected at a MOI = 200 for 24 hours. BepCBhe**** = BepCBhe H146A, K150A, R154A, 
R157A. 
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Figure 3.12. BepCBhe localizes to cell-to-cell contacts during infection of HUVECs. 
HUVECs were infected with the indicted bacterial strain at MOI = 100. After 48 hours of 
infection, the cells were fixed and stained by immunocytochemistry before being analyzed by 
fluorescence microscopy. 3XFlag-BepCBhe is represented in green or white, DNA in blue, and 
F-actin in red (scale bar = 50 µm). White arrows indicate BepCBhe localized to cell junctions. 
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Figure 3.13A. The FIC and the BID domains of BepCBhe but not the conserved Flap or 
FIC motif are required for localization to cell-to-cell contacts in HeLa cells. 
HeLa cells were infected with the indicated bacterial strain at a MOI = 400. After 48 hours of 
infection, the cells were fixed and stained by immunocytochemistry before being analyzed by 
fluorescence microscopy. F-actin is represented in red, DNA in blue, and 3XFlag-BepCBhe in 
green (scale bar = 50 µm). White arrows indicate BepCBhe localized to cell junctions. 
BepCBhe**** = BepCBhe H146A, K150A, R154A, R157A. 
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Figure 3.13B. The FIC and the BID domains of BepCBhe but not the conserved Flap region 
or FIC motif are required for localization to cell-to-cell contacts in HeLa cells. 
HeLa cells were infected with the indicated bacterial strain at a MOI = 400. After 48 hours of 
infection, the cells were fixed and stained by immunocytochemistry before being analyzed by 
fluorescence microscopy. 3XFlag-BepCBhe is represented in white (scale bar = 50 µm). White 
arrows indicate BepCBhe localized to cell junctions. BepCBhe**** =  BepCBhe H146A, K150A, 
R154A, R157A. 
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Figure 3.S1. The intensity of the actin phenotype mediated by BepC is related to the MOI 
and the duration of infection. 
HeLa cells were infected with the indicated bacterial strain at a different MOI for 24 or 48 hours. 
After infection, the cells were fixed and stained by immunocytochemistry before being analyzed 
by fluorescence microscopy. F-actin is represented in green, DNA in blue, and Bartonella in 
red (scale bar = 100 µm). 
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Figure 3.S2. BepCBhe induces tubulin network reorganization in HeLa cells and HUVECs 
during infection. 
Human cells were infected with the indicated bacterial strain. After infection, the cells were 
fixed and stained by immunocytochemistry before being analyzed by fluorescence microscopy. 
Tubulin is represented in green or white, DNA in blue, and F-actin in red (scale bar = 50 µm). 
A) HeLa cells were infected at a MOI = 800 for 48 hours. B) HUVECs were infected at a MOI 
= 200 for 24 hours. 
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Figure 3.S3. BepCBhe induces the aggregation of vimentin intermediate filaments in HeLa 
cells and HUVECs during infection. 
Human cells were infected with the indicated bacterial strain. After infection, the cells were 
fixed and stained by immunocytochemistry before being analyzed by fluorescence microscopy. 
Vimentin is represented in green or white, DNA in blue, and F-actin in red (scale bar = 50 µm). 
A) HeLa cells were infected at a MOI = 800 for 48 hours. B) HUVECs were infected at a MOI 
= 200 for 24 hours. BepCBhe**** = BepCBhe H146A, K150A, R154A, R157A. 
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Figure 3.S4. BepCBhe induces the re-localization of the cytosolic fraction of talin but 
does not have an effect on focal adhesions. 
HeLa cells were infected with the indicated bacterial strain. After infection, the cells were and 
stained by immunocytochemistry before being analyzed by fluorescence microscopy. A) HeLa 
cells were infected for 48 hours at a MOI = 800. Phosphorylated paxillin is represented in green 
or white, DNA in blue, and F-actin in red. B) HeLa cells were infected for 48 hours at a MOI = 
400. Talin is represented in green or white, DNA in blue, and F-actin in red. 
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Figure 3.S5. HUVECs are still able to form adherens junctions after infection with Bhe 
ΔbepA-G expressing BepCBhe. 
HUVECs were infected with the indicated bacterial strain at a MOI = 200. After 24 hours of 
infection, the cells were fixed and stained by immunocytochemistry before being analyzed by 
fluorescence microscopy. VE-cadherin is represented in green or white, DNA in blue, and F-
actin in red (scale bar = 50 µm). 
 
  
- Research article - 
77 
 
3.4 References 
1. Okujava, R., et al., A translocated effector required for Bartonella dissemination from 
derma to blood safeguards migratory host cells from damage by co-translocated 
effectors. PLoS Pathog, 2014. 10(6): p. e1004187. 
2. Truttmann, M.C., P. Guye, and C. Dehio, BID-F1 and BID-F2 domains of Bartonella 
henselae effector protein BepF trigger together with BepC the formation of invasome 
structures. PloS one, 2011. 6(10): p. e25106. 
3. Truttmann, M.C., T.A. Rhomberg, and C. Dehio, Combined action of the type IV 
secretion effector proteins BepC and BepF promotes invasome formation of 
Bartonella henselae on endothelial and epithelial cells. Cellular microbiology, 2011. 
13(2): p. 284-99. 
4. Dehio, C., et al., Interaction of Bartonella henselae with endothelial cells results in 
bacterial aggregation on the cell surface and the subsequent engulfment and 
internalisation of the bacterial aggregate by a unique structure, the invasome. J Cell 
Sci, 1997. 110 ( Pt 18): p. 2141-54. 
5. Dehio, C., Bartonella-host-cell interactions and vascular tumour formation. Nat Rev 
Microbiol, 2005. 3(8): p. 621-31. 
6. Dehio, C. and R.M. Tsolis, Type IV Effector Secretion and Subversion of Host 
Functions by Bartonella and Brucella Species. Curr Top Microbiol Immunol, 2017. 
413: p. 269-295. 
7. Rhomberg, T.A., et al., A translocated protein of Bartonella henselae interferes with 
endocytic uptake of individual bacteria and triggers uptake of large bacterial 
aggregates via the invasome. Cell Microbiol, 2009. 11(6): p. 927-45. 
8. Harms, A., F.V. Stanger, and C. Dehio, Biological Diversity and Molecular Plasticity of 
FIC Domain Proteins. Annu Rev Microbiol, 2016. 70: p. 341-60. 
9. Yarbrough, M.L., et al., AMPylation of Rho GTPases by Vibrio VopS disrupts effector 
binding and downstream signaling. Science, 2009. 323(5911): p. 269-72. 
10. Worby, C.A., et al., The fic domain: regulation of cell signaling by adenylylation. Mol 
Cell, 2009. 34(1): p. 93-103. 
11. Xiao, J., et al., Structural basis of Fic-mediated adenylylation. Nat Struct Mol Biol, 
2010. 17(8): p. 1004-10. 
12. Kinch, L.N., et al., Fido, a novel AMPylation domain common to fic, doc, and AvrB. 
PLoS One, 2009. 4(6): p. e5818. 
13. Palanivelu, D.V., et al., Fic domain-catalyzed adenylylation: insight provided by the 
structural analysis of the type IV secretion system effector BepA. Protein Sci, 2011. 
20(3): p. 492-9. 
14. Pulliainen, A.T., et al., Bacterial effector binds host cell adenylyl cyclase to potentiate 
Galphas-dependent cAMP production. Proc Natl Acad Sci U S A, 2012. 109(24): p. 
9581-6. 
15. Rossman, K.L., C.J. Der, and J. Sondek, GEF means go: turning on RHO GTPases 
with guanine nucleotide-exchange factors. Nat Rev Mol Cell Biol, 2005. 6(2): p. 167-
80. 
16. Ren, X.D., W.B. Kiosses, and M.A. Schwartz, Regulation of the small GTP-binding 
protein Rho by cell adhesion and the cytoskeleton. EMBO J, 1999. 18(3): p. 578-85. 
17. Aktories, K., C. Wilde, and M. Vogelsgesang, Rho-modifying C3-like ADP-
ribosyltransferases. Rev Physiol Biochem Pharmacol, 2004. 152: p. 1-22. 
18. Heikkila, T., et al., Co-crystal structures of inhibitors with MRCKbeta, a key regulator 
of tumor cell invasion. PLoS One, 2011. 6(9): p. e24825. 
19. Tan, I., et al., Chelerythrine perturbs lamellar actomyosin filaments by selective 
inhibition of myotonic dystrophy kinase-related Cdc42-binding kinase. FEBS Lett, 
2011. 585(9): p. 1260-8. 
20. Hauert, B., Identification of cellular protein targets for Bartonella effector proteins. 
Master thesis, 2009. 
- Research article - 
78 
 
21. Matsuzawa, T., et al., Enteropathogenic Escherichia coli activates the RhoA signaling 
pathway via the stimulation of GEF-H1. EMBO J, 2004. 23(17): p. 3570-82. 
22. Shaw, R.K., et al., Enteropathogenic Escherichia coli type III effectors EspG and 
EspG2 disrupt the microtubule network of intestinal epithelial cells. Infect Immun, 
2005. 73(7): p. 4385-90. 
23. Chang, L. and R.D. Goldman, Intermediate filaments mediate cytoskeletal crosstalk. 
Nat Rev Mol Cell Biol, 2004. 5(8): p. 601-13. 
24. Ridley, A.J. and A. Hall, The small GTP-binding protein rho regulates the assembly of 
focal adhesions and actin stress fibers in response to growth factors. Cell, 1992. 
70(3): p. 389-99. 
25. Mitra, S.K., D.A. Hanson, and D.D. Schlaepfer, Focal adhesion kinase: in command 
and control of cell motility. Nat Rev Mol Cell Biol, 2005. 6(1): p. 56-68. 
26. Lemichez, E., et al., Breaking the wall: targeting of the endothelium by pathogenic 
bacteria. Nat Rev Microbiol, 2010. 8(2): p. 93-104. 
27. van Buul, J.D. and I. Timmerman, Small Rho GTPase-mediated actin dynamics at 
endothelial adherens junctions. Small GTPases, 2016. 7(1): p. 21-31. 
28. Horiguchi, Y., et al., Bordetella bronchiseptica dermonecrotizing toxin induces 
reorganization of actin stress fibers through deamidation of Gln-63 of the GTP-
binding protein Rho. Proc Natl Acad Sci U S A, 1997. 94(21): p. 11623-6. 
29. Klink, B.U., et al., Structure of Shigella IpgB2 in complex with human RhoA: 
implications for the mechanism of bacterial guanine nucleotide exchange factor 
mimicry. J Biol Chem, 2010. 285(22): p. 17197-208. 
30. Hopkins, A.M., et al., Constitutive activation of Rho proteins by CNF-1 influences tight 
junction structure and epithelial barrier function. J Cell Sci, 2003. 116(Pt 4): p. 725-
42. 
31. Ohlson, M.B., et al., Structure and function of Salmonella SifA indicate that its 
interactions with SKIP, SseJ, and RhoA family GTPases induce endosomal 
tubulation. Cell Host Microbe, 2008. 4(5): p. 434-46. 
32. Hiyoshi, H., et al., Interaction between the type III effector VopO and GEF-H1 
activates the RhoA-ROCK pathway. PLoS Pathog, 2015. 11(3): p. e1004694. 
33. Lang, A.E., et al., Photorhabdus luminescens toxins ADP-ribosylate actin and RhoA 
to force actin clustering. Science, 2010. 327(5969): p. 1139-42. 
34. Arbeloa, A., et al., Subversion of actin dynamics by EspM effectors of attaching and 
effacing bacterial pathogens. Cell Microbiol, 2008. 10(7): p. 1429-41. 
35. Ren, Y., et al., Cloning and characterization of GEF-H1, a microtubule-associated 
guanine nucleotide exchange factor for Rac and Rho GTPases. J Biol Chem, 1998. 
273(52): p. 34954-60. 
36. Maekawa, M., et al., Signaling from Rho to the actin cytoskeleton through protein 
kinases ROCK and LIM-kinase. Science, 1999. 285(5429): p. 895-8. 
37. Riento, K. and A.J. Ridley, Rocks: multifunctional kinases in cell behaviour. Nat Rev 
Mol Cell Biol, 2003. 4(6): p. 446-56. 
38. Leung, T., et al., The p160 RhoA-binding kinase ROK alpha is a member of a kinase 
family and is involved in the reorganization of the cytoskeleton. Mol Cell Biol, 1996. 
16(10): p. 5313-27. 
39. Lee, I.C., T. Leung, and I. Tan, Adaptor protein LRAP25 mediates myotonic 
dystrophy kinase-related Cdc42-binding kinase (MRCK) regulation of LIMK1 protein 
in lamellipodial F-actin dynamics. J Biol Chem, 2014. 289(39): p. 26989-7003. 
40. Watanabe, N., et al., Cooperation between mDia1 and ROCK in Rho-induced actin 
reorganization. Nat Cell Biol, 1999. 1(3): p. 136-43. 
41. Tan, I., et al., Phosphorylation of a novel myosin binding subunit of protein 
phosphatase 1 reveals a conserved mechanism in the regulation of actin 
cytoskeleton. J Biol Chem, 2001. 276(24): p. 21209-16. 
42. Leung, T., et al., Myotonic dystrophy kinase-related Cdc42-binding kinase acts as a 
Cdc42 effector in promoting cytoskeletal reorganization. Mol Cell Biol, 1998. 18(1): p. 
130-40. 
- Research article - 
79 
 
43. Wilkinson, S., H.F. Paterson, and C.J. Marshall, Cdc42-MRCK and Rho-ROCK 
signalling cooperate in myosin phosphorylation and cell invasion. Nat Cell Biol, 2005. 
7(3): p. 255-61. 
44. Worthylake, R.A., et al., RhoA is required for monocyte tail retraction during 
transendothelial migration. J Cell Biol, 2001. 154(1): p. 147-60. 
45. Totsukawa, G., et al., Distinct roles of ROCK (Rho-kinase) and MLCK in spatial 
regulation of MLC phosphorylation for assembly of stress fibers and focal adhesions 
in 3T3 fibroblasts. J Cell Biol, 2000. 150(4): p. 797-806. 
46. Tan, I., et al., A tripartite complex containing MRCK modulates lamellar actomyosin 
retrograde flow. Cell, 2008. 135(1): p. 123-36. 
47. Huber, F., et al., Cytoskeletal crosstalk: when three different personalities team up. 
Curr Opin Cell Biol, 2015. 32: p. 39-47. 
48. Leduc, C. and S. Etienne-Manneville, Intermediate filaments in cell migration and 
invasion: the unusual suspects. Curr Opin Cell Biol, 2015. 32: p. 102-12. 
49. Dave, J.M. and K.J. Bayless, Vimentin as an integral regulator of cell adhesion and 
endothelial sprouting. Microcirculation, 2014. 21(4): p. 333-44. 
50. Goto, H., et al., Phosphorylation of vimentin by Rho-associated kinase at a unique 
amino-terminal site that is specifically phosphorylated during cytokinesis. J Biol 
Chem, 1998. 273(19): p. 11728-36. 
51. Sin, W.C., et al., RhoA-binding kinase alpha translocation is facilitated by the collapse 
of the vimentin intermediate filament network. Mol Cell Biol, 1998. 18(11): p. 6325-39. 
52. Jiu, Y., et al., Vimentin intermediate filaments control actin stress fiber assembly 
through GEF-H1 and RhoA. J Cell Sci, 2017. 130(5): p. 892-902. 
53. Pieles, K., et al., An experimental strategy for the identification of AMPylation targets 
from complex protein samples. Proteomics, 2014. 14(9): p. 1048-52. 
54. Icenogle, L.M., et al., Molecular and biological characterization of Streptococcal 
SpyA-mediated ADP-ribosylation of intermediate filament protein vimentin. J Biol 
Chem, 2012. 287(25): p. 21481-91. 
55. Benais-Pont, G., et al., Identification of a tight junction-associated guanine nucleotide 
exchange factor that activates Rho and regulates paracellular permeability. J Cell 
Biol, 2003. 160(5): p. 729-40. 
56. Popoff, M.R., Bacterial factors exploit eukaryotic Rho GTPase signaling cascades to 
promote invasion and proliferation within their host. Small GTPases, 2014. 5. 
57. Patel, M. and A.V. Karginov, Phosphorylation-mediated regulation of GEFs for RhoA. 
Cell Adh Migr, 2014. 8(1): p. 11-8. 
58. Krendel, M., F.T. Zenke, and G.M. Bokoch, Nucleotide exchange factor GEF-H1 
mediates cross-talk between microtubules and the actin cytoskeleton. Nat Cell Biol, 
2002. 4(4): p. 294-301. 
59. Zenke, F.T., et al., p21-activated kinase 1 phosphorylates and regulates 14-3-3 
binding to GEF-H1, a microtubule-localized Rho exchange factor. J Biol Chem, 2004. 
279(18): p. 18392-400. 
60. Birkenfeld, J., et al., Cellular functions of GEF-H1, a microtubule-regulated Rho-GEF: 
is altered GEF-H1 activity a crucial determinant of disease pathogenesis? Trends Cell 
Biol, 2008. 18(5): p. 210-9. 
61. Popa, C.M., M. Tabuchi, and M. Valls, Modification of Bacterial Effector Proteins 
Inside Eukaryotic Host Cells. Front Cell Infect Microbiol, 2016. 6: p. 73. 
62. Alto, N.M., et al., Identification of a bacterial type III effector family with G protein 
mimicry functions. Cell, 2006. 124(1): p. 133-45. 
63. Palecek, S.P., et al., Physical and biochemical regulation of integrin release during 
rear detachment of migrating cells. J Cell Sci, 1998. 111 ( Pt 7): p. 929-40. 
64. Glading, A., D.A. Lauffenburger, and A. Wells, Cutting to the chase: calpain 
proteases in cell motility. Trends Cell Biol, 2002. 12(1): p. 46-54. 
65. Heasman, S.J., et al., Coordinated RhoA signaling at the leading edge and uropod is 
required for T cell transendothelial migration. J Cell Biol, 2010. 190(4): p. 553-63. 
- Research article - 
80 
 
66. Nalbant, P., et al., Guanine nucleotide exchange factor-H1 regulates cell migration 
via localized activation of RhoA at the leading edge. Mol Biol Cell, 2009. 20(18): p. 
4070-82. 
67. Kurokawa, K. and M. Matsuda, Localized RhoA activation as a requirement for the 
induction of membrane ruffling. Mol Biol Cell, 2005. 16(9): p. 4294-303. 
68. Gagliardi, P.A., et al., PDK1-mediated activation of MRCKalpha regulates directional 
cell migration and lamellipodia retraction. J Cell Biol, 2014. 206(3): p. 415-34. 
69. Amano, M., et al., Formation of actin stress fibers and focal adhesions enhanced by 
Rho-kinase. Science, 1997. 275(5304): p. 1308-11. 
70. Barth, H., et al., Clostridial C3 Toxins Target Monocytes/Macrophages and Modulate 
Their Functions. Front Immunol, 2015. 6: p. 339. 
71. Williams, N.L., et al., Migration of dendritic cells facilitates systemic dissemination of 
Burkholderia pseudomallei. Infect Immun, 2014. 82(10): p. 4233-40. 
72. Bar-Haim, E., et al., Interrelationship between dendritic cell trafficking and Francisella 
tularensis dissemination following airway infection. PLoS Pathog, 2008. 4(11): p. 
e1000211. 
73. Skinner, J.A., et al., Bordetella type III secretion modulates dendritic cell migration 
resulting in immunosuppression and bacterial persistence. J Immunol, 2005. 175(7): 
p. 4647-52. 
74. Salcedo, S.P., et al., Brucella control of dendritic cell maturation is dependent on the 
TIR-containing protein Btp1. PLoS Pathog, 2008. 4(2): p. e21. 
75. Birukova, A.A., et al., GEF-H1 is involved in agonist-induced human pulmonary 
endothelial barrier dysfunction. Am J Physiol Lung Cell Mol Physiol, 2006. 290(3): p. 
L540-8. 
76. Tornavaca, O., et al., ZO-1 controls endothelial adherens junctions, cell-cell tension, 
angiogenesis, and barrier formation. J Cell Biol, 2015. 208(6): p. 821-38. 
77. Terry, S.J., et al., Spatially restricted activation of RhoA signalling at epithelial 
junctions by p114RhoGEF drives junction formation and morphogenesis. Nat Cell 
Biol, 2011. 13(2): p. 159-66. 
78. Wojciak-Stothard, B. and A.J. Ridley, Rho GTPases and the regulation of endothelial 
permeability. Vascul Pharmacol, 2002. 39(4-5): p. 187-99. 
79. Mikelis, C.M., et al., RhoA and ROCK mediate histamine-induced vascular leakage 
and anaphylactic shock. Nat Commun, 2015. 6: p. 6725. 
80. van Hinsbergh, V.W. and G.P. van Nieuw Amerongen, Intracellular signalling involved 
in modulating human endothelial barrier function. J Anat, 2002. 200(6): p. 549-60. 
81. van Nieuw Amerongen, G.P., et al., Activation of RhoA by thrombin in endothelial 
hyperpermeability: role of Rho kinase and protein tyrosine kinases. Circ Res, 2000. 
87(4): p. 335-40. 
82. Spindler, V., N. Schlegel, and J. Waschke, Role of GTPases in control of 
microvascular permeability. Cardiovasc Res, 2010. 87(2): p. 243-53. 
83. Schmid, M.C., et al., The VirB type IV secretion system of Bartonella henselae 
mediates invasion, proinflammatory activation and antiapoptotic protection of 
endothelial cells. Mol Microbiol, 2004. 52(1): p. 81-92. 
84. Rahman, M.M. and G. McFadden, Modulation of NF-kappaB signalling by microbial 
pathogens. Nat Rev Microbiol, 2011. 9(4): p. 291-306. 
85. Harms, A. and C. Dehio, Intruders below the radar: molecular pathogenesis of 
Bartonella spp. Clin Microbiol Rev, 2012. 25(1): p. 42-78. 
86. Fukazawa, A., et al., GEF-H1 mediated control of NOD1 dependent NF-kappaB 
activation by Shigella effectors. PLoS Pathog, 2008. 4(11): p. e1000228. 
87. Zhao, Y., et al., Control of NOD2 and Rip2-dependent innate immune activation by 
GEF-H1. Inflamm Bowel Dis, 2012. 18(4): p. 603-12. 
88. Keestra, A.M., et al., Manipulation of small Rho GTPases is a pathogen-induced 
process detected by NOD1. Nature, 2013. 496(7444): p. 233-7. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 Additional results 
  
- Additional results - 
82 
 
4.1 Results 
4.1.1 Recombinant BepCBhe (FIC-OB) is modified after overexpression in E. coli. 
Since BepC is a Fic protein, we speculated that the FIC domain may catalyze posttranslational 
modifications on host target proteins. Furthermore, the crystal structure of the FIC domain of 
BepC from Bartonella tribocorum shows binding of AMP-PNP (a non-hydrolysable analog of 
ATP) in an AMPylation-competent conformation (Fig. 1.9). Nevertheless, an enzymatic activity 
has never been demonstrated.  
To perform biochemical studies, BepCBhe was overexpressed in E. coli and purified. As the full-
length effector is mostly insoluble (Fig. 4.S1), only the FIC domain and the OB fold of the 
protein (FIC-OB) were cloned into an expression vector with C-terminal His-tag. After the first 
step of purification by affinity chromatography via the His-tag, the fractions were separated 
according to their size on a gel filtration column. The elution fractions containing BepCBhe 
(FIC-OB) were analyzed by SDS-PAGE and pooled before being concentrated by filtration 
(Fig. 4.1A). The pooled and concentrated eluate, as well as the flow-through, were analyzed 
with Nanodrop (Fig. 4.1B). The absorbance spectra showed the presence of a contaminant 
absorbing at 260 nm in the flow-through and in the concentrated eluate, suggesting that an 
unknown compound was co-purifying with BepCBhe (FIC-OB).  
As some Fic proteins transfer an AMP moiety on one of their own residue (auto-modification) 
[1-3], it is conceivable that BepCBhe (FIC-OB) would already be modified if its substrate is 
present in E. coli. Thus, it is likely that the presence of this moiety would prevent further auto-
modification during enzymatic experiments, which could be interpreted as a low activity.  
To test whether the purified BepCBhe (FIC-OB) was already auto-modified, we analyzed the 
protein by mass spectrometry. As we measure the mass of the non-digested polypeptide, a 
difference could correspond to a single or to a combination of modifications on different 
residues. Four samples from independent purifications were tested, three of BepCBhe (FIC-OB) 
wild-type, including one with the co-expression of the antitoxin, and one of BepCBhe with the 
mutated histidine of the FIC motif (H146A) (Fig. 4.2A).  
The mass spectra showed that the wild-type proteins had a mass of 34’715 Da in the three 
conditions. The mass of BepCBhe H146A was 34’648 Da, the difference of 66 Da in comparison 
with the wild-type protein corresponded exactly to the difference of mass between a histidine 
and an alanine. The measured mass of the antitoxin (8’676 Da) correlates with its theoretical 
mass without the N-terminal methionine, suggesting that it has been removed by the E. coli 
methionine aminopeptidase [4]. If we also assume that the first methionine of BepC is cleaved, 
the difference between the measured mass and the theoretical mass is 284 Da for the wild-
type protein and 283 Da for the mutant (Fig. 4.2B). This result suggests that the wild-type and 
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the mutant proteins are similarly modified. As only one peak corresponding to BepC is visible 
on the mass spectra, we can also assume that the vast majority of the recombinant proteins 
carry the same modification(s).  
Overall, an unidentified compound seems to co-purify with BepCBhe (FIC-OB) after expression 
in E. coli. However, it remains elusive whether it corresponds to a contamination or to a 
relevant ligand. Furthermore, our results indicate that the majority of recombinant protein is 
modified but independently from the presence of the antitoxin or the conserved histidine. 
4.1.2 BepCBhe (FIC-OB) has residual auto-AMPylation and auto-phosphorylation 
activities in vitro. 
As indicated before, some Fic proteins are known to auto-modify themselves [1-3]. Therefore, 
we decided to investigate the auto-modification activity of BepC as a read-out for a potential 
catalytic activity that would serve for posttranslational modifications. 
To test it, we incubated recombinant BepCBhe (FIC-OB) at 30°C in presence of ATP carrying a 
radioactive phosphate either in α or γ position (α-32P-ATP or γ-32P-ATP) (Fig. 4.S2A). The 
autoradiography indicated that BepCBhe (FIC-OB) is AMPylating and phosphorylating itself at 
the same time (Fig. 4.3). This result suggests that ATP can adopt two different orientations in 
the active site of BepC, one compatible with AMPylation and one with phosphorylation. 
Nevertheless, the auto-modification of BepC is rather slow and did not arrive at equilibrium 
even after 8 hours. Interestingly, a dimer of BepC is slightly visible on the polyacrylamide gel 
after 24 hours of incubation, although the proteins have been denatured at 95°C for 5 minutes 
in presence of SDS.  
Based on these results, we wanted to determine which residue of the FIC domain is 
AMPylated. To do so, we incubated BepCBhe (FIC-OB) in absence or in presence of ATP. After 
stopping the reaction, the protein was trypsinized and the peptides were analyzed by mass 
spectrometry to find an additional mass of 329 Da, which corresponds to an AMP moiety. Other 
modifications have not been investigated.  
The peptide coverage was high for both samples (Fig. 4.4). Interestingly, one of the few 
peptides that were not detected in both conditions (MPAMRPK) is located at the beginning of 
the Flap region (Alignment 1.2). Some of the methionines were oxidized, probably due to 
technical manipulations, which resulted in a mass shift of 16 Da per residue. Surprisingly, no 
additional AMP moiety was found in association with any of the peptides, which suggests that 
BepCBhe (FIC-OB) was not AMPylated in presence of ATP. However, it is possible that the 
amount of AMPylated peptides was too low to be detected or that we lost the modified peptide 
during the sample processing.  
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In summary, the radioactive assays indicate that BepCBhe is enzymatically active and is able 
to slowly auto-modify itself by AMPylation and phosphorylation. Nevertheless, the AMPylated 
peptide could not be detected by mass spectrometry although other modifications are possible. 
4.1.3 A conserved FIC motif is not required for the auto-AMPylation of BepC Bhe 
(FIC-OB). 
To confirm that the auto-AMPylation activity depends on the FIC motif, we partially purified 
BepCBhe (FIC-OB) with the mutated conserved histidine (H146A). After incubation with 
radioactive ATP at 25°C, the substitution of the histidine did not seem to reduce the auto-
AMPylation activity of BepC in comparison with the wild-type protein (Fig. 4.5). As the mutation 
of the histidine is not always sufficient to prevent AMPylation [5], we also decided to mutate 
the residues of the FIC motif (BepCBhe****) that were shown to interact with the ATP derivative 
in the active site of BepCBtr (Fig. 1.9). Although the activity seemed to be reduced in 
comparison with the wild-type effector, a signal corresponding to BepCBhe**** (FIC-OB) was 
still detected (Fig. 4.5). This result suggests that the modification is not dependent on a 
functional active site and might not be linked to an enzymatic activity. 
The non-canonical FIC motif of BepCBhe (HxFxKGNGRxxR) only differs from the canonical 
motif (HxFx(D/E)GNGRxxR) by a lysine residue instead of a negatively charged amino acid 
(D/E). Thus, we assumed that the exchange for a glutamate might restore a defective 
AMPylation activity. However, BepCBhe K150E (FIC-OB) did not show an increase in 
radioactive signal (Fig. 4.5), suggesting that other residue(s) than the canonical FIC motif are 
necessary for an auto-AMPylation activity. Another hypothesis would be that BepC is not able 
to actively auto-modify itself but would still be able to AMPylate a target protein in vivo. 
Therefore, the FIC motif does not seem to actively participate in the auto-modification of BepC. 
4.1.4 BepCBhe (FIC-OB) does not AMPylate or ADP-ribosylate host proteins in 
vitro. 
Host-targeted Fic proteins such as Bep1 [6], VopS [7] and IbpA [5] AMPylate a subset of small 
GTPases by using ATP. As BepC activates the RhoA pathway and interacts with GEF-H1 and 
MRCKα during infection, we were wondering if BepC could modify one of these host proteins. 
To test it, we incubated BepCBhe (FIC-OB) with a lysate of HeLa cells in presence of 
radioactively labeled ATP (α-32P-ATP ) for one hour (Fig. 4.6A). Although an auto-AMPylation 
activity was detected for BepC, no radioactive signal corresponding to an AMPylated host 
target could be observed.  
As nicotinamide adenine dinucleotide (NAD+) can be used by the bacterial toxin TccC5 to 
modify and activate RhoA by ADP-ribosylation to induce actin stress fibers [8], we decided to 
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test whether BepC could also use it as a substrate (Fig. 4.S2B). Recombinant BepCBhe 
(FIC-OB) was incubated in presence of HeLa cell lysate and radioactive NAD+ (α-32P-NAD+) 
for one hour (Fig. 4.6B). Only a weak signal that could reflect an auto-modification of BepC 
was detected while no signal corresponding to a modified target was visible in the cell lysate. 
Overall, BepC (FIC-OB) does not AMPylate or ADP-ribosylate a host protein in the tested 
conditions. However, we can not exclude that BepC is actually able to modify a target protein, 
such as RhoA, GEF-H1, or MRCKα in vivo or in other experimental conditions in vitro. 
4.1.5 BepCBhe (FIC-OB) is stabilized by nucleoside tri- and di-phosphates as well 
as pyrophosphate. 
Fic proteins with a non-canonical FIC motif have been shown to use other substrates than ATP 
to posttranslationally modify their target protein, such as CDP-choline or UTP [9, 10]. As BepC 
also display a non-canonical FIC motif and a slow auto-modification activity in presence of 
ATP, we formulated the hypothesis that this effector might use another substrate. 
To test different substrates, we mixed purified BepCBhe (FIC-OB) with increasing 
concentrations of nucleotide derivatives (Fig. 4.S3) and measured the thermal stability of the 
protein by TSA (thermal shift assay). An increase of the melting temperature (Tm) of the protein 
in function of the concentration of the tested molecule indicates the binding of a ligand. 
All tested nucleoside triphosphates (NTPs: ATP, GTP, CTP, UTP) increased the stability of 
BepCBhe (FIC-OB) with a similar effect (Fig. 4.7A), suggesting that the composition of the 
nitrogenous base is not critical for binding. Nucleoside diphosphates (ADP, GDP) and 
pyrophosphate (PPi) were also able to stabilize the FIC domain but with less efficiency than 
NTP (Fig. 4.7B). The incubation with AMP, a nucleoside monophosphate, did not stabilize the 
protein which was rather surprising knowing that phosphate or sulfate buffers already increase 
its stability (data not shown). These data suggest that having three phosphates is optimal for 
the nucleosides to bind to the FIC domain of BepC. However, having only two phosphates was 
already reducing the ability of the nucleoside to stabilize the protein while having one 
phosphate completely abolished it. 
To test whether a larger substrate could bind to the effector, we mixed BepCBhe (FIC-OB) with 
dinucleotides (Fig. 4.7C). The result showed that NADH stabilized the FIC domain only at 
millimolar concentrations, implying that it is a really poor binding partner compared to NTPs. 
However, NADPH was as efficient as nucleoside di-phosphates, suggesting that a negative 
charge on the ribose helps to stabilize the FIC domain. This hypothesis is in accordance with 
the observation that CoASH (Fig. 4.7E), which has a phosphate on the other hydroxyl group 
of the ribose, was able to increase the stability of BepC. 
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Finally, we also tested nucleotide derivatives with diverse extensions on the β-phosphate, such 
as flavin adenine dinucleotide (FAD), ADP/UDP-glucose, CDP-choline, and UDP-GlcNAc (Fig. 
4.7D and Fig. 4.8A). Although they are all composed of a nucleotide di-phosphate moiety, they 
were not able to increase the thermal stability of BepC. These data suggest that either these 
molecules were too large to fit in the active site of BepC or that their extensions were interfering 
with the binding in the FIC domain. 
Overall, our results suggest that BepCBhe (FIC-OB) is stabilized by a wide variety of nucleotide 
derivatives although it preferentially binds to nucleoside triphosphates. 
4.1.6 A conserved FIC motif is required for the thermal stability of BepC. 
According to our previous results, BepCBhe H146A (FIC-OB) is still able to auto-AMPylate itself 
(Fig. 4.5). Thus, we wanted to determine whether the mutation of the conserved histidine has 
an influence on the binding of different nucleotide derivatives. 
To answer this question, we mixed BepCBhe H146A (FIC-OB) with ATP, NADPH, and UDP-
GlcNac and compared its thermal stability to the wild-type protein (Fig. 4.8A). Even at a high 
concentration of nucleotide derivatives, our data did not show any stabilization of the FIC 
domain of BepC H146A, neither by ATP nor by NADPH. Moreover, the incubation of BepCBhe 
(FIC-OB) with mutations in the FIC motif (BepC H146A, BepC****, BepC K150E) at 30°C in 
presence of 1 mM ATP indicated that all the mutants were less stable than the wild-type protein 
and precipitated over time (Fig. 4.8B).  
In conclusion, these observations suggested that mutations in the FIC motif prevented the ATP 
to bind and stabilize BepC. 
4.1.7 BepC does not require magnesium to have auto-AMPylation activity and 
to bind nucleotides derivatives. 
In Fic proteins with a canonical FIC motif, a negatively charged residue is necessary to stabilize 
an ion of magnesium (Mg2+) that mediates the interaction with the α- and β-phosphates of the 
ATP [2]. In the non-canonical FIC motif of BepC, the lysine directly interacts with the 
phosphates via its positive charge (Fig. 1.9). According to this observation, BepC should not 
require Mg2+ to bind nucleotides derivatives or for its enzymatic activity. 
To test this hypothesis, we mixed BepCBhe (FIC-OB) with different concentrations of nucleotide 
derivatives in presence or absence of MgCl2 and measured the thermal stability of the protein. 
Although we could not exclude that there was no Mg2+ left in the condition without MgCl2, 
preliminary results showed that the addition of magnesium slightly reduced the ability of 
nucleotides derivatives to stabilize the FIC domain (Fig. 4.9A). This effect suggests that Mg2+ 
seemed to prevent the nucleotides derivatives to bind to the active site of BepC. 
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In order to determine whether Mg2+ is necessary for the activity of BepC, we incubated BepCBhe 
(FIC-OB) with radioactive ATP or NAD+ in presence or in absence of MgCl2 (Fig. 4.9B). The 
autoradiography only showed an auto-AMPylation of BepC and no auto-ADP-ribosylation. This 
result was in accordance with the findings of the binding experiments suggesting that NAD+ 
does not bind to the FIC domain of BepC. The presence of Mg2+ greatly reduced the auto-
AMPylation of BepC, possibly by interacting with the ATP in solution and preventing its binding 
to the active site.  
In accordance with the presence of the lysine residue in its FIC motif, these results confirm 
that BepC does not need Mg2+ to bind nucleotides derivatives or have an enzymatic activity. 
4.1.8 BepC belongs to the class I Fic proteins. 
The overexpression of Fic protein effectors can inhibit the growth of Bartonella in absence of 
antitoxin [2]. Therefore, we decided to test whether the overexpression of BepC in Bhe is also 
inducing growth inhibition, which could be problematic for infection assays. 
Thus, we incubated Bhe ΔbepA-G overexpressing BepC of different Bartonella species, or 
GFP as a negative control, on agar plates at different concentrations of IPTG (Fig. 4.10). In 
the absence or at low concentration of IPTG (10 µM), the expression of BepC had no effect on 
Bhe growth. By contrast, all effectors inhibited the growth of the bacteria at 100 µM of IPTG. 
Interestingly, the inhibition due to BepCBtr was less drastic but this difference does not seem 
to be linked to an expression defect (data not shown). 
The role of the antitoxin is to inhibit the activity of class I Fic protein, which could be deleterious 
for the cell [2]. As some Bartonella species of the lineage 4, such as Bqu and Bta, have an 
antitoxin encoded directly in front of bepC, our hypothesis was that BepCBhe might interact with 
the antitoxin of Bartonella henselae (ATBhe), which could reduce its adverse effect on bacterial 
growth. 
To test it, we co-expressed the HA-tagged ATBhe with His-tagged BepCBhe (FIC-OB) in E. coli. 
After cell lysis, BepCBhe was purified by affinity chromatography and gel filtration. The analysis 
of the elution fractions by SDS-PAGE showed that the antitoxin was co-purified with BepCBhe 
(FIC-OB), confirming an interaction with the FIC domain in vitro (Fig. 4.11A). The identity of 
the two proteins was confirmed by western blot and compared to a purified fraction of BepCBhe 
(FIC-OB) that has not been co-expressed with the antitoxin (Fig. 4.11B). Interestingly, the 
signal detected between 37 and 50 kDa on the anti-HA western blot could correspond to a 
toxin-antitoxin complex although it was not visible by SDS-PAGE or by anti-Flag western blot. 
Despite the presence of the endogenous antitoxin gene in Bhe ΔbepA-G, the expression would 
probably not be sufficient to inhibit the overexpressed Fic proteins. Therefore, we co-
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expressed the antitoxin and BepCBhe from the same plasmid in order to reduce growth inhibition 
(Fig. 4.12). Typically, the transcription of the BepCBhe is under the control of a single Ptaclac 
promoter, inducible with IPTG (A). For coupled expression, the antitoxin sequence is located 
downstream of a Shine-Dalgarno (SD) sequence, leading to a high expression level (strong 
SD) while two different combinations were tested for the effector. The first construct (B) is 
based on translational coupling with the stop codon of the antitoxin overlapping the start codon 
of the effector (TAATG). In the second construct (C), the sequence encoding BepCBhe is 
located downstream a mutated SD sequence (weak SD) in order to reduce the affinity with the 
ribosome. 
Nevertheless, the co-expression of the antitoxin could not prevent the growth defect induced 
by the expression of BepCBhe at 100 µM of IPTG, suggesting that either the growth defect was 
not due to a potential activity of BepC or that the antitoxin was not able to inhibit it. 
To determine if a putative activity of BepC is playing a role in growth inhibition of Bhe ΔbepA-
G, we overexpressed BepCBhe with mutations in the non-canonical FIC motif as well as BepFBhe 
and BepEBhe as negative controls (Fig. 4.13). Only BepC with a combination of the mutated 
conserved histidine and mutations of the residues interacting with the phosphates of the 
nucleotide (BepC****) showed a slight reduction in growth inhibition at 100 µM of IPTG. 
According to this result, the active site of BepC is probably not participating in growth inhibition. 
To identify other regions that could be involved in the growth defect, truncated versions of 
BepCBhe were overexpressed in Bartonella (Fig. 4.14). The deletion of the first α helix, the FIC 
domain, and the FIC-OB domains did not restore bacterial growth, indicating that the BID 
domain alone has an inhibiting effect on Bartonella growth. This result is in accordance with 
the observation that mutations in the FIC motif or the co-expression of the antitoxin did not 
reduce the growth inhibition due to the overexpression of BepCBhe. 
As the co-expression of the antitoxin does not reduce growth inhibition, we wanted to 
determine whether it could have another function. As the thermal stability of the BepCBhe (FIC-
OB) is below 30°C at a low concentration of nucleotide (Fig. 4.7), we formulated the hypothesis 
that the antitoxin could stabilize it. 
To test it, we measured the stability of BepCBhe (FIC-OB), that has been expressed alone or 
co-purified with the antitoxin, in presence or in absence of ATP. Our results suggest that the 
presence of the antitoxin greatly increased the thermal stability of the protein, even at low ATP 
concentration (Fig. 4.15). This could suggest that the antitoxin acts as a chaperone by 
stabilizing the FIC domain of BepC inside the bacteria. 
In summary, our results indicate that BepCBhe binds to the antitoxin, which attributes the 
effector to the class I Fic proteins. Although it does not reduce the growth inhibition resulting 
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from the overexpression of BepCBhe, which is associated with the BID domain, it may act as 
the chaperone to stabilize the FIC domain inside Bartonella. 
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4.2 Discussion 
V. parahaemolyticus and H. somni subvert Rho GTPase signaling cascades via the two T3SS 
effectors VopS and IbpA, respectively, which AMPylate Rac, Cdc42, and RhoA via their FIC 
domain. The modification leads to the collapse of the actin cytoskeleton and eventually to the 
disruption of phagocytosis [5, 7]. Bartonella evolved a large panel of effectors carrying a FIC 
domain, suggesting a central role in pathogenesis. However, the enzymatic activity and the 
host target remain largely unknown for most of them. BepC is characterized by a non-canonical 
FIC motif (HxFxKGNGRxxR), which differs from the canonical motif in a lysine instead of an 
acidic residue. In protein with a canonical FIC motif, the negatively charged residue interacts 
with an ion of magnesium that mediates the interaction with the phosphate of the nucleotide 
(Fig. 1.9). Nevertheless, structural studies show that the lysine present in the FIC motif of BepC 
directly interacts with the phosphates of the nucleotide. Although the nucleotide binds in a 
conformation that is compatible with AMPylation, no enzymatic activity have ever been 
demonstrated for BepC. Interestingly, the fact that the conserved FIC motif is not required for 
actin rearrangements suggests that the putative activity of BepC would have another function. 
Recombinant BepC (FIC-OB) is modified after overexpression in E. coli.  
The analysis of full recombinant BepC (FIC-OB) by mass spectrometry indicates that the vast 
majority of purified proteins, both wild-type and histidine mutant, are modified after 
overexpression in E.coli. As many Fic proteins are able to auto-modify themselves via 
AMPylation [11], it is reasonable to think that BepC might modify itself if it has an enzymatic 
activity and is in presence of its substrate during expression. However, this would imply that 
the co-expression of the antitoxin or the mutation of the conserved histidine in the FIC motif do 
not interfere with the auto-modification activity. 
If we assume that the first methionine is cleaved by the E. coli methionine aminopeptidase,  
the mass change (283-284 Da) can not correspond to auto-AMPylation as the transfer of an 
AMP moiety corresponds to an additional mass of 329 Da. Accordingly, the analysis of the 
peptides of BepC after tryptic digestion did not show any AMPylated peptide. However, other 
modifications have not been investigated yet. 
As the mass of the full protein is measured, the mass change can correspond to several 
modifications. Considering that the mass spectrometry realized on peptides shows that five 
methionines of BepCBhe (FIC-OB) are oxidized (Δ mass 80 Da), the remaining difference would 
be 203 Da. This could correspond to a transfer of N-acetylglucosamine (GlcNac) from UDP-
GlcNac. Interestingly, the proposed mechanism of the human O-GlcNAc transferase is based 
on a catalytic histidine and a lysine to stabilize the UDP moiety (Fig. 4.S4). Furthermore, a 
toxin from Clostridium novyi, TcnA,  is using UDP-GlcNac to modify and inactivate Rho 
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GTPases by transferring a GlcNac moiety [12]. However, its catalytic domain has nothing in 
common with the FIC domain of BepC and is characterized by a DxD motif surrounded by a 
hydrophobic region. Although UDP-GlcNAc seems to be a poor substrate according to thermal 
shift assay, it might be worth to test it as a substrate for BepC by using a radioactive assay. 
BepC displays slow AMPylation and auto-phosphorylation activities, 
independently from the FIC motif. 
In presence of ATP, BepC has concomitant auto-AMPylation and auto-phosphorylation 
activities with similar kinetics. This suggests that the effector binds the ATP in two different 
conformations, one compatible with AMPylation and one with phosphorylation. Similarly, a dual 
conformation has been already observed for VbhT, a Fic protein of Bartonella 
schoenbuchensis [13], which AMPylates a bacterial gyrase [14]. However, this could also 
suggest that ATP is not the physiological substrate of BepC. The presence of a lysine in the 
FIC motif instead of a negatively charged residue might facilitate this dual activity. Thus, it 
would be relevant to test whether BepC with the restored canonical FIC motif still shows an 
auto-phosphorylation activity.  
Surprisingly, no AMPylated peptide could be identified by mass spectrometry after incubation 
in presence of ATP. Although a loss of the AMPylated peptide during sample preparation 
cannot be excluded, this result suggests either that only a small fraction of protein is modified 
and could not be detected by mass spectrometry or that the missing peptide (MPAMRPK) 
carries the modification. As this peptide does not contain any tyrosine, serine or threonine 
residue that could be modified, it is likely that BepC is hardly AMPylated.  
Furthermore, multiple mutations in the FIC motif do not result in a complete loss of activity and 
the restoration of a canonical motif does not increase AMPylation. This result suggests that 
the modification is independent of a functional active site and might not be due to an enzymatic 
activity. Therefore, it is possible that BepC is not able to auto-modify itself, in contrast to other 
Fic proteins. Additionally, the modification of the recombinant protein might interfere with a 
potential activity. 
As BepC interacts with GEF-H1 and MRCKα during infection, it could be possible that BepC 
posttranslationally modifies them, although this activity might not be crucial for actin 
rearrangements. Nevertheless, no AMPylated or ADP-ribosylated host protein could be 
detected in HeLa cell lysate after incubation in presence of BepC with radioactive ATP or 
NAD+. However, BepC could still modify a protein in vivo, by using ATP or another substrate. 
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BepC preferentially binds to nucleoside triphosphates. 
A molecule absorbing at 260 nm is co-purified with BepC (FIC-OB) after overexpression in 
E.coli. As the OB fold has been described to bind nucleic acid [15, 16] and DNA absorbs at 
260 nm, it could results from a contamination despite the use of DNAse. However, this 
compound could correspond to a nucleotide binding to the active site of the FIC domain of 
BepC. Further investigation is required to identify this compound, possibly by mass 
spectrometry. 
Due to its non-canonical FIC motif, it is conceivable that BepC uses another substrate to modify 
a protein target during infection. The increased thermal stability of BepC (FIC-OB) in presence 
of nucleotides triphosphate suggests that BepC could potentially use GTP, CTP or UTP to 
catalyze posttranslational modifications. Interestingly, BepA, which has a canonical FIC motif, 
can also use CTP and GTP for auto-modification [1]. However, it is unknown whether BepA 
can use these nucleotides to modify its host target during infection. The auto-modification of 
BepC, as well as the transfer on a protein target, could be tested by using radioactive NTPs 
and cell lysates. 
Larger substrates such as NADPH and Co-enzyme A can also bind to the effector, possibly 
due to the presence of a phosphate group on the ribose. According to the structure of the FIC 
domain of BepCBtr (Fig. 1.9), this phosphate should be stabilized by a residue that is not part 
of the FIC motif. Although these two molecules are not described as a substrate for 
posttranslational modifications, they could be used as a co-factor to stabilize the FIC domain.  
As proposed by the structure of the FIC domain of BepCBtr (Fig. 1.9), the conserved histidine 
of the FIC motif is necessary for the stabilization of the FIC domain in presence of ATP. 
Strikingly, each mutation in the FIC motif seems to affect the solubility of the protein, which 
could suggest that the ability to bind a nucleotide is crucial to stabilize the folding of the FIC 
domain. This observation could eventually explain why BepC with multiple mutations in the 
FIC motif (BepC****) has a reduced interaction with GEF-H1 and MRCKα (Fig. 3.7A). 
BepC does not need magnesium to bind nucleotide derivatives. The conserved lysine residue 
in the non-canonical FIC motif seems to be sufficient to stabilize the ATP in the active site. 
Interestingly, Mg2+ also reduces auto-modification activity, probably by binding to the 
phosphate of the ATP and competing with the binding in the active site.  
As the FIC motif of BepC is highly conserved, it is very likely that it plays a significant role in a 
function of BepC that is not linked to actin rearrangements. Whether this function would require 
posttranslational modification remains unknown. Even though ATP seems to be the best 
candidate, we cannot exclude that BepC uses another nucleotide derivative as co-factor to 
stabilize the FIC domain or as a substrate for posttranslational modification. 
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BepC belongs to the class I of Fic proteins 
As already observed for VbhT [2], Bep1, and Bep2, (data not shown) the overexpression of 
BepC from different Bartonella species inhibits the growth of Bhe in absence of antitoxin.  
Surprisingly, the co-expression of the antitoxin in Bartonella did not restore bacterial growth. 
In contrast with VbhT, mutations in the FIC motif hardly reduce growth inhibition. Therefore, 
the active site of BepC is probably not participating in the growth defect of Bartonella. In fact, 
the expression of the BID domain alone is sufficient to prevent bacterial growth, which is in 
accordance with the absence of positive effect of the antitoxin co-expression. The deleterious 
effect of the BID domain is presumably related to its tendency to localize to membranes [17] 
as the accumulation of effector would likely disrupts them. Although we cannot exclude that 
the antitoxin inhibits a potential activity that would be detrimental to the bacteria, its main role 
might be to serve as a chaperone to stabilize the protein. As Beps needs to be translocated 
inside the host cell via the T4SS, the FIC domain is probably not so stable in order to be 
unfolded during the process. Therefore, the antitoxin might bind to BepC to prevent unfolding 
and degradation before translocation.  
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4.3 Figures 
 
Figure 4.1. An unknown compound absorbing at 260 nm co-purifies with BepCBhe (FIC-
OB). 
His-tagged BepCBhe (FIC-OB) was overexpressed in E.coli and purified by affinity 
chromatography and gel filtration. Elution fractions were pooled and concentrated. A) SDS-
PAGE of purified fractions from the gel filtration. B) Absorbance spectra of pooled fractions 
B3-C3 (green), pooled fractions C4-C9 (brown), flow-through from concentration of pooled 
fractions B3-C3 (black) and flow-through from concentration of pooled fractions C4-C9 (red). 
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Figure 4.2. Purified BepCBhe (FIC-OB) have a mass shift of 283 Da. 
A) The masses of various recombinant BepCBhe (FIC-OB) were analyzed by mass 
spectrometry after overexpression in E.coli followed by affinity purification and gel filtration. B) 
Calculation of the mass shift by subtracting the theoretical mass to the measured mass. 
Masses of posttranslational modification of interest.   
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Figure 4.3. BepCBhe (FIC-OB) has both auto-AMPylation and auto-phosphorylation 
activities in presence of ATP. 
Purified BepCBhe (FIC-OB) was incubated 0.5, 1, 2, 4, 8 or 24 hours at 30°C in presence of 
radioactive ATP (α-32P-ATP or γ-32P-ATP) and 10 mM of nonradioactive ATP. The samples 
were loaded on a SDS-PAGE gel (left panel) and the auto-modification were detected by 
autoradiography (right panel). 
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Figure 4.5. The auto-AMPylation activity of BepCBhe (FIC-OB) is independent of the FIC 
motif. 
Partially purified BepCBhe (FIC-OB) wild-type and mutants were incubated 4 and 24 hours at 
25°C in presence of radioactive ATP (α-32P-ATP)  and 1 mM of nonradioactive ATP. Samples 
were loaded on a SDS-PAGE gel (right panel) and analyzed by autoradiography (left panel). 
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Figure 4.6. BepCBhe (FIC-OB) does not AMPylate or ADP-ribosylate a protein target in 
HeLa cell lysate in the tested conditions. 
Purified BepCBhe (FIC-OB) wild-type was incubated 1 hour at 30°C in presence of HeLa cell 
lysate. Samples were loaded on a SDS-PAGE gel (left panels) and analyzed by 
autoradiography (right panels). A) Incubation with ATP (α-32P-ATP) B) Incubation with NAD+ 
(α-32P-NAD) and 1mM of non-radioactive NAD+.  
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Figure 4.7. BepCBhe (FIC-OB) preferentially 
binds to nucleotide tri-phosphate. 
Purified BepCBhe (FIC-OB) wild-type was 
mixed with increased concentrations of 
nucleotide derivatives. The thermal stability of 
BepCBhe (FIC-OB) was measured by thermal 
shift assay (TSA). 
A) Nucleotide tri-phosphate 
B) Nucleotide di-phosphate + pyrophosphate 
C) Di-nucleotides 
D) Other nucleotide derivatives 
E) Co-enzyme A 
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Figure 4.8. BepCBhe (FIC-OB) with a mutated FIC motif seems less stable than the WT 
protein in presence of ATP. 
Purified BepCBhe (FIC-OB) wild-type or H146A mutant were mixed with increased 
concentrations of nucleotide derivatives. The thermal stability of the protein was measured by 
thermal shift assay (TSA). B) Purified BepCBhe (FIC-OB) wild-type and mutants were 
incubated 4 or 24 hours at 30°C in presence of radioactive ATP (α-32P-ATP) and 1 mM of 
nonradioactive ATP. Samples were loaded on a SDS-PAGE gel. BepCBhe**** =  BepCBhe 
H146A, K150A, R154A, R157A. 
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Figure 4.9. Mg2+ seems to reduce the stability of BepCBhe (FIC-OB) and its auto-
AMPylation activity. 
A) Purified BepCBhe (FIC-OB) wild-type was mixed with increased concentrations of nucleotide 
derivatives in presence or in absence of 1 mM MgCl2. The thermal stability of BepCBhe (FIC-
OB) was measured by thermal shift assay (TSA). B) Purified BepCBhe (FIC-OB) WT was 
incubated 1 hour at 30°C in presence of radioactive ATP (α-32P-ATP) or NAD+ (α-32P-NAD) 
with or without 5 mM of MgCl2. Samples were loaded on a SDS-PAGE gel (left panel) and 
analyzed by autoradiography (right panel). 
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Figure 4.10. Overexpression of BepC of different Bartonella species in Bhe ΔbepA-G 
induces growth inhibition. 
The expression of the indicated BepC was induced in Bhe ΔbepA-G in presence of different 
IPTG concentrations. Serial dilutions of bacteria were plated on CBA plates and incubated at 
35°C for 7 days. The number of bacteria spotted on the plate is indicated on the left side. 
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Figure 4.11. The antitoxin of Bhe binds to BepCBhe (FIC-OB).  
His-tagged BepCBhe (FIC-OB) was co-expressed with or without HA-tagged antitoxin (AT) in 
E. coli. After bacterial lysis, BepCBhe (FIC-OB) was purified by affinity chromatography and gel 
filtration. A) SDS-PAGE gel of the gel filtration elution fractions from the co-expression of BepC 
(FIC-OB) and the antitoxin. B) The purified proteins were resolved by SDS-PAGE (left panel) 
and the identity of BepC and AT was confirmed by western blot against Flag-tag (middle panel) 
or HA-tag (right panel).  
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Figure 4.12. Co-expressing the antitoxin does not reduce the growth inhibition mediated 
by BepCBhe in Bhe ΔbepA-G. 
The expression of the indicated constructs was induced in Bhe ΔbepA-G in presence of 
different IPTG concentrations. Serial dilutions of bacteria were plated on CBA plates and 
incubated at 35°C for 7 days. The number of bacteria spotted on the plate is indicated on the 
left side. 
 
- Additional results - 
106 
 
 
Figure 4.13. The growth inhibition mediated by the overexpression of BepCBhe in Bhe 
ΔbepA-G is independent of the FIC motif. 
The expression of the indicated constructs was induced in Bhe ΔbepA-G in presence of 
different IPTG concentrations. Serial dilutions of bacteria were plated on CBA plates and 
incubated at 35°C for 7 days. BepCBhe*** = BepCBhe K150A, R154A, R157A. BepCBhe**** = 
BepCBhe H146A, K150A, R154A, R157A. The number of bacteria spotted on the plate is 
indicated on the left side. 
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Figure 4.14. The overexpression of the BID domain of BepCBhe is sufficient to induce 
growth inhibition of Bhe ΔbepA-G. 
The expression of the indicated constructs was induced in Bhe ΔbepA-G in presence of 
different IPTG concentrations. Serial dilutions of bacteria were plated on CBA plates and 
incubated at 35°C for 7 days. The number of bacteria spotted on the plate is indicated on the 
left side. 
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Figure 4.15. The antitoxin- BepCBhe (FIC-OB) complex is more stable than BepCBhe (FIC-
OB) alone. 
Purified BepCBhe (FIC-OB) alone or BepCBhe (FIC-OB) co-purified with the antitoxin were mixed 
with increased concentrations of ATP. The thermal stability of the proteins was measured by 
thermal shift assay (TSA). 
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Figure 4.S1. BepCBhe full-length is mostly insoluble in comparison with BepCBhe (FIC-
OB). 
His-tagged BepCBhe full length and BepCBhe (FIC-OB) were overexpressed in E.coli. After cell 
lysis, the samples were centrifuged and only the supernatant was kept. Left panel: bacterial 
lysate before centrifugation. Right panel: supernatant after centrifugation. 
 
 
 
 
 
 
 
 
 
 
  
Figure 4.S2. Schematic representation of posttranslational modifications 
A) Structural diagram of ATP illustrating AMPylation with the transfer of the AMP moiety 
carrying the radioactive α phosphate (in red) or phosphorylation by transfer of the γ 
phosphate (in blue). B) Structural diagram of NAD+ illustrating ADP-ribosylation with the 
transfer of the ADP-ribose carrying the radioactive α phosphate.  
B A 
ADP-ribosylation 
β 
α 
β α γ 
Phosphorylation 
AMPylation 
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Figure 4.S3. Molecular structure of the nucleotides derivatives tested by thermal shift 
assay with BepCBhe (FIC-OB).  
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Figure 4.S4. Proposed molecular mechanism of O-GlcNAcylation by O-GlcNAc 
transferase [18].  
Figure from: https://commons.wikimedia.org/w/index.php?curid=31371846  
(Author: Messien17) 
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5.1 General conclusion 
Bacteria of the genus Bartonella disseminate in the environment via arthropods to infect a wide 
variety of mammals. Several species are associated with human diseases such as Oroya fever 
for B. bacilliformis, trench fever for B. quintana, or cat-scratch disease for B. henselae. 
Although the infection can be life-threatening for the infected host, it usually remains 
asymptomatic and develops in long-lasting bacteremia. The stealth infection strategy that most 
Bartonella species adopted goes hand in hand with the evolution of a panel of virulence factors 
in order to compete with the host immune system and to persist in an intracellular niche [1]. 
During infection, the bacteria translocate a cocktail of effectors into the cell via a VirB/D4 T4SS 
and thereby subvert cellular processes to their advantage. Among these effectors, BepC is 
one of the most conserved in the Bartonella species of the lineage 4, indicating an important 
role in pathogenesis. This effector was previously shown to interfere with cell migration [2] and 
to be involved in the engulfment of large bacterial aggregates, suggesting its contribution to 
cell invasion [3, 4].  
In this study, we could demonstrate that BepC modulates the Rho GTPase signaling cascade, 
a well-known target of bacterial pathogens and their hosts (see chapter 1.2). In human cells, 
BepC localizes to cell contacts and induces bacterial aggregation as well as cytoskeleton 
rearrangements. The stimulation of actin stress fiber formation is conserved among BepC 
orthologs of different Bartonella species, such as the human pathogens Bhe and Bqu, 
suggesting that a significant contribution to the bacterial life cycle stands behind this 
phenotype. 
During infection, BepC interacts with GEF-H1 and MRCKα, two proteins involved in actin stress 
fiber formation via the RhoA and Cdc42 pathways, respectively [5, 6]. We could show that the 
ability of BepC to induce actin rearrangement highly correlates with its ability to bind GEF-H1 
and MRCKα. Accordingly, infected cells display an increase of GTP-bound RhoA and 
phosphorylated myosin light chain. Additionally, the actin phenotype mediated by BepC is 
visibly reduced after treatment with inhibitors of RhoA and its downstream target ROCK. 
Thereby our data indicate that BepC triggers actin rearrangement by activating the RhoA 
pathway via its interaction with GEF-H1, although MRCKα could act synergistically. BepC is 
the only known T4SS effector and the sole Fic protein that is described to modulate a Rho 
GTPase signaling cascade by directly interacting with GEF-H1. Apart from BepC, only the 
T3SS effector VopO from Vibrio parahaemolyticus showed an interaction with this host factor 
[7]. 
The interaction with GEF-H1 and MRCKα, the actin rearrangements, and the localization of 
BepC to cell contacts are completely abolished in a truncation mutant, in which the N-terminal 
FIC domain is missing. This indicates a central role for the FIC domain of BepC in these 
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processes. As the conserved FIC motif is not required to induce actin rearrangements, BepC 
is probably not activating the RhoA pathway by posttranslational modifications but rather via 
protein-protein interactions. 
The FIC domain of BepC displays only low auto-AMPylation and auto-phosphorylation 
activities, which suggest that it might not be enzymatically active due to its non-canonical FIC 
motif. Despite such minor activity, structural analysis and binding assays demonstrate that 
nucleotide derivatives bind to the FIC domain of BepC and increase its thermal stability. The 
interesting finding that a FIC domain exerts a biological function unrelated to its catalytic activity 
is unique and only remotely reminiscent of the Fic protein AvrB, which lacks all residues 
needed for an enzymatic activity [8]. Furthermore, it opens new perspectives for the function 
of Beps carrying a non-canonical FIC motif and lacking an enzymatic activity. 
As GEF-H1 and MRCKα are involved in a multitude of cellular processes, the function of BepC 
might vary according to the different cell types infected by Bartonella through the different 
stages of the infection cycle. Based on the activation of the Rho GTPases signaling pathway, 
we can speculate that BepC might participate in pathogenesis by preventing phagocytosis and 
immune cell migration, or help overcome the endothelial barrier in order to colonize the blood 
and establish bacteremia. 
Finally, the identification of the host proteins and the signaling pathway targeted by BepC gives 
a better insight on how Bartonella manipulates the host cell via the injection of bacterial 
effectors. Concretely, the results obtained in this study provide a sound basis for future in-
depth investigations on the biological function of BepC during pathogenesis in its interaction 
with host factors as well as with Bartonella effectors proteins. 
5.2 Outlook 
5.2.1 Enzymatic activity of the FIC domain of BepC. 
As the FIC motif of BepC is highly conserved and binds nucleotide derivatives, it is reasonable 
to think that it displays an enzymatic activity and modifies a host protein. However, the 
substrate, the type of reaction, and the target remain unidentified despite our efforts. Knowing 
that BepC interacts with GEF-H1 and MRCKα during infection, it would be interesting to test 
whether they are posttranslationally modified. To do so, the two proteins could be pulled-down 
from cells infected with Bhe ΔbepA-G expressing BepC and analyzed by mass spectrometry 
in order to identify a modified peptide. Additionally, we could perform AMPylation and 
phosphorylation assays with radioactive ATP and purified proteins.  
Nevertheless, it is also possible that BepC modifies another host protein. As an enzymatic 
reaction generally implies a short interaction with the target, it is likely that we would not be 
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able to co-immunoprecipitate the host protein together with BepC. To avoid this issue, we could 
use BepC with multiple mutations in the FIC motif (BepC****), which is probably not catalytically 
functional, to stabilize a complex and be able to pull-down further targets of BepC. 
Additionally, the association of a phenotype with the FIC motif would provide a significant 
indication of a potential host target modified by BepC. Therefore, we could determine whether 
BepC with mutations in the FIC motif are also able to participate in invasome formation. 
Further, as Bartonella infects dendritic cells in vitro, we could test whether BepC is able to 
modulate cytokines production by those cells in a FIC-motif dependent manner.   
Although our results show that BepC binds to the antitoxin of Bhe, this interaction does not 
prevent the growth inhibition associated with the overexpression of the effector in Bartonella. 
We conclude from our experiments that the growth defect is distinct from the activity of the 
effector on host cell as it is solely BID-dependent. Whether the antitoxin inhibits a putative 
activity or acts as a chaperone remains to be elucidated. 
Finally, purified BepC from other Bartonella species could be tested by AMPylation and 
phosphorylation assay in order to detect a target protein in cell lysates from different cell types.  
5.2.2 Antagonism between BepC and BepE. 
Although the identity of BepE host target remains unknown, the effector was proposed to 
modulate the RhoA pathway during infection [2]. Additionally, BepE interferes with cell 
fragmentation mediated by BepC in HUVECs, suggesting an antagonist effect. Having 
identified BepC host targets sheds new light on the function of BepE during infection. 
As BepC activates the RhoA pathway by interacting with GEF-H1, it is unlikely that BepE is 
also stimulating this signaling cascade. By contrast, it is conceivable that BepE counteracts 
the effect of BepC by disrupting the RhoA signaling. Interestingly, our data indicate that actin 
stress fiber formation mediated by BepC can be reversed by inhibiting the RhoA pathway with 
Rho and ROCK inhibitors. Thus, it would be reasonable to think that BepE could act in a similar 
manner to down-regulate the pathway by targeting one of its components. To determine 
whether BepE would prevent actin stress fiber formation, we could co-infect HeLa cells with 
two strains of Bhe ΔbepA-G, one expressing BepC and the other one BepE.  
The strategies developed by pathogenic bacteria to inactivate Rho GTPases consist of GDI 
mimicry, GAP mimicry, GTPase release from the plasma membrane, GEF inhibition, and 
posttranslational modification of the GTPase (see chapter 1.2.2). As the abolition of the cell 
fragmentation phenotype is mediated by the BID domains of BepE, it is likely that the effector 
would interfere with the GTPase signaling rather by protein-protein interaction than via an 
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enzymatic activity. As it was performed for BepC, pulling down BepE after cell infection could 
lead to the identification of a potential host target, possibly associated with the RhoA pathway.  
Another possibility for BepE to reduce the cell fragmentation phenotype would be to interact 
directly with BepC in order to inhibit its function. Interestingly, the localization of BepE and 
BepC to cell junctions suggests that they might be in close proximity during infection [2]. To 
test this hypothesis, we could determine if BepC and BepE co-localize at cell-to-cell contacts 
and if they interact together by co-immunoprecipitation. 
5.2.3 Cooperation between BepC and BepF. 
In contrast to BepE, which has an antagonist effect on the cell fragmentation mediated by 
BepC, BepF has a synergetic effect that results in the engulfment of large bacterial aggregates 
(invasome). Although the host target of BepF is still unknown, the effector seems to regulate 
the Cdc42 and the Rac1 signaling pathway [4]. Thus, it is conceivable to think that the two 
effectors cooperate to tightly modulate the RhoA, Rac1 and Cdc42 pathways, which leads to 
invasome formation. However, our data suggest that inducing actin rearrangements or 
bacterial aggregation is not sufficient to trigger invasome formation. To confirm that BepC 
participates in invasome formation via the activation of the RhoA pathway, it would be 
interesting to determine whether RhoA and ROCK inhibitors would prevent the process of 
bacterial clustering and/or engulfment.  
Furthermore, we could check if invasome formation correlates with the ability of BepC to 
interact GEF-H1 and MRCKα. To do so, the different mutants and the truncated version of 
BepC could be tested for invasome formation. These results would also determine if the FIC 
motif, the Flap region, or the BID domain of BepC are necessary for invasome formation 
together with BepF.  
Both BepF and BepC localize to the invasome during infection with Bhe wild-type [4], which 
could indicate a potential interaction during infection. Therefore, it would be relevant to pull-
down BepF after cell infection to check whether it binds to BepC. Additionally, it could reveal 
a potential host target that is involved in the Rac1 and/or Cdc42 pathways. 
5.2.4 Participation of MRCKα in the actin phenotype mediated by BepC. 
Although BepC interacts with both GEF-H1 and MRCKα, our results do not allow us to 
conclude whether MRCKα participates in the actin rearrangements. However, we could exploit 
the fact that ROCK and MRCKα both phosphorylate myosin light chain (MLC2) but not on the 
same residue. While ROCK di-phosphorylates MLC2 (ppMLC) on Thr18 and Ser19, MRCKα 
only mono-phosphorylate MLC2 on Ser19 (pMLC) [8]. Thus, the difference of phosphorylation 
site could be used to determine if MRCKα contributes to the increase of phosphorylated myosin 
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light chain during cell infection with Bhe ΔbepA-G expressing BepC. If pMLC increases in the 
same proportion as ppMLC in comparison with a negative control (Bhe ΔbepA-G pEmpty), this 
would suggest that ROCK is mainly responsible for the MLC2 phosphorylation. By contrast, if 
pMLC increases while ppMLC stays at the same level, the phosphorylation of MLC2 can be 
attributed to MRCKα. Another method to determine the participation of MRCKα in actin 
rearrangement would be to use a selective inhibitor called chelerythrine [8]. Therefore, we 
could treat HeLa cells or HUVECs with this molecule to check whether BepC is still able to 
induce actin rearrangements or if the activity of MRCKα is necessary. 
5.2.5 Characterization of the interaction between BepC, GEF-H1, and MRCKα. 
Until now, the interface of the FIC domain of BepC that is necessary for binding GEF-H1 and 
MRCKα, and therefore for the actin phenotype, remains unidentified. Our finding that BepC 
from different Bartonella species is able to trigger actin rearrangements indicates that the 
interaction is probably mediated via a highly conserved region. As neither the first helix nor a 
conserved Flap or FIC motif is necessary for interaction and most of the remaining residues 
conserved in the FIC domain of BepC are also found in BepA, it considerably reduces the 
possibilities. One candidate is a region composed of eleven highly conserved residues 
(MFMEKLGQAAG) that is located at the end of the α-helix carrying the FIC motif (Fig. 5.1). 
Although several residues of this region are also conserved in BepA, some of them are specific 
to BepC and might be involved in target recognition. Therefore, it would be relevant to 
substitute this region with the region of BepA or introduce mutations to test whether the hybrid 
protein could still bind GEF-H1 and MRCKα and trigger actin rearrangements. 
Reciprocally, it is unknown which domain(s) of GEF-H1 and MRCKα participate in the 
interaction with BepC. To answer this question, truncated versions of GEF-H1 and MRCKα 
could be ectopically expressed in eukaryotic cells that would be subsequently infected with 
Bhe ΔbepA-G expressing BepC. Then, a pull-down experiment would indicate which region of 
the host proteins are required for interaction. Another option would be to purify truncated GEF-
H1 and MRCKα for pull-downs experiments with BepC. 
- General conclusion and outlook - 
119 
 
 
Fig 5.1. BepC displays a highly conserved region following the FIC motif. 
A. Alignment of the α-helices carrying the FIC motif of BepC and BepA from Bartonella species 
of the lineage 4. B. Surface representation of the crystal structure of BepCBtr with AMP-PNP in 
the active site. The red color gradient represents pairwise identity based on 14 alignments of 
BepC from different Bartonella species. The most conserved residues are represented in red 
and less conserved residues in white. The FIC motif is represented in magenta and the 
following conserved region in cyan. C. Cartoon representation of (B).  
 
5.2.6 Host specificity 
BepC of Bhe, Bqu, Btr, Bta all trigger actin stress fiber formation in HeLa cells but at a different 
level of intensity. Furthermore, BepC of Bgr did not show any actin phenotype. A translocation 
defect, host specificity, or a loss of function could explain these differences. To exclude a 
translocation defect, a plasmid encoding BepC from the different species could be transfected 
into eukaryotic cells in order to bypass the secretion by the T4SS. Thus, the ectopic expression 
would answer whether BepC from these species can trigger actin rearrangements with a 
similar intensity. Additionally, the host specificity of BepC could be addressed by infecting 
rodent cells instead of humans cells as Bgr, Bta and Btr have the mouse, the vole, and the rat 
for reservoir host, respectively. 
5.2.7 Investigation of the role of BepC in pathogenesis. 
Although we present here the host targets of BepC and describe its phenotype on endothelial 
and epithelial cell infection, the overall function of the effector during pathogenesis remains to 
be elucidated. As BepC might disrupt cellular junctions via the activation of the RhoA pathway, 
it could also affect the integrity of the endothelial barrier and facilitate the colonization of the 
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blood by Bartonella. In order to investigate this possibility, the permeability can be evaluated 
by an in vitro model in which HUVECs are seeded on a cell culture insert with a porous 
membrane. After growing to confluence and occluding the pores, the endothelial cell 
monolayer can be infected with Bhe ΔbepC and compared to Bhe wild-type. Then, the 
permeability can be tested by adding fluorescent dextran on top of the cells, which will diffuse 
through the porous membrane if the barrier integrity has been compromised. Additionally, this 
assay can be used to test whether Bartonella can cross the endothelial cell layer via 
transcytosis or by disturbing cell junctions. 
During infection of HeLa cells and EA.hy926, BepC leads to the aggregation of bacteria, which 
seems to correspond to the first phase of invasome formation. Furthermore, BepC and BepF 
inhibit the endocytosis of inert microspheres [4]. If the bacterial clusters mediated by BepC 
remain outside the cell, this could signify that the effector alone is sufficient to block the 
internalization of Bartonella containing vacuoles. Whether the bacterial clusters are engulfed 
or sitting on top of the cell can be addressed by confocal microscopy. Subsequently, the 
inhibition of endocytosis could be investigated by measuring the uptake of fluorescent 
microspheres by infected cells expressing BepC. 
A potential consequence of the activation of the RhoA pathway by BepC is an activation of 
NF-κB via NOD1 and/or NOD2 signaling, which could eventually lead to an immune response. 
This hypothesis can be tested by infecting HUVECs with Bhe ΔbepA-G expressing BepC and 
measure IL-8 secretion in the culture supernatant or the expression of the adhesion molecule 
ICAM-1 at the cell surface [9]. If BepC induces a pro-inflammatory response, it would be 
interesting to test whether the presence of BepE could reduce the phenotype and thereby 
preventing the stimulation of an immune response by the infected host.   
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DNA manipulations  
Plasmids and primers used in this study are listed in at the end of the chapter. 
Bacterial strains and growth conditions 
The bacterial strains used in this study are listed in at the end of the chapter.  
Bartonella species were grown on Columbia blood agar (CBA, Oxoid, CM0331) plates 
containing 5% defibrinated sheep blood (CBA plates) at 35°C and 5% CO2 for 3 days then 
expended for 2 days on new plates. When indicated, media were supplemented with 30 μg/ml 
kanamycin, 100 μg/ml streptomycin, and/or isopropyl-β-D-thiogalactoside (IPTG, Biochemica, 
A1008).  
E. coli strains were cultivated in Luria-Bertani liquid medium (LB) or on Luria-Bertani agar on 
plates (LA) at 37°C overnight. Media were supplemented with 50 μg/ml kanamycin, and/or 1 
mM diaminopimelic acid (DAP, Sigma, D1377). 
LB - Medium (1 liter) Amount for 1 liter 
Tryptone (Difco, 211701) 10 g 
Yeast extract (Oxoid, L0021) 5 g 
NaCl (Merck, 106404) 10 g 
 
LB - agar (LA plate) (1 liter)  Amount for 1 liter 
Tryptone (Difco, 211701) 10 g 
Yeast extract (Oxoid, L0021) 5 g 
NaCl (Merck, 106404) 10 g 
Agar (Difco, 214530) 13 g 
 
Conjugation of Bartonella-expression plasmids into Bartonella 
Bartonella henselae ΔbepA-G (SIM B1-01) was grown on CBA plates in presence of 100 μg/ml 
streptomycin at 35°C and 5% CO2 for 3 days then expanded on new plates for 2 days. The 
day before conjugation, 5 ml of LB containing 1 mM DAP (Sigma, D1377) and 50 μg/ml 
kanamycin were inoculated with the conjugation strain (JKE170) containing the plasmid of 
interest. After overnight incubation at 37°C, a subculture was prepared by inoculating 5 ml of 
LB containing 1 mM DAP (Sigma, D1377) and 50 μg/ml kanamycin with 200 µl of overnight 
culture before being incubated for 2 hours at 37°C.   
In order to remove antibiotics, 500 µl of the subculture was centrifuged for 4 min at 4’500 rpm 
and the bacterial pellet was resuspended in 500 µl of M199 (Gibco, 22340-020) supplemented 
with 10 % of heat-inactivated fetal calf serum (ΔFCS), the washing step was repeated once. 
The same process was applied to Bartonella, bacteria were harvested in 1 ml of M199 10% 
ΔFCS and centrifuged for 4 min at 4’500 rpm. The bacterial pellet was resuspended in 500 µl 
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of M199 10% ΔFCS before being centrifuged again and resuspended in 100 µl of M199 10% 
ΔFCS.  
20 µl of E. coli was mixed with 100 µl of Bartonella and incubated for 5 hours at 35°C, 5% CO2 
on a nitrocellulose filter deposited on a CBA plate supplemented with 1 mM of DAP. The filter 
was transferred in an Eppendorf tube containing 1 ml of M199 10% ΔFCS and the bacteria 
were resuspended by gently shaking. 5 µl and 50 µl were plated on a CBA plate supplemented 
with 30 μg/ml kanamycin and 100 μg/ml streptomycin. 
Cell culture  
Human umbilical vein endothelial cells (HUVEC) were isolated as described before (Dehio et 
al., 1997) and cultured at 37°C and 5 % CO2 in Endothelial Cell Growth Medium (ECGM) 
(Promocell, C-22010) supplemented with Endothelial Cell Growth Medium SupplementMix 
(Promocell, C-39215). 
HeLa cells and EA.hy926 cells were cultured at 37°C and 5 % CO2 in DMEM (Sigma, D6429) 
supplemented with 10 % of heat-inactivated fetal calf serum (FCS). 
Cell infection for microscopy 
HUVECs were plated at a density of 3’000 cells/well while on a 96-well plate (Corning, #3904) 
pre-coated with 0.2 % of gelatin using supplemented ECGM.  
HeLa cells and EA.hy926 cells were plated at a density of 2’000 cells/well on a 96-well plate 
(Corning, #3904) using DMEM supplemented with 10 % of heat-inactivated FCS.  
The next day, cells were infected with Bartonella at the indicated MOI in M199 (Gibco, 22340-
020) supplemented with 10 % of heat-inactivated FCS in presence of 10 µM of IPTG.  After 
incubation at 35°C and 5 % CO2, cells were fixed with 50 µl of 3.7 % of paraformaldehyde for 
10 minutes and washed 3 times with 100 µl of PBS. 
PBS pH 7.4   Amount for 1 liter 
NaCl (Merk, 106404) 8 g 
KCl (Merk, 104936) 0.2 g 
Na2HPO4 2 H2O (Merk, 106580) 1.44 g 
KH2PO4 (Merk, 104873) 0.24 g 
 
Immunostaining  
Fixed cells were permeabilized for 10 minutes with 50 µl of PBS 0.2 % BSA (Sigma, A9647) 
and 0.5 % Triton X-100 (Sigma, T9284). After being washed 3 times with 100 µl of PBS with 
0.2 % BSA, cells were incubated overnight at 4°C in presence of the primary antibody (see 
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table below) diluted in 50 µl of PBS with 0.2 % BSA. After 2 more washes with 100 µl of PBS 
with 0.2 % BSA, cells were incubated for 2 hours in the dark in presence of the secondary 
antibody, DAPI (Sigma, D9542, 1 µg/ml) and DY-547P1 phalloidin (Dyomics GmbH, final 
concentration 1/250) diluted in 50 µl of PBS with 0.2 % BSA. Cells were finally washed 3 times 
with 100 µl of PBS and imaged with an MD ImagXpress Micro automated microscope from 
Molecular devices.  Fluorescence was detected at 10x or 20x magnification, and the images 
were processed in MetaXpress. 
Antigen Producer (ref) Final dilution 
Rabbit anti-Bartonella (primary) In-house (serum n° 2035) 1/1000 
Mouse anti-Flag (primary) Sigma, F1804 1/1000 
Mouse anti-β-tubulin (primary) Sigma, T8328 1/100-250 
Mouse anti-pMLC (primary) Cell signaling, # 3675  1/100 
Mouse anti-Vimentin (primary) Abcam ab8978  1/100-250 
Mouse anti-Talin (primary) Sigma, T3287 1/250 
Rabbit anti-pPaxillin (primary) Santa Cruz, sc-14036  1/50 
Rabbit anti-VE cadherin (primary) Bender Medsystems, BMS158 1/100 
Goat anti-mouse AlexaFluor 488 (secondary) Jackson Immuno, 115-545-146 1/250 
Goat anti-rabbit Cy5 (secondary) Jackson Immuno, 111-175-045 1/250 
 
Pull-down assay  
HeLa cells or HUVECs were plated in round plates (Falcon, REF 353003) at a density of 
363’120 or 544’000 cells per plate, respectively. The cells were then incubated overnight at 
37°C and 5% CO2 in DMEM complemented with 10 % heat-inactivated FCS. In the morning, 
cells have been infected with the indicated strain of Bartonella at an MOI of 200 for 24 hours 
at 35°C and 5% CO2 in M199 (Gibco, 22340-020) supplemented with 10 % of heat-inactivated 
FCS in presence of 10 µM of IPTG. 
After infection, cells were washed 3 times with ice-cold PBS and lysed with lysis buffer 
containing 50 mM Hepes (pH 7.5), 150 mM NaCl, protease inhibitor (Roche, 11836170001), 
phosphatase inhibitor (Roche, 04906837001), 1 % Nonidet P40 substitute (Sigma, 74385). 
Cell lysates were collected with a cell scraper and incubated 30 minutes on ice. After 
centrifugation at 20’000 x g for 30 min at 4°C, the protein concentration in the supernatant was 
measured with Precision Red Advanced Protein Assay Reagent (Cytoskeleton, Cat. # ADV02-
A). Protein concentration was adjusted between the samples with lysis buffer. 
The lysates were incubated in presence of 20 µl of protein G agarose beads (Roche, 
11243233001) for 3 hours at 4°C on a rotor to reduce unspecific binding. After removing the 
beads by centrifugation for 30 seconds at 12’000 x g, 2 µg of mouse anti-Flag antibody (Sigma 
F1804) was added to the supernatant. After 3 hours of incubation at 4°C on a rotor, 20 µl of 
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protein G agarose was added to the lysates and incubated overnight at 4°C on a rotor. The 
next morning, agarose beads were collected by centrifugation for 30 seconds at 12’000 x g 
before being washed 2 times with lysis buffer and 2 more times with lysis buffer without NP-
40. Proteins were eluted from the beads by incubation 10 minutes at 95°C in SDS sample 
buffer. Elution fractions and cell lysates before pull-down were analyzed by western blot. 
The same protocol was applied for samples analyzed by mass spectrometry although one cell 
culture flask of 150 cm2 was used per infection.  
SDS sample buffer (1X) Concentration 
SDS 20 mg/ml 
Tris HCl pH 6.8 40 mM 
Bromophenol blue 1 mg/ml 
Glycerol 5 % 
 
Protein expression and purification 
100 ml of LB supplemented with 50 μg/ml of kanamycin was inoculated with SIME3-58 (E. coli 
BL21 (DE3)) containing pSIM072 encoding BepCBhe (FIC-OB). After overnight incubation at 
37°C, 50 ml of overnight culture were used to inoculate 2 liters of Terrific Broth supplemented 
with 50 μg/ml of kanamycin (see composition below). The culture was incubated 4 hours at 
25°C to reach an OD600 of approximatively 0.5. Protein expression was induced with 100 µM 
of IPTG for 16 hours at 25°C. Bacteria were pelleted at 4°C and resuspended in 40 ml of cold 
lysis buffer (50 mM Tris-HCl pH 7.5, 100 mM NaCl, 2,5 mM beta-mercaptoethanol, DNAseI 
(AppliChem, A3778), protease inhibitor (Roche, 11836170001).  
Bacteria were disrupted using French press and cell debris were pelleted by 
ultracentrifugation. Imidazole was then added to the supernatant to a final concentration of 20 
mM. After loading on a His-Trap column (GE Healthcare), proteins binding non-specifically to 
the column were removed with washing buffer (50 mM Tris-HCl pH 7.5, 100 mM NaCl, 2,5mM 
beta-mercapto-ethanol, 150 mM imidazole). Remaining proteins were eluted with the elution 
buffer (50 mM Tris-HCl pH 7.5, 100 mM NaCl, 2,5mM beta-mercapto-ethanol, 500 mM 
imidazole) and injected on gel filtration column (HiLoad 16/60 Superdex 75 prep grade, GE 
Healthcare) pre-equilibrated with buffer (50 mM Tris-HCl pH 7.5, 100 mM NaCl, 2,5mM beta 
mercapto-ethanol). Pure protein was concentrated by filtration (Amicon Ultra-15 Centrifugal 
Filter Units – 10,000 NMWL). 
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Terrific Broth Amount for 1 liter 
Bacto-Tryptone 12 g 
Bacto-Yeast Extract 24 g 
Glycerol 100 % 5 ml 
KH2PO4 2.31 g  
K2HPO4 12.54 g 
 
Protein expression and partial purification 
40 ml of LB supplemented with 50 μg/ml of kanamycin and 1% of glucose was inoculated with 
E. coli BL21 (DE3) containing the plasmid of interest. After overnight incubation at 37°C, 25 ml 
of overnight culture was centrifuged and the pellet was resuspended in 10 ml in Terrific Broth. 
Then, the bacterial suspension was used to inoculate 1 liter of Terrific Broth supplemented 
with 50 μg/ml of kanamycin. The culture was incubated 4 hours at 25°C to reach an OD600 of 
approximatively 0.5. Protein expression was induced with 100 µM of IPTG for 18 hours at 
25°C. Bacteria were pelleted at 4°C and resuspended in 10 ml of cold lysis buffer (50 mM Tris-
HCl pH 7.5, 100 mM NaCl, 2,5 mM beta-mercaptoethanol, DNAseI (AppliChem, A3778), 
protease inhibitor (Roche, 11836170001).  
Bacteria were disrupted using French press and cell debris were pelleted by 
ultracentrifugation.  To bind the His-tagged protein, 2 ml of nickel beads (Protino Ni-NTA 
Agarose, Macherey-Nagel) was added to the supernatant and incubated 1 hour at 4°C on a 
rotor. Subsequently, the supernatant with beads was loaded on a Poly-Prep® Chromatography 
Columns (Biorad). The beads were washed three times with 10 ml of cold washing buffer (50 
mM Tris-HCl pH 7.5, 100 mM NaCl, 2,5mM beta-mercaptoethanol, 20 mM imidazole) to 
remove proteins with unspecific binding. Then, His-tagged proteins were eluted with 5 x 500 
µl of elution buffer (50 mM Tris-HCl pH 7.5, 100 mM NaCl, 2,5mM beta-mercaptoethanol, 500 
mM imidazole). Finally, the most concentrated fractions were pooled together and desalted by 
dialysis two times in 2 liters of cold buffer (50 mM Tris-HCl pH 7.5, 100 mM NaCl, 2,5mM beta 
mercapto-ethanol). 
Sample preparation for mass spectrometry 
Proteins were precipitated with trichloroacetic acid and incubated 10 min at 4°C. The protein 
pellet was washed twice with cold acetone and resuspended with 4 M urea. Then the samples 
were treated with 5 mM of tris(2-carboxyethyl)phosphine (TCEP) for 30 min at 37°C in order 
to reduce disulfide bonds. After incubation, iodoacetamide (1.8 mg/ml final) was added to the 
samples to irreversibly prevent the formation of disulfide bonds and incubated for 30 min at 
25°C in the dark. The samples were subsequently diluted with 0.1 M ammonium bicarbonate 
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to have a final concentration of urea of 1.6 M. For digestion, the proteins were incubated 
overnight at 37°C in presence of 1 µg of trypsin. After acidification with trifluoroacetic acid 
(TFA, 1 % final), the peptides were loaded on a C-18 column (The Nest group, SS18V) pre-
equilibrated with buffer A (0.1 % TFA). The column was washed 3 times with buffer C (5 % 
acetonitrile / 95 %water (v/v) and 0.1 % TFA) and peptides were eluted with buffer B (50 % 
acetonitrile / 50 %water (v/v) and 0.1 % TFA). The peptides were finally dried under vacuum 
and kept at - 80°C. Before LC-MS/MS mass analysis, samples were resuspended in 0.1 % 
formic acid by sonication. 
RhoA activation 
HeLa cells were seeded at a density of 362’656 cells/plate in DMEM 1 % FCS in three round 
plates (Falcon, REF 353003). After overnight incubation at 37°C and 5 % CO2, the medium 
was removed and HeLa cells were infected at MOI 400 with M199 1% FCS containing Bhe 
ΔbepA-G carrying the empty plasmid (SIM B1-52) or expressing BepC (SIM B2-06), one 
plate was left uninfected. After 24 hours of infection at 35°C, 5% CO2, the activation of RhoA 
was estimated using a G-LISA RhoA Activation Assay Biochem Kit (Cytoskeleton, BK124-S), 
according to the manufacturer’s instructions. 
Growth inhibition test for Bartonella 
Bartonella ΔbepA-G overexpressing the indicated protein was grown on CBA plates for 3 days 
at 35°C with 5 % CO2. Bacteria were collected with a cotton swab and resuspended in M199 
with 10 % heat-inactivated FCS. After OD600 measurement, bacteria were diluted to have an 
OD600 of 10-1. A serial dilution of 1/10 was performed in a 96-well plate until OD600 10-7 and 10 
µl of each dilution was plated on a CBA square plate supplemented with the indicated 
concentration of ITPG. Bartonella was grown for one week at 35°C with 5 % CO2 and picture 
of the colonies were taken with a camera. Indicated bacterial number was estimated 
considering that OD600=1 is equal to 109 bacteria. 
 
Western blotting 
The samples used for western blotting were separated by SDS-PAGE on a 4-20 % gradient 
gel (Mini-PROTEAN TGX Gels, Biorad, Cat# 456-1093).  Gel electrophoresis was performed 
for 1h15 at 120 V in running buffer (Tris-glycine, 0.1% SDS). Protein were transferred on a 
PVDF membrane (GE Healthcare, 10600021) via wet electroblotting for 1 hour at 100 V in 
transfer buffer (20 % methanol, Tris-glycine) at 4°C. After transfer, the membrane was 
incubated for 1 hour in blocking buffer (PBS, 0.1% Tween 20 (Sigma, 93773) supplemented 
with 5% milk or 5% BSA according to antibody recommendation). After washing with PBS 0.1% 
Tween 20, the membrane was incubated overnight at 4°C in blocking buffer with the primary 
antibody (see table below). The membrane was washed again with PBS 0.1% Tween 20 before 
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being incubated 1 hour at room temperature in blocking buffer with the secondary antibody 
(see table below). The blots were incubated 1 min in dark with a mix of solution A and B from 
LumiGLO Reserve Chemiluminescent Substrate System (KPL, 54-70-00, 54-69-00). Finally, 
the signal was detected with LAS4000 (Fujifilm). 
Tris-glycine  Amount for 1 liter  
Tris (Merck, 108382) 3 g 
Glycin  (Sigma, 50050) 14.4 g 
 
Antigen Producer (ref) Final dilution 
Rabbit anti-GEF-H1 (primary) Cell signaling, #4076 1/500 
Rabbit anti-MRCKα (primary) Abcam, ab96659 1/500 
Mouse anti-Flag (primary) Sigma, F1804 1/1000-2000 
Mouse anti-HA (primary) Cell Signaling, #2367 1/2000 
Donkey anti-rabbit IgG, HRP linked  (secondary) GE Healthcare, NA934 1/1000 
Sheep anti-mouse IgG, HRP linked (secondary) GE Healthcare, NA931V 1/1000 
 
Thermal shift assay 
Each step was performed on ice until analysis. Purified proteins were mixed with Sypro Orange 
(ThermoFisher, S6650) (12.5 X final concentration). 12 µl of mix was transferred per well in a 
white 96 well qPCR plate. 3 µl of dilution buffer (Tris 50 mM pH 7.5, 100 mM NaCl, 2.5 mM β-
mercaptoethanol) or 3 µl of nucleotide derivatives in dilution buffer were added per well to 
reach the desired concentration. The plate was spun down at 100 x g to ensure mixing. In 
qPCR machine (Biorad, CFX96 Real-time system), the plate was heated up from 10°C to 90°C 
with an increase of 0.5°C/min and fluorescence was measured at each temperature. The 
fluorescence intensity is then plotted against the temperature, the melting temperature (Tm) 
corresponds to the inflection point of the curve. 
Radioactive enzymatic assays 
Recombinant BepC (FIC-OB) 0.25 mg/ml was incubated with radioactively labeled ATP or 
NAD+ in buffer (100 mM NaCl, 50 mM Tris pH 7.5, 2.5 mM β-mercaptoethanol). When 
indicated, the buffer was supplemented with MgCl2 and non-radioactivate ATP or NAD+. 
Samples were then incubated at 25°C or 30°C for the indicated period. Reactions were 
stopped by the addition of SDS-loading buffer and incubated for 5 min at 95°C. Samples were 
loaded onto 4-20 % gradient gel (Mini-PROTEAN TGX Gels, Biorad, Cat# 456-1093). 
Electrophoresis was performed 120 V for 90 min. The gel was stained overnight in Maier blue, 
gels were sealed in plastic bags and exposed on PhoSphor Screen overnight. Screens were 
developed using a Typhoon FLA 7000 system (GE Healthcare). 
- Materials and methods - 
130 
 
Maier Blue  Amount for 1 liter 
H2O 850 ml 
Ethanol (Sigma, 02890) 50 ml 
ortho-Phosphoric acid (Merck, 100565) 80 g 
α-Cyclodextrin (Roth, Nr. 4122.3) 5 g 
Coomassie Brilliant Blue G-250 (Bio-rad, #1610406) 80 mg 
 
Cell lysate preparation for AMPylation assay 
HeLa cells at passage 18 were grown at 37°C with 5 % CO2 in 4 flasks of 175 cm2.  After four 
washes with 5 ml of resuspension buffer (50 mM Tris pH 7.5, 100 mM NaCl, 2.5 mM β-
mercapto-ethanol), cells were scraped in presence of 5 ml of resuspension buffer with 
proteases inhibitors (Roche, 11836170001) and DNAseI (AppliChem, A3778). Then, 
resuspended cells were pooled together and centrifuged for 10 min at 2’000 x g at 4°C. The 
supernatant was discarded and the cell pellet was resuspended with 500 µl of resuspension 
buffer supplemented with protease inhibitor and DNAseI before being lysed by sonication. Cell 
lysates were centrifuged at 20’000 x g for 30 min at 4°C and the supernatant was used for 
AMPylation assay. 
Inhibitor treatment of infected HeLa cells 
HeLa cells (passage 13) were seeded at a density of 2’000 cells/well on a 96-well plate 
(Corning, #3904) using DMEM supplemented with 10 % of heat-inactivated FCS. After 
overnight incubation at 37°C with 5 % CO2, cells were infected with Bhe ΔbepA-G carrying the 
empty plasmid (SIM B1-52) or expressing BepC (SIM B2-06) at MOI=200 in M199 (Gibco, 
22340-020) supplemented with 10 % of heat-inactivated FCS in presence of 10 µM of IPTG.  
After 24 hours of incubation at 35°C and 5 % CO2, the medium was removed and cells were 
incubated with 100 µl of inhibitor diluted in DMEM at 35°C with 5 % CO2. The treatment 
consisted of 2 µg/ml of Rho inhibitor I (Cytoskeleton, CT04) for 2 hours or 20 µM of Y27632 
(Sigma, Y0503) for 1 hour. The experiment was stopped by fixation with 50 µl of 3.7 % of 
paraformaldehyde for 10 minutes. Finally, the cells were washed 3 times with 100 µl of PBS 
before being stained for F-actin and imaged by microscopy. 
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Alignments and crystal structures 
List of Bartonella species of the lineage 4 used for the amino acid alignments of BepC and 
BepA as well as for the modelization of conserved residues on the structure of BepCBtr (FIC). 
Abbreviation Genus - specie 
Bal Bartonella alsatica IBS 382 
Bbi Bartonella birtlesii LL-VM9 
Bdo Bartonella doshiae NCTC 12862 
Bel Bartonella elizabethae F9251 
Bgr Bartonella grahamii as4aup 
Bhe Bartonella henselae Houston-1 
Bko Bartonella koehlerae C-29 
Bqu Bartonella quintana str. Toulouse 
Bra Bartonella rattimassiliensis 15908 
Bsp. DB5-6 Bartonella sp. DB5-6 
Bta Bartonella taylorii 8TBB 
Btr Bartonella tribocurum CIP 105476 
Bvi Bartonella vinsonii arupensis OK-94-513 
Bwa Bartonella washoensis 085-0475 
 
Crystal structures of the FIC domain 
PDB ID Genus – specie 
PDB 4WGJ Bartonella tribocurum CIP 105476 
PDB 3ZCB Bartonella schoenbuchensis DSM 13525 
 
Bartonella strains 
SIM Genome  Determinant Plasmid  Description 
SIM B1-01 rpsL (SmR), ΔbepA-G None   
SIM B1-08 rpsL (SmR), ΔbepA-G pSIM027 pHA-ATBro 
SIM B1-09 rpsL (SmR), ΔbepA-G pSIM028 pHA-ATBsp.1-1C 
SIM B1-10 rpsL (SmR), ΔbepA-G pSIM011 pHA-ATBro-SD (strong)-Flag-Bep2Bro 
SIM B1-11 rpsL (SmR), ΔbepA-G pSIM013 pHA-ATBro-SD (weak)-Flag-Bep2Bro 
SIM B1-17 rpsL (SmR), ΔbepA-G pSIM015 pFlag-Bep1Bro 
SIM B1-18 rpsL (SmR), ΔbepA-G pSIM016 pFlag-Bep1Bsp.1-1C 
SIM B1-19 rpsL (SmR), ΔbepA-G pSIM020 pHA-ATBro-Flag-Bep1Bro 
SIM B1-20 rpsL (SmR), ΔbepA-G pSIM021 pHA-ATBsp.1-1C-Flag-Bep1Bsp.1-1C 
SIM B1-27 rpsL (SmR), ΔbepA-G pSIM029 pHA-ATBro-SD (strong)-Flag-Bep1Bro 
SIM B1-28 rpsL (SmR), ΔbepA-G pSIM030 pHA-ATBsp.1-1C-SD (strong)-Flag-Bep1Bsp.1-1C 
SIM B1-29 rpsL (SmR), ΔbepA-G pSIM031 pHA-ATBro-SD (weak)-Flag-Bep1Bro 
SIM B1-30 rpsL (SmR), ΔbepA-G pSIM032 pHA-ATBsp.1-1C-SD (weak)-Flag-Bep1Bsp.1-1C 
SIM B1-40 rpsL (SmR), ΔbepC, G None   
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SIM B1-45 rpsL (SmR), ΔbepA-G pSIM051 pFlag-bepCBgr 
SIM B1-46 rpsL (SmR), ΔbepA-G pSIM054 pFlag-bepCBqu 
SIM B1-47 rpsL (SmR), ΔbepA-G pSIM056 pHA-ATBhe-TAATG-Flag-BepCBhe 
SIM B1-48 rpsL (SmR), ΔbepA-G pSIM037 Pgfp 
SIM B1-49 rpsL (SmR), ΔbepA-G pSIM058 pFlag-bepCBta 
SIM B1-50 rpsL (SmR), ΔbepA-G pSIM059 pFlag-bepCBhe K150A, R154A R157A 
SIM B1-51 rpsL (SmR), ΔbepA-G pSIM057 pHA-ATBhe-SD(weak)-Flag-bepCBhe 
SIM B1-52 rpsL (SmR), ΔbepA-G pBZ485_a_empty pEmpty 
SIM B1-63 rpsL (SmR), ΔbepA-G pSIM062 pFlag-bepCBtr 
SIM B1-70 rpsL (SmR), ΔbepA-G pSIM060 pFlag-bepCBhe 
SIM B1-74 rpsL (SmR), ΔbepA-G pSIM073 pHA-ATBhe 
SIM B2-01 rpsL (SmR), ΔbepA-G pSIM064 pFlag-bepFBhe 
SIM B2-02 rpsL (SmR), ΔbepA-G pSIM071 pFlag-bepEBhe  
SIM B2-03 rpsL (SmR), ΔbepA-G pSIM086 pFlag-bepCBhe K150E 
SIM B2-05 rpsL (SmR), ΔbepA-G pSIM090 pFlag-bepCBhe H146A  
SIM B2-06 rpsL (SmR), ΔbepA-G pSIM091 pFlag-bepCBhe 
SIM B2-07 rpsL (SmR), ΔbepA-G pSIM062b pFlag-bepCBtr 
SIM B2-08 rpsL (SmR), ΔbepA-G pSIM081 pFlag - bepCBhe BepC**** 
SIM B2-14 rpsL (SmR), ΔbepA-G pSIM097 pFlag-bepCBhe (BID) 
SIM B2-15 rpsL (SmR), ΔbepA-G pSIM096 pFlag-bepCBhe 19-532  
SIM B2-16 rpsL (SmR), ΔbepA-G pSIM098 pFlag-bepCBhe (OB-BID)  
SIM B2-18 rpsL (SmR), ΔbepA-G pSIM107 p3xFlag-bepCBhe 
SIM B2-25 rpsL (SmR), ΔbepA-G pSIM117 pFlag-bepCBhe (FLAP BepA)  
SIM B2-33 rpsL (SmR), ΔbepA-G pSIM121 p3XFlag-bepCBhe (BID BepA)  
SIM B2-36 rpsL (SmR), ΔbepA-G pSIM125 p3xFlag bepFBhe 
SIM B2-37 rpsL (SmR), ΔbepA-G pSIM126 p3xFlag-bepEBhe 
SIM B2-38 rpsL (SmR), ΔbepA-G pSIM127 p3xFlag-bepCBhe**** 
SIM B2-39 rpsL (SmR), ΔbepA-G pSIM128 p3xFlag-bepCBhe K150E  
SIM B2-40 rpsL (SmR), ΔbepA-G pSIM129 p3xFlag-bepCBhe H146A 
SIM B2-41 rpsL (SmR), ΔbepA-G pSIM130 p3xFlag-bepCBhe 19-532  
SIM B2-42 rpsL (SmR), ΔbepA-G pSIM131 p3xFlag-bepCBhe (OB-BID) 
SIM B2-43 rpsL (SmR), ΔbepA-G pSIM132 p3xFlag-bepCBhe (FLAP BepA) 
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E. coli strains 
SIM E3-58 BL21(DE3) : E. coli B; F–, ompT, hsdSB(rB-, mB-), dcm, gal, λ(DE3) pSIM072 pbepCBhe  (FIC-OB) - 6XHis 
SIM E3-71 BL21(DE3) : E. coli B; F–, ompT, hsdSB(rB-, mB-), dcm, gal, λ(DE3) pSIM076 pbepCBhe (FIC-OB) -6XHis + HA-ATBhe 
SIM E4-25 BL21(DE3) : E. coli B; F–, ompT, hsdSB(rB-, mB-), dcm, gal, λ(DE3) pSIM094 pbepCBhe H164A (FIC-OB) - 6XHis 
SIM E4-26 BL21(DE3) : E. coli B; F–, ompT, hsdSB(rB-, mB-), dcm, gal, λ(DE3) pSIM095 pbepCBhe**** (FIC-OB) - 6XHis 
SIM E4-37 BL21(DE3) : E. coli B; F–, ompT, hsdSB(rB-, mB-), dcm, gal, λ(DE3) pSIM080 pbepCBhe K150E (FIC-OB) - 6XHis 
JKE170 
MG1655 RP4-2-Tc::[ΔMu1::aac(3)IV-
ΔaphA-Δnic35-ΔMu2::zeo] ΔdapA::(erm-pir) 
ΔrecA ΔmcrA Δ(mrr-hsdRMS-mcrBC) 
None   
 
E. coli plasmids 
Plasmid  Description Template PCR PCR  Cloned in 
pSIM049 pRSF-Duet-1 with inactivated NdeI  pRSF-Duet-1 
prSIM163 
prSIM164 PCR mutagenesis 
pSIM065 pSIM049 with NcoI->NdeI pSIM049 
prSIM165 
prSIM166 PCR mutagenesis 
pSIM072 pbepCBhe  (FIC-OB) - 6XHis Genomic DNA 
prSIM162 
prSIM161 pSIM065 (NdeI/NotI) 
pSIM075 pHA-ATBhe Genomic DNA 
prSIM172 
prSIM173 
pRSF-Duet-1 
(NcoI/NotI) 
pSIM076 pHA-ATBhe + bepCBhe (FIC-OB) -6XHis pSIM072 
prSIM162 
prSIM171 pSIM075 (NdeI/XhoI) 
pSIM080 pbepCBhe K150E (FIC-OB) - 6XHis pSST033 
prSIM162 
prSIM161 pSIM065 (NdeI/NotI) 
pSIM094 pbepCBhe H164A (FIC-OB) - 6XHis pRC019 
prSIM162 
prSIM161 pSIM072 (NdeI/SalI) 
pSIM095 pbepCBhe**** (FIC-OB) - 6XHis pSIM084 
prSIM162 
prSIM161 pSIM072 (NdeI/SalI) 
 
 Bartonella plasmids 
Plasmid Description Template PCR1 PCR 1 Template PCR2 PCR 2 PCR 3 Cloned in 
pBZ485_a pccdB       
pBZ485_a_empty pEmpty pSIM037 X X X X PCR mutagenesis 
pSIM033 pccdB pBZ485_a prSIM131 prSIM132 X X X PCR mutagenesis 
pSIM035 pgfp pSIM033 prSIM133 prSIM138 X X X pSIM033 (SacI/XhoI) 
pSIM037 pgfp pSIM035 prSIM149 prSIM150 X X X PCR mutagenesis 
pSIM051 pFlag-bepCBgr Genomic DNA prSIM106 prSIM110 PCR 1 
prSIM076 
prSIM110 X pSIM037 (SacI/NotI) 
pSIM054 pFlag-bepCBqu Genomic DNA prSIM107 prSIM111 PCR 1 
prSIM076 
prSIM111 X pSIM037 (SacI/NotI) 
pSIM056 pHA-ATBhe-TAATG-Flag-BepCBhe Genomic DNA prSIM117 prSIM109 Genomic DNA 
prSIM113 
prSIM118 
SOEING: 
prSIM078/prSIM109 pSIM037 (SacI/NotI) 
pSIM057 pHA-ATBhe-SD(weak)-Flag-bepCBhe Genomic DNA prSIM099 prSIM109 Genomic DNA 
prSIM113 
prSIM101 
SOEING: 
prSIM078/prSIM109 pSIM037 (SacI/NotI) 
pSIM058 pFlag-bepCBta Genomic DNA prSIM155 prSIM156 PCR 1 
prSIM076 
prSIM156 X pSIM037 (SacI/NotI) 
pSIM059 pFlag-bepCBhe K150A, R154A, R157A pSST036 prSIM105 prSIM109 PCR 1 
prSIM076 
prSIM109 X pSIM037 (SacI/NotI) 
pSIM062 pFlag-bepCBtr Genomic DNA prSIM108 prSIM112 PCR 1 
prSIM076 
prSIM112 X pSIM037 (SacI/NotI) 
pSIM073 pHA-ATBhe Genomic DNA prSIM113 prSIM173 PCR 1 
prSIM078 
prSIM173 X pSIM037 (SacI/NotI) 
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Plasmid Description Template PCR1 PCR 1 Template PCR2 PCR 2 PCR 3 Cloned in 
pSIM081 pFlag - bepCBhe BepC**** pSIM084 prSIM105 prSIM109 PCR 1 
prSIM076 
prSIM109 X pSIM037 (SacI/NotI) 
pSIM086 pFlag-bepCBhe K150E pSST033 prSIM105 prSIM109 PCR 1 
prSIM076 
prSIM109 X pSIM037 (SacI/NotI) 
pSIM090 pFlag-bepCBhe H146A pRC019 prSIM105 prSIM109 PCR 1 
prSIM076 
prSIM109 X pSIM037 (SacI/NotI) 
pSIM091 pFlag-bepCBhe Genomic DNA prSIM105 prSIM109 PCR 1 
prSIM076 
prSIM109 X pSIM037 (SacI/NotI) 
pSIM096 pFlag-bepCBhe 19-532 pSIM091 prSIM195 prSIM109 PCR1 
prSIM076 
prSIM109 X pSIM037 (SacI/NotI) 
pSIM097 pFlag-bepCBhe (BID) pSIM091 prSIM196 prSIM109 PCR1 
prSIM076 
prSIM109 X pSIM037 (SacI/NotI) 
pSIM098 pFlag-bepCBhe (OB-BID) pSIM091 prSIM197 prSIM109 PCR1 
prSIM076 
prSIM109 X pSIM037 (SacI/NotI) 
pSIM107 p3xFlag-bepCBhe pSIM091 prSIM202 prSIM109 PCR1 
prSIM203 
prSIM109 X pSIM037 (SacI/NotI) 
pSIM117 pFlag-bepCBhe (Flap BepA) pSIM113 prSIM202 prSIM109 PCR 1 
prSIM203 
prSIM109 X pSIM037 (SacI/NotI) 
pSIM121 p3XFlag-bepCBhe (BID BepA) pSIM107 prSIM203 prSIM221 pPG101 
prSIM222 
prSIM220 
SOEING: 
prSIM203/prSIM220 pSIM037 (SacI/NotI) 
pSIM127 p3xFlag-bepCBhe**** pSIM081 prSIM202 prSIM109 PCR 1 
prSIM203 
prSIM109 X pSIM037 (SacI/NotI) 
pSIM128 p3xFlag-bepCBhe K150E pSIM086 prSIM202 prSIM109 PCR 1 
prSIM203 
prSIM109 X pSIM037 (SacI/NotI) 
pSIM129 p3xFlag-bepCBhe H146A pSIM090 prSIM202 prSIM109 PCR 1 
prSIM203 
prSIM109 X pSIM037 (SacI/NotI) 
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Plasmid Description Template PCR1 PCR 1 Template PCR2 PCR 2 PCR 3 Cloned in 
pSIM130 p3xFlag-bepCBhe 19-532 pSIM096 prSIM202 prSIM109 PCR 1 
prSIM203 
prSIM109 X pSIM037 (SacI/NotI) 
pSIM131 p3xFlag-bepCBhe (OB-BID) pSIM098 prSIM202 prSIM109 PCR 1 
prSIM203 
prSIM109 X pSIM037 (SacI/NotI) 
pSIM132 p3xFlag-bepCBhe (Flap BepA) pSIM117 prSIM202 prSIM109 PCR 1 
prSIM203 
prSIM109 X pSIM037 (SacI/NotI) 
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